 
 
 Protocol J2A -MC-GZGE (b) 
 
 
A Phase 2 Study of Once-Daily LY3502970 Compared with Placebo and Once- Weekly 
Dulaglutide in Participants with Type 2 Diabetes Mellitus  
 
NCT0 5048719 
 
Approval Date: 27- Oct-2021 
 
 
  
 
 
CONFIDENTIAL Protocol  J2A-MC-GZGE (b)
1Title Page
Confidential Information
The information contained in this document is confidential and is intended for the use of clinical investigators. It is the p roperty of 
Eli Lilly and Company or its subsidiaries and should not be copi[INVESTIGATOR_104441]3502970 , unless such persons are bound by a confidentiality agreement with Eli Lilly and Company or its 
subsidiaries . 
Note to Regulatory Authorities: This document may contain protected personal data and/or commercially confidential information 
exempt from public disclosure. Eli Lilly and Company requests consultation regarding release/redaction prior to any public re lease. 
In the [LOCATION_002], this document is subject to Freedom of Information Act (FOIA) Exemption 4 and may not be reproduced or 
otherwise disseminated without the written approval of Eli Lilly and Company or its subsidiaries .
Protocol Title: A Phase 2 Study  ofOnce -Daily LY3502970 Com pared wi th Placebo and Once -
Weekly Dulaglut ide in Participants with Ty pe 2 Diabetes Mellitus
Protocol Number: J2A-MC-GZGE
Amendment Number: b
Compound :LY3502970
Brief Title: Effect of LY 3502970 V ersus Placebo and Dulaglut ide in Participants with Ty pe 2 
Diabetes Melli tus
Study Phase: 2
Sponsor Name: [CONTACT_32868]: Indianapo lis, Indiana, [LOCATION_003] [ZIP_CODE]
Regulatory Agency Identifier Number(s)
IND: [ADDRESS_1036906]: 2021-002806-29
Approval Dat e:Protocol Amendment ( b) Electronically Signed and Approved by [CONTACT_41378].
Approval Date: 27-Oct-2021 GMT
CONFIDENTIAL Protocol  J2A-MC-GZGE (b)
2Medical Monitor Name [CONTACT_9352] [CONTACT_757402] .
CONFIDENTIAL Protocol  J2A-MC-GZGE (b)
3Protocol Amendment Summary of Changes Table
DOCUMENT HISTORY
Document Date
Protocol amendment [a] 30-Jun-2021
Original Protocol 15-Jun-2021
Amendment [b]
This amendment is considered to be nonsubstant ial.
Overall Rationale for the Amendment:
Section # and Name [CONTACT_23688]
1.3.Schedule of 
Activities Modified frequency o f 
blood pressure collect ions at 
a visit from [ADDRESS_1036907] ives, 
Endpoints, and 
EstimandsAdjusted the wording for 
safet y estimand.To m ore precisely  define safet y 
estimand for the study .
4.1.1 .Overview of 
Study  PeriodsCorrected visit number for 
dose escalat ions.Typographi cal error. Dose 
escalat ions occur at Visits 4 through 
10.
5.1.Inclusio n Cri teria Added a note to Inclusion 
Criterion#[ADDRESS_1036908] 2 to 4 hours.Oversight in original protocol.
CONFIDENTIAL Protocol  J2A-MC-GZGE (b)
4Section # and Name [CONTACT_757434]3A inducers.To address regulatory  agency  
request.
Added language stating that 
orally  administered drugs 
with a narrow therapeutic 
index should not be taken 
simultaneously  with 
LY3502970 due to delayed 
gastri c empt ying. Also 
provi ded exam ples of these 
drugs commo nly taken by 
[CONTACT_447590] T2DM.To address regulatory  agency  
request.
7.1.3 .Temporary  
Discontinuati onRemoved the sentence 
regarding eCRF recording.The eCRF was designed to capture 
any missed doses, including those 
associ ated wi th nonco mpliance. It 
also allows for the reason as “subject 
decisio n ”.
7.1.[ADDRESS_1036909] ions 
immediately  prior to PK specific 
visit co llection.
9.3.1. S tatistical 
Analyses: General 
ConsiderationsClarified HbA1c stratum. Fixed the language to be less 
cumberso me.
HbA1c stratum will be 
included in the model for 
the analysis o f HbA1c. Inclusio n of discret ized strata based 
on the continuous variable.
Removed l anguage about 
SAS computation 
procedure.The analysis so ftware may not be 
limited to SAS.
Added that addit ional 
supplemental  estimands 
may be explored for the 
primary  and secondary 
efficacy  endpoints. Oversight in original protocol.
CONFIDENTIAL Protocol  J2A-MC-GZGE (b)
5Section # and Name [CONTACT_757435] n model to 
logistic regressio n model. A simulat ion has shown that logist ic 
regression wit h missing values 
imputed with mult iple imputati ons 
can lead to smaller variance 
estimates than longitudinal logist ic 
regression and the analysis was 
updated accordingly .
9.3.2. Primary 
Endpoint(s)/Estimand(s) 
AnalysisCorrected visit number for 
Week [ADDRESS_1036910] ic 
regression and the analysis was 
update d accordingly.
9.3.7. Subgroup 
AnalysesCorrected “efficacy  stand” 
to “est imand” Typographi cal error.
HbA1c stratum will be 
included in the model for 
the subgroup analysis of 
HbA1c.Inclusio n of discret ized strata based 
on the continuous variable.
10.10. Appendix 10: 
Provisio ns for Changes 
in Study Conduct 
During Except ional 
CircumstancesCorrected visit numbers that 
need centralized laboratory  
collect ions rather than local 
laboratory  collect ions.Typographi cal error. Visi ts 3, 10, 
and [ADDRESS_1036911] ion 
through the central laboratory .
Corrected table with 
adjustm ents to vi sit 
windows.Typographi cal error.
Throughout the protocol Minor edi torial changes 
made throughout the 
protocol .Correcti on.
CONFIDENTIAL Protocol  J2A-MC-GZGE (b)
6Table of Contents
1. Protocol Summary ...................................................................................................... [ADDRESS_1036912] ivities (SoA) ...................................................................................... 12
2. Introduction .............................................................................................................. 21
2.1. Study  Rati onale .......................................................................................................... 21
2.2. Backgro und................................................................................................................ 21
2.3. Benefit/Risk Assessment ............................................................................................ [ADDRESS_1036913] yle Considerat ions............................................................................................. 39
5.4. Screen Failures ........................................................................................................... 40
5.5. Criteria for Tem porarily  Delaying 
Enrollment/Rando mizat ion/Administrati on of  Study  Intervent ion 
of a Parti cipant ........................................................................................................... 41
6. Study Intervention(s) and Concomitant Therapy ................................................... 42
6.1. Study  Intervent ion(s) Administered ............................................................................ 43
6.1.1. Medical Devices ......................................................................................................... 44
6.2. Preparati on, Handling, Storage, and Acc ountabili ty.................................................... 44
6.3. Measures to Minimize Bias: Rando mizat ion and Blinding .......................................... 44
6.4. Study  Intervent ion Compliance ................................................................................... 45
6.5. Dose Modificat ion...................................................................................................... 46
6.6. Continued Access to Study  Intervent ion after the End of the 
Study .......................................................................................................................... 46
6.7. Treatment of Overdose ............................................................................................... 46
6.8. Concomitant Therapy .................................................................................................47
6.8.1. Management of Participants with Gastrointestinal Symptoms ..................................... 49
6.8.2. Hyperglycemia Rescue Medicine ................................................................................ 50
7. Discontinuation of Study Intervention and Participant 
Discontinuation/Withdrawal .................................................................................... 51
7.1. Discontinuati on of  Study  Intervent ion........................................................................ 51
7.1.1. Liver Chemistry  Stoppi[INVESTIGATOR_226349].............................................................................. 52
7.1.2. QTc Stoppi[INVESTIGATOR_2121] .................................................................................................52
CONFIDENTIAL Protocol  J2A-MC-GZGE (b)
77.1.3. Temporary  Discont inuat ion........................................................................................ 52
7.1.4. Restarti ng Study  Drug after Interruption ..................................................................... 53
7.2. Parti cipant Discontinuation/Wit hdrawal fro m the Study ............................................. [ADDRESS_1036914] .............................................................................. 63
8.4. Pharmacokinet ics........................................................................................................ 68
8.5. Pharmacodynamics ..................................................................................................... 69
8.6. Genet ics..................................................................................................................... 69
8.7. Biomarkers ................................................................................................................. 69
8.8. Immunogenicit y Assessments ..................................................................................... 69
8.9. Health Economics ....................................................................................................... 69
9. Statistical Considerations ......................................................................................... 70
9.1. Statistical Hypotheses .................................................................................................70
9.1.1. Multiplicity Adjustm ent.............................................................................................. 70
9.2. Analyses Sets ............................................................................................................. 70
9.3. Statistical Analyses ..................................................................................................... 71
9.3.1. General Considerations ............................................................................................... 71
9.3.2. Primary Endpo int(s)/Estimand(s) Analysis .................................................................72
9.3.3. Secondary  Analyses .................................................................................................... 72
9.3.4. Terti ary/Exploratory  Analysis ..................................................................................... 73
9.3.5. Safety Analyses .......................................................................................................... 73
9.3.6. Pharmacokinet ic/Pharmacodynamic Analyses ............................................................ 74
9.3.7. Subgroup Analyses ..................................................................................................... 74
9.4. Interim Analysis ......................................................................................................... 74
9.5. Sample Si ze Determinat ion......................................................................................... 75
10. Supporting Documentation and Operational Considerations ................................ 76
10.1. Appendix 1: Regulatory , Ethical , and Study  Oversight 
Considerations ............................................................................................................ 76
10.1.1. Regulatory  and Ethi calConsiderat ions........................................................................ 76
10.1.2. Inform ed Consent Process .......................................................................................... 76
10.1.3. Data Protection ........................................................................................................... 77
CONFIDENTIAL Protocol  J2A-MC-GZGE (b)
810.1.4. Disseminat ion of Clinical Study  Data ......................................................................... [ADDRESS_1036915] igator Informat ion............................................................................................. 81
10.2. Appendix 2: Clinical Laboratory  Tests ........................................................................ 82
10.3. Appendix 3: Adverse Events and Serious Adverse Events: 
Definit ions and Procedures for Recording, Evaluating, Fo llow-
up, and Reporting ....................................................................................................... [ADDRESS_1036916] Complaint s............................................................................... 88
10.3.4. Recording and Fo llow-Up of AE and/or SAE and Product 
Com plaint s................................................................................................................. 89
10.3.5. Reporting of SAEs ...................................................................................................... 91
10.3.6. Regulatory  Reporting Requirements ........................................................................... 91
10.4. Appendix 4: Contraceptive and Barrier Guidance ....................................................... 93
10.4.1. Definit ions.................................................................................................................. 93
10.4.2. Contraception Guidance .............................................................................................. 93
10.5. Appendix 5: Liver Safet y: Suggested Actions and Follow - up 
Assessments ............................................................................................................... 96
10.6. Appendix 6: World Healt h Organizat ion Classificati on of  
Diabetes and Di agnostic Cri teria................................................................................. 98
10.7. Appendix 7: [LOCATION_001] Heart Associat ion Funct ional 
Classificat ion of Heart Failure .................................................................................... 99
10.8. Appendix 8: Protocol GZGE Standardized Protocols for the 
Measurement of Height, Weight, Waist Circumference, Vital 
Signs and 7-Point Self- Moni toring Bl ood Gl ucose (SMBG) ..................................... 100
10.9. Appendix 9: Patient -Reported Outcomes .................................................................. 102
10.10. Appendix 10: Provisio ns for Changes in Study  Conduct During 
Except ional Circumstances ....................................................................................... 104
10.11. Appendix 11: Abbreviat ions and Definit ions............................................................ 108
10.12. Appendix 12: Protocol  Amendment Hi story
............................................................. 113
11. References ............................................................................................................... 114
CONFIDENTIAL Protocol  J2A-MC-GZGE (b)
91. Protocol Summary
1.1. Synopsis
Protocol Title: A Phase 2 Study  of Once -Daily  LY3502970 Com pared wi th Placebo and Once -
Weekly Dulaglut ide in Pa rticipant s with Ty pe 2 Diabetes Melli tus
Brief Title: Effect of LY 3502970 V ersus Placebo and Dulaglut ide in Participants with Ty pe 2 
Diabetes Melli tus
Rationale :
LY3502970 is a non-pepti de glucagon -like peptide -1 (GLP -1) receptor agonist that is being 
developed as a daily  oral adjunct therapy  to di et and exercise to improve glycemic control in 
adults wi th type 2 di abetes m ellitus (T2DM). Unlike the peptide GLP -1 receptor agonists 
approved by  [CONTACT_226373] -date, LY3502970 is a small mo lecule being developed for daily oral 
administratio n.  
Study  J2A-MC-GZGE (GZGE) is a Phase 2, mult icenter, randomized, doubl e-blind, parallel, 
placebo -and active comparator (1.5 mg dulaglut ide QW) -controlled [ADDRESS_1036917] ion and dose escalat ion scheme for Phase 3.
Objectives and Endpoint s:
Objectives Endpoints
Primary
To demonstrate that at least one dose level of QD oral 
doses of LY3502970 is superior in change from 
baseline for HbA1c relative to placebo at Week 26, in 
participants with T2DM inadequately controlled with 
diet and exercise alone or treated with a stable dose of 
metformin.Difference between LY [ADDRESS_1036918] of QD LY3502970 versus 
placebo and versus dulaglutide on glucose control at 
Week 26Difference between LY3502970 and 
dulaglutide in change from baseline in HbA1c 
atWeek 26 
Percentage of participants with HbA1c ≤6.5% 
and of <7.0% at Week 26
Change f rom baseline infasting blood glucose 
at [ADDRESS_1036919] of QD LY3502970 versus 
placebo and v ersus dulaglutide on body weight at 
Week 26Change f rom baseline i n body weight atWeek 
26
Percent change in body weight from baseline 
at Week 26
CONFIDENTIAL Protocol  J2A-MC-GZGE (b)
10Objectives Endpoints
Percentage of participants with ≥5%, ≥10% 
body weig ht loss from baseline at Week 26
To assess safety and tolerability of LY3502970Adverse events overall
Adverse events of special interest
Laborato ry parameters
Electrocardiogram
Vital signs 
To assess the PK of LY3502970 and potential 
participant factors that may influence its PKPopulation PK Parameters
Abbreviations: HbA1c =hemoglobin A1c; PK=pharmacokinetics; QD=once daily; T2DM = type 2 diabetes 
mellitus.
Overall Design
Brief Summary:
The purpose of this study  is to m easure the change in hemoglo bin A1c ( HbA1c )with oral daily  
LY3502970 compared wi th placebo and compared wi th once -weekly subcutaneously  delivered 
dulaglut ide 1.5 mg inparticipants wi thT2DM who failed to achieve adequate glycemic control 
on diet and exercise alo ne or when treated wi th a stabl e dose of m etformin.
Study  details include:
●The study  durati on will be up to 30weeks .
●
The treatment duration will be up to 26 weeks.
Number of Participant s:
Approximately  530 participants will be screened to achieve 370rando mly assigned to study  
intervent ion.
Intervention Groups and Duration :
The durati on of  study  parti cipat ion for each participant will be approximately [ADDRESS_1036920] of an approximately 2-week screening/lead in period followed by  a [ADDRESS_1036921] ion 6.5regarding dose adjustments for participants who are having difficult y 
tolerating a specific dose.
Data Monitoring Committee: No
CONFIDENTIAL Protocol  J2A-MC-GZGE (b)
111.2. Schema
Abbreviations: DPB O= dulaglutide placebo; LY= LY 3502970 ; LY1 =LY3 mg ; LY2 =LY 12 mg; LY3 =LY24 mg; LY4 =LY 36 mg; LY5 =LY45mg.

CONFIDENTIAL Protocol  J2A-MC-GZGE (b)
121.3. Schedule of Activities (SoA)
The Schedule o f Activities(SoA) described below should be fo llowed for all  participant s enrolled in Study  GZGE . However, for those 
participants whose participat ion in this study  is affected by  [CONTACT_261730] (such as pandemics or natural disasters), please 
refer to Section 10.10 (Appendix 10)for addi tional gui dance.
Study Period I
Screening/Lead -inStudy Period II
Treatment period
For early terminations that occur before the last visit in treatment period, see the activities 
listed for ET in this table. Shaded columns represent the dose escalation period Weeks 0- 12.Study 
Period 
III 
Safety 
Follow
-UpScreening Lead -
In
Visit number [ADDRESS_1036922] 
end of 
TXP
Allowable 
interval 
tolerance (days)- ±3 ±3 ±3 ±3 ±3 ±3 ±3 ±3 ±3 ±3 ±3 ±3 - ±[ADDRESS_1036923] rative
Informed 
consentX
Inclusion and 
exclusion 
criteria review X X
Demographics X
Preexisting 
conditions and 
medical history, 
including 
surgical historyX X
Concomitant 
medicationsX X X X X X X X X X X X X X X X X
Anti-diabetic 
medicationX X X X X X X X X X X X X X X X
CONFIDENTIAL Protocol  J2A-MC-GZGE (b)
13Study Period I
Screening/Lead -inStudy Period II
Treatment period
For early terminations that occur before the last visit in treatment period, see the activities 
listed for ET in this table. Shaded columns represent the dose escalation period Weeks 0- 12.Study 
Period 
III 
Safety 
Follow
-UpScreening Lead -
In
Visit number [ADDRESS_1036924] 
end of 
TXP
Allowable 
interval 
tolerance (days)- ±3 ±3 ±3 ±3 ±3 ±3 ±3 ±3 ±3 ±3 ±3 ±3 - ±3
Fasting Visit X X X X X X X X X X X X X X X X
Substance use 
(alcohol, 
caffeine, 
tobacco use)X X
Adverse events 
(AEs) and 
Product 
ComplaintsX X X X X X X X X X X X X X X X X
Physical Evaluation
Height X
Weight X X X X X X X X X X X X X X X X
Waist 
circumferenceX X X X X X X X X
Vital signs (2
sitting BP and PR 
measurements)X X X X X X X X X X X X X X X X X
Vital signs include pulse rate, blood pressure, and temperature.  Vital sign measurements should be measured after participan t has been sitting for 
at least 5 minutes and before obtaining ECG tracings and before collection of blood samples for laboratory t esting (See Section 8.2.2 ).
Physical 
examination
X
CONFIDENTIAL Protocol  J2A-MC-GZGE (b)
14Study Period I
Screening/Lead -inStudy Period II
Treatment period
For early terminations that occur before the last visit in treatment period, see the activities 
listed for ET in this table. Shaded columns represent the dose escalation period Weeks 0- 12.Study 
Period 
III 
Safety 
Follow
-UpScreening Lead -
In
Visit number [ADDRESS_1036925] 
end of 
TXP
Allowable 
interval 
tolerance (days)- ±3 ±3 ±3 ±3 ±3 ±3 ±3 ±3 ±3 ±3 ±3 ±3 - ±[ADDRESS_1036926] of care. May be performed by [CONTACT_81239].
12-Lead ECGs X X X X X X X X X
Central ECGs should be collected prior to collection of blood samples, including PK samples. ECG measurements should be obtai ned per the 
instructions in Section 8.2.3 .
Participant Education and Supplies
Blood glucose 
(BG) meter, 
instructionsX
Dispense BG 
meter/supplies 
(if needed)X X X X X X X X X X X X X
Diabetes 
educationX X
Diabetes education to be performed by [CONTACT_757403], 
SMBG, self -injection, and diabetes management. All trainings should be repeated as needed to ensure participant compl iance.

CONFIDENTIAL Protocol  J2A-MC-GZGE (b)
15Study Period I
Screening/Lead -inStudy Period II
Treatment period
For early terminations that occur before the last visit in treatment period, see the activities 
listed for ET in this table. Shaded columns represent the dose escalation period Weeks 0- 12.Study 
Period 
III 
Safety 
Follow
-UpScreening Lead -
In
Visit number [ADDRESS_1036927] 
end of 
TXP
Allowable 
interval 
tolerance (days)- ±3 ±3 ±3 ±3 ±3 ±3 ±3 ±3 ±3 ±3 ±3 ±3 - ±[ADDRESS_1036928] the 7 -point SMBG during the week prior to the visit in which the 7 -point SMBG is required. All 
7-points of the SMBG should be completed in a single day.
7-point SMBG X X X X X
Baseline 7 -point SMBG to be explained to the participant at Visit 2 with participant completing the 7 -point SMBG during the week prior to Visit 3.  
All other 7 -point SMBGs should be completed during the week prior to the visit in which the 7 -point SMBG is required.
Review SMB G 
values and 
hypoglycemic 
events collected 
in the diaryX X X X X X X X X X X X X X X
Participant diary 
dispensedX X X X X X X X X X X X X X
Diary 
compliance 
checkX X X X X X X X X X X X X X X
Diary return X X X X X X X X X X X X X X X
CONFIDENTIAL Protocol  J2A-MC-GZGE (b)
16Study Period I
Screening/Lead -inStudy Period II
Treatment period
For early terminations that occur before the last visit in treatment period, see the activities 
listed for ET in this table. Shaded columns represent the dose escalation period Weeks 0- 12.Study 
Period 
III 
Safety 
Follow
-UpScreening Lead -
In
Visit number [ADDRESS_1036929] 
end of 
TXP
Allowable 
interval 
tolerance (days)- ±3 ±3 ±3 ±3 ±3 ±3 ±3 ±3 ±3 ±3 ±3 ±3 - ±3
Fasting Visit X X X X X X X X X X X X X X X X
Patient -Reported Ou tcomes (paper)
SF-36 v2 acute 
formX X X X
DTSQs X X X X
DTSQc X X X
Participant 
SurveyX X
Laboratory Tests and Sample Collections
Hematology X X X X X X
Hemoglobin A1c 
(HbA1c)X X X X X X X X X X
Clinical 
chemistryX X X X X X X
Glucose X X X X X X X X X X
Glucagon X X
Lipid panel X X X X X
Calcitonin X X X X
Pancreatic 
AmylaseX X X X X X X
Lipase X X X X X X X
Urinalysis X X X
CONFIDENTIAL Protocol  J2A-MC-GZGE (b)
17Study Period I
Screening/Lead -inStudy Period II
Treatment period
For early terminations that occur before the last visit in treatment period, see the activities 
listed for ET in this table. Shaded columns represent the dose escalation period Weeks 0- 12.Study 
Period 
III 
Safety 
Follow
-UpScreening Lead -
In
Visit number [ADDRESS_1036930] 
end of 
TXP
Allowable 
interval 
tolerance (days)- ±3 ±3 ±3 ±3 ±3 ±3 ±3 ±3 ±3 ±3 ±3 ±3 - ±3
Fasting Visit X X X X X X X X X X X X X X X X
Serum 
pregnancyX
Follicle 
stimulating 
hormone (FSH)X
Collect serum estradiol, FSH, and LH in women whose menopausal status needs to be determined. For participants known to be either 
premenopausal or postmenopausal, these tests do not need to be collected.
Luteinizing 
Hormone (LH)X
Estradiol X
Insulin X X X X
C-peptide X X X X
HIV screening 
testsX
Hepatitis C Virus 
(HCV) screening 
testsX
Hepatitis B Virus 
(HBV) screening 
testsX
Cytokeratin 18 X X X
Pro-C3 X X X
eGFR (CKD -EPI) X X X
CONFIDENTIAL Protocol  J2A-MC-GZGE (b)
18Study Period I
Screening/Lead -inStudy Period II
Treatment period
For early terminations that occur before the last visit in treatment period, see the activities 
listed for ET in this table. Shaded columns represent the dose escalation period Weeks 0- 12.Study 
Period 
III 
Safety 
Follow
-UpScreening Lead -
In
Visit number [ADDRESS_1036931] 
end of 
TXP
Allowable 
interval 
tolerance (days)- ±3 ±3 ±3 ±3 ±3 ±3 ±3 ±3 ±3 ±3 ±3 ±3 - ±3
Fasting Visit X X X X X X X X X X X X X X X X
Urinary 
albumin/creatini
ne ratio (UACR)X X X X
Pharmacokinetic 
(PK) samplePredose X X X X
Postdose X X X X X
PK Predose sample should be collected predose (~up to 1 hour predose).
PK Postdose sample time windows: 3 -6 hours postdose (Week 4), 6-12 hours postdose (week 8), 1- 3 hours postdose (Week 16), 3 -6 hours postdose 
(Week 20). Participants may need to return to clinical site for additional PK -specific visits to provide Postdose P K samples.
Stored Samples
Exploratory 
biomarker 
samples X X X X X
Randomization and Dosing
IWRS X X X X X X X X X X X X X X X X X
Randomization X
Injection 
trainingX X
CONFIDENTIAL Protocol  J2A-MC-GZGE (b)
19Study Period I
Screening/Lead -inStudy Period II
Treatment period
For early terminations that occur before the last visit in treatment period, see the activities 
listed for ET in this table. Shaded columns represent the dose escalation period Weeks 0- 12.Study 
Period 
III 
Safety 
Follow
-UpScreening Lead -
In
Visit number [ADDRESS_1036932] 
end of 
TXP
Allowable 
interval 
tolerance (days)- ±3 ±3 ±3 ±3 ±3 ±3 ±3 ±3 ±3 ±3 ±3 ±3 - ±3
Fasting Visit X X X X X X X X X X X X X X X X
Dispense study 
intervention 
capsulesX X X X X X X X X X X
One bottle of capsules isto be dispensed at Visits 3 and 4. Two bottles of capsules 
are to be dispensed at Visits 5-9 (during the dose escalation period). The site 
pharmacy should clearly label which bottle to take first. At Visits 10 -13, 4 bottles of 
capsules should be dispensed. At Visit 14, 2 bottles should be dispensed.
Dispense study 
intervention 
injection and 
suppliesX X X X X X X
One package of 4 single dose pens should be dispensed at Visits 3 -14.
Participant 
returns unused 
study 
intervention and 
injection 
suppliesX X X X X X X X X X X X
Assess drug 
complianceX X X X X X X X X X X X
CONFIDENTIAL Protocol  J2A-MC-GZGE (b)
20Abbreviations : AEs = adverse events; BG=blood glucose; BP=blood pressure; CKD -EPI =chronic kidney disease epi[INVESTIGATOR_623]; DTSQc =Diabetes 
Treatment Satisfaction Questionnaire -Change Version ;DTSQs =Diabetes Treatment Satisfaction Questionnaire -Status Version; ECG = electrocardiogram; 
eGFR = estimated glomerular filtration rate ; ET= early termination; FSH = follicle stimulating hormone; GLP-1= glucago n-like peptide -1;HbA1c = 
hemoglobin A1c; HBV= hepatitis B virus; HCV =hepatitis C virus; HIV = human immunodeficiency virus ; IWRS =interactive web response systems; PK= 
pharmacokinetic; LH = luteinizing hormone; PR= pulse rate; Pro-C3 = biomarker for liver fibrosis ; SF-36 v 2 acute form =Short Form 36 version 2 health 
survey acute form ; SMBG = self -monitoring of blood glucose; TXP = treatment; UACR = urinary albumin creatinine ratio; Wks = weeks .
Note: If the time between Visit 1 (Screening), Visit 2 (Lead In) and Visit 3 (Randomization) takes longer or less time than 2 weeks , it is not considered a 
protocol deviation.
CONFIDENTIAL Protocol  J2A-MC-GZGE (b)
212. Introductio n
2.1. Study Rationale
LY3502970 is an oral non-pepti de GLP -[ADDRESS_1036933] therapy  to diet and exercise to improve glycemic control in adults with T2DM. Unlike 
the pepti de GLP -1 receptor agonists approved by  [CONTACT_757404] -date, LY3502970 is a small 
molecule being developed for daily oral administratio n.  
Study  J2A-MC-GZGE (GZGE) is a Phase 2, mult icenter, randomized, double -blind, parallel, 
placebo -and active comparator (1.5 mg dulaglut ide QW) -controlled [ADDRESS_1036934] s(GLP -1 RA) are highly effect ive pept ide drugs that mimic the 
incret in hormone GLP -1(Werner et al. 2010; Lau et al. 20 15;Scheen 2017) . The hormone is 
secreted from the intest ine upon food consumption ,and its effects include augmented glucose -
dependent insulin secret ion, prol onged sat iety, reduced gl ucagon release, and delayed gastric 
emptyin g(Bayless et al . 1902; Baggio et al. 2007; Nauck et al .1997). The GLP -1RAshave good 
glucose -lowering effects with the addit ional benefits of low risk o f hypoglycemia and weight 
loss(Pratley  et al . 2018).
Dulaglut ide was chosen as the active comparator in this study . It is a subcutaneously delivered 
QW GLP -
[ADDRESS_1036935] 
weight loss (ap proximately 2.3 kg m ean weight l oss at 26 weeks) in T2DM patients (Trulicit y
[LOCATION_002] Package Insert [USPI], 2020; Trulicity Summary  of Product Characteri stics 
[SmPC], 2021).
The safet y, tolerabilit y
,and pharmacokinet ics/pharmacodynamics ( PK/PD )of LY3502970 have
been evaluated in 2Phase 1 clinical  pharmacol ogy studi es, J2A-MC-GZGA and J2A -MC-
GZGC . Study  GZGA was a single ascending dose (SAD) and a 4- week m ultiple ascending dose 
(MAD) study  in healt hy 
volunteers that evaluated the safet y, tolerability, PK, and PD of 
LY3502970 . Study  GZGC was a m ultiple dose study  in participants with T2DM designed to 
evaluate the safet y, tolerabilit y, PK, and PDof LY3502970 fo llowing 12 weeks of treatment .
In Study GZGA the SAD part of the study  evaluated single oral doses 0.3 -, 1-, 3-, and 6 mg. 
The MAD part of the study  eval uated 28 daily  LY3502970 doses of 2 mg and weekly dose 
CONFIDENTIAL Protocol  J2A-MC-GZGE (b)
22escalat ion evaluat ing different dose escalat ion schemes that ranged fr om 2 mg through 24 m g 
with terminal doses of 6 -, 16-, or 24 -mg. In both the SAD and MAD , gastrointestinal 
(GI)-related adverse events (AEs) were the most commo nly reported AEs, consistent with GLP -[ADDRESS_1036936] pharmaco logy(Nauck et al . 2009; Dungan et al. 2014; Gi orgino et al . 2015; 
Jendle et al. 2016; Nauck et al. 2016) . All AEs were mild to moderate in severit y. The incidence 
of GI AEs decreased with continued dosing in the MAD, thus demonstrating tachyphylaxis to the 
GI AEs . The MAD showed that LY3502970 init ially delayed gastric em ptying, an effect that was 
greatly  diminished wi th continued LY3502970 exposure . Furthermore, LY3502970 showed a 
decrease in glucose and body  weight. All the findings were similar to those observed with 
marketed GLP -[ADDRESS_1036937] of food on the 
PK of LY3502970 was a slight decrease in the area under the curve (AUC )and the maximum  
plasma concentration Cmax .
There has been no apparent concentration -dependent increase in systo lic or diastolic blood 
pressure (BP) after single or mult iple doses or pulse rate (PR) after single doses . There has been 
atrend in concentration -dependent increase in PRafter m ultiple doses of LY3502970, similar to 
that observed with other GLP -1 receptor agonists .
LY3502970 PK was studied across a range of doses administered as single doses or multiple 
doses (28 doses) via a once daily ( QD) dosing regimen . LY3502970 PK appeared approximately 
dose proportional over the dose range studied after a single and mult iple dosesfrom 0.3 to 24
mg. Peak concentrati ons were observed at approximately 4-12 hours postdose, and the half -life 
was approximately 24.6-67.5 hours .
Study GZGC evaluate sLY3502970 treatment for 12 weeks in participants with T2DM 
controlled with diet and exercise wit h or without a stable dose of met formin. Stud y GZGC 
included 5 dosing cohorts evaluat ing different target doses and dose escalat ions. Dose 
escalat ions occurred weekly  
untilthe target dose was reached and then maintained at the target 
dose for the duration of the study . The following were the dosing cohorts :
Cohort A:  3, 6, 12, and 21 mg
Cohort B:  3, 6, and 9 mg
Cohort C:  3, 6, 12, and 15 mg
Cohort D:  3, 6, 12, 21, and 27 mg
Cohort E:  3, 6, 9, 21, 36, and [ADDRESS_1036938] been observed to date . LY3502970 treatment has also
demonstrated a decrease in fasting plasma glucose and a decreased in 7-point self -monitoring 
blood glucose levels. There has been a decrease in HbA1c and body  weight. An increase in PR
has been observed, which i s of a similar magnitudeas seen in other early phase studies of GLP -1 
CONFIDENTIAL Protocol  J2A-MC-GZGE (b)
23RAs. There have been no clinically significant effects on electrocardi ogram  (ECG )parameters or 
other l aboratory  param eters.
2.3. Benefit/Risk Assessment
More detailed informat ion about the known and expected benefits and risks and reasonably 
expected AEs ofLY3502970 may be found in the Invest igator’s Brochure (IB) andDevelopment 
Safety Update Reports .
2.3.1. Risk Assessment
Study Intervention
The Sponsor has evaluated the preclinical and clinical risks associated with LY3502970 .
Nonclinical safet y of LY3502970 was evaluated in 6-mont h and [ADDRESS_1036939] ively . Monkey  doses were 0, 1.35, and 3mg/kg/day and were 
administered via oral gavage QDat a vol ume of 1mL/kg. Rat doses were 0, 5, 30, and 200
mg/kg/day  given by  [CONTACT_226375] a vol ume of 10 mL/kg. Important LY3502970 -related
findings in the monkey included vomit ing, decreased body  weight,anddecreased food 
consumption. Addit ional findings fro m the monkey  studi es includ echanges in CV param eters 
(such as increases in HR and decreased blood pressure) , and ECG changes (PR interval 
prolongati on). The No -observed -adverse -effect l evel (NOAEL for target organ toxicit yin the 
monkey 9 -month toxi cology study  was 3.0 m g/kg. The m onkey exposure m ultiplesfor the 
LY3502970 45-mg dose:  males= 0.773 -fold; females= 0.875 -fold.
The only clinically  relevant observat ion in the rat 6 -month repeat toxico logy study  was 
LY3502970 dose -related minimally higher total bilirubin in both sexes at ≥30 mg/kg, and 
minimally  higher bile acid in both sexes at 200 mg/kg/day . These differences likely indicated a 
hepatobiliary  effect but l acked any correlat ive microscopi c findings in the liver . The NOAEL for 
target organ toxicit yin the 6 -month rat toxi cology study  was 200 mg/kg . The rat exposure 
multiples for the LY3502970 45 -mg dose:  males = 16.5 -fold; females = 31.[ADDRESS_1036940] findings were associated with the pharmaco logy of 
LY3502970 and include :
nausea
vomiting
loss of appet ite, and
increased HR.
Of note, there have not been any liver transaminase or bilirubin changes observed in any  of the 
Phase 1 clinical trials.
All ident ified risks fro m preclinical and clinical studies to date are associated with LY3502970 
pharmaco logy and are considered m onitorabl e and manageable at the planned dose range of 2 to 
45 mg o f LY3502970 . 
These r isks are similar to those noted during development of marketed
GLP -1 receptor agonists. Participants will be closely mo nitored wi th scheduled medical 
assessment s, vital signs, laboratory  evaluat ions, and tri plicate ECG m easurements.
CONFIDENTIAL Protocol  J2A-MC-GZGE (b)
24For the dulaglut ide co mparator, r efer to the Prescribing Informat ion for Trulicit y (Trulici ty 
[LOCATION_002] Prescribing Information, 2021, Trulicit ySummary  of Product Characteri stics 
[SmPC], 20 21)for more informati on about the known and expected benefit s and risks of 
dulaglut ide.
Benefit Assessment
Data from the Phase [ADDRESS_1036941] been ident ified which woul d consti tute undue ri sk to study  parti cipants. The safet y profile 
continues to be refined as more clinical safet y data beco me available. The benefit -risk profile 
continues to support further development of LY3502970.
CONFIDENTIAL Protocol  J2A-MC-GZGE (b)
253. Objectives , Endpoints ,and Estimands
Objectives Endpoints
Primary
To demonstrate that at least one dose level of QD oral 
doses of LY3502970 is superior in change from 
baseline for HbA1c relative to placebo at Week 26, in 
participants with T2DM inadequately controlled with 
diet and exercise alone or treated with a stable dose of 
metformin.Difference between LY [ADDRESS_1036942] of QD LY3502970 versus 
placebo and versus dulaglutide on glucose control at 
Week 26Difference between LY3502970 and 
dulaglutide in change from baseline in HbA1c 
atWeek 26 
Percentage of participants with HbA1c ≤6.5% 
and of <7.0% at Week 26
Change f rom baseline infasting blood glucose 
at [ADDRESS_1036943] of QD LY3502970 versus 
placebo and versus dulaglutide on body weight at 
Week 26Change f rom baseline in body weight atWeek 
26
Percent change in body weight from baseline 
at Week 26
Percentage of participants with ≥5%, ≥10% 
body weig ht loss from baseline at Week 26
To assess safety and tolerability of LY3502970Adverse events overall
Adverse events of special interest
Laborato ry parameters
Electrocardiogram
Vital signs 
To assess the PK of LY3502970 and potential 
participant factors that may influence its PKPopulation PK Parameters
Exploratory
To assess the relationship between QDLY3502970
dose and/o r exposure and key efficacy and safety 
measures and potential participant factors that may 
influence these relationships Dose -response and concentration -response 
analy ses for key  efficacy and safety 
parameters
To evaluate the effect of QD LY3502970 versus 
placebo and versus dulaglutide on body weight as 
measured by [CONTACT_757405] 26Change f rom baseline in BMI at 26 weeks
Change f rom baseline in waist circumference 
at 26 weeks
To evaluate the effects of QDLY3502970 versus 
placebo and versus dulaglutide on7-point SMBG 
profileChange f rom baseline in 7-point SMBG 
values at Week 26
CONFIDENTIAL Protocol  J2A-MC-GZGE (b)
26Objectives Endpoints
To evaluate the effects of QD LY3502970 versus 
placebo and versus dulaglutide on biomarkersChange f rom baseline in mechanistic 
biomarkers (Section 1.3)at Week 26
To evaluate the effects of QD LY3502970 versus 
placebo and versus dulaglutide on patient -reported 
outcomes
Health -related quality of life Change from baseline inSF
-36v2 acute form 
domain sand summary scores at Week 24
 Diabetes treatment satisfactionChange f rom baseline in DTSQs at Week 24 
Actual responses to DTSQc at Week 24
 Participant experienceSummary statistics of actual responses to 
Participant survey at Week 24
Abbreviations: BMI = body mass index; DT SQc =Diabetes Treatment Satisfaction Questionnaire -Change Version ; 
DTSQs = Diabetes Treatment Satisfaction Questionnaire -Status Version ; HbA1c =hemoglobin A1c; PK= 
pharmacokinetics; QD =once daily; SF-36v2 = Short Form 36 version 2 health survey acute form ;SMBG =self-
monitor ing of blood glucose; T2DM = type [ADDRESS_1036944] is: What is the treatm ent difference in HbA1c change 
from baseline after [ADDRESS_1036945] com pleted the treatment period without addit ional ant i-hyperglycemic rescue 
medicat ion?
The “efficacy estimand ”is described by [CONTACT_757406]:
Popul ation: participants who meet the inclusio n criteri a
.Further details can be found in 
Secti on 5and Sect ion 9.
Endpoint: change fro m baseline in HbA1c at Week 26 .
Treatment condit ion: the randomized treatment with allo wance for down -titration based 
on GI tol erabilit y. 
The twointercurrent events “ permanent discont inuation of study  drug” and “init iation of rescue 
medicat ion” are handled by [CONTACT_757407] e of interest is the 
response in the efficacy measurement if participant s had adhere dto the randomized treatment 
without using additional anti -hyperglycemic rescue medicat ion. There are no other defined
intercurrent events. Down-titration will not be considered as intercurrent events for the definit ion 
of estimand in this study. Further detail s on study  intervent ions and conco mitant, including 
rescue ,intervent ions maybe found in Sect ion 6.
Popul ation
-level summary: difference in mean change sin HbA1c at Wee k 26 between QD 
LY3502970 and placebo.
CONFIDENTIAL Protocol  J2A-MC-GZGE (b)
27Rationale for “efficacy estimand ”:This phase 2 study  aims to studythe efficacy of LY3502970
under the ideal condit ion that all participants adhere to the randomized treatment without using 
additional anti-hyperglycemic rescue medicat ion.
Estimand(s) for Secondary Objectives
The same est imand for the primary object ive will be used for the following efficacy endpo ints 
forthe secondary  object ives: 
Difference between LY3502970 and dulaglut ide in change fro m baseline in HbA1c at 
Week 26 
percentage of participants with HbA1c ≤6.5% and of <7.0% at Week 26
change from baseline in fasting blood glucose at 26 weeks
Change from baseline in body  weight at Week 26
Percent change in body  weight f rom baseline at Week 26
Percentage of participants with ≥5%, ≥10% body  weight loss from baseline at Week [ADDRESS_1036946] imand 
comparing safet y of LY3502970 doses wi th placebo and dulaglut idefor the entire study  period 
(the treatm ent peri od pl us safet y follow
-up period) irrespective of adherence to study  
intervent ionfor all study  popul ation (including advertent ly enro lled participants) .
CONFIDENTIAL Protocol  J2A-MC-GZGE (b)
284. Study Design
4.1. Overall Design
Study  GZGEis a Phase 2, mult icenter, randomized, double -blind ed, parallel, placebo -and active 
comparator (1.5 mg dulaglut ide QW) -controlled 26-week study , toinvest igate the safet y and 
efficacy  of LY3 [ADDRESS_1036947] 3 months prior to 
Visit
1)(see Section 1.2).
4.1.1. Overview of Study Periods
Screening Period
Visit [ADDRESS_1036948] sign 
the informed consent form (ICF) before the study  procedures are performed, as outlined in the 
SoA, Section 1.3. 
Screening procedures will be performed according to the SoA (Secti on 1.3). 
Visit [ADDRESS_1036949] key  study 
inform ation, as appropriate. Participants will start recording their self-monitoring of blood 
glucose (SMBG) values and hypoglycemic events immediately  after Visi t [ADDRESS_1036950] study  visit. 
Participants will recei ve training on the routine BGmonitoring and paper diary co mpletion 
requi red during the study . Participant s should fo llow the investigator’s instructions related to 
frequency  of SMBG but should test their glucose a minimum o f 3 times per week and as 
specified for determination o f 7-point glucose profiles (see Sect ion10.8). Eligible pa rticipants
will return to the site for some baseline procedures during the lead -in phase (Visi t 2) 
and again 
for randomizat ion to treatment and to receive their first dose of study  drug at Visit 3.
Diabetes educat ion willbe perform ed by  [CONTACT_757408] s and 
management of hyperglycemi a and hypoglycemia, SMBG, self -inject ion,and diabetes 
management according to American Diabetes Associat ion Standards of Medical Care in Diabetes 
(ADA 2020) or local standards . Parti cipants will be trained on how to utilize BG meters and how 
to collect SM BG, including 7 -point m easurements as appropri ate. Bl ood gl ucose m eters or 
supplies will be provided to measure SMBG values (see Section 10.8).
Of note, if the screening period between Visit 1 and Visit 3 (randomizat ion) takes less or more 
time than 2 weeks, it is not a protocol deviat ion.
Randomization 
Visit 3 
At Visit 3, eligible participants, those who meet all applicable inclusio n criteria and none of the 
applicable exclusio n criteria, will perform all required study  procedures pri or to randomizat ion.
CONFIDENTIAL Protocol  J2A-MC-GZGE (b)
29Patient-reported outcomes quest ionnaires should be administered accordi ng to the S oA(Section 
1.3), as early as possible during the visit. Preferred administration order of these quest ionnaires 
throughout the trial is
1.SF-[ADDRESS_1036951] dose of study  com parator/pl acebo 
according to the randomized treatment group .Site personnel will also observe the study  
participant take the first oral dose of study  drug capsule. The date and time of the fi rst dose of 
study  drug swillbe recorded on the electroni c case report form (eCRF) . Beginning at 
rando mization, all  parti cipants will receive study  drugsaccording to the randomized treatment 
arm for the durati on of  the 26-week treatm ent period as per the SoA (Section 1.3). 
Treatment Period 
During the Treatment Period, study drugs and injection supplies will be returned per the SoA 
(Secti on1.3) and according to local requirements. New supplies will be dispensed as needed. 
Parti cipants shoul d be instructed to contact [CONTACT_757409]. Whenever 
possible, participants should take their study  medicati on (both capsul e and injecti on) at the study  
site during a visit.
Parti cipants shoul d also be advised about the appropria te course of act ion if study  drugs are not 
taken at the required time (late/missing doses) (see Section 6.5)
.Study  parti cipants will be 
permitted to use concomitant medications that they require duri ng the study , except certain 
excluded medicat ions (see Secti on6.8)that may interf ere wi th the assessment of efficacy  and 
safet y characteri stics of the study  treatm ents. 
Dose- Escalation Period (Visits 4 -10)
For m aintenance doses of LY350
2970 starting at 3mg, the init ial dose will be 2 or 3mg 
followed by [CONTACT_757410] .The dose will be increased unt il the 
maintenance dose is achieved (see Secti on 1.2for dosing details andthe LY3502970 Treatment 
Group Dose Escalat ionRegimen table bel ow).
The m aintenance doses of LY3502970 or dul aglut ide 1.5 mg will be continued for the remainder 
of the study . For participants who experience intolerable GI symptoms or may need dose 
adjustm ent for other reasons, the dose modificat ion procedures are described in Section6.5.
CONFIDENTIAL Protocol J2A-MC-GZGE (b)
30LY3502970 Treatment Group Dose Escalation Regimen
W 0123 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26
V 345 6 7 8 9 10 11 12 13 14 15
LY1 2222 2 2 2 2 2 2 2 2 3 3 3 3 3 3 3 3 3 3 3 3 3 3
LY2 226612 12 12 12 12 12 12 12 12 12 12 12 12 12 12 12 12 12 12 12 12 12
LY3 336812 24 24 24 24 24 24 24 24 24 24 24 24 24 24 24 24 24 24 24 24 24
LY4-1 236812 24 36 36 36 36 36 36 36 36 36 36 36 36 36 36 36 36 36 36 36 36
LY4-2 3336 6 6 12 12 12 24 24 24 36 36 36 36 36 36 36 36 36 36 36 36 36 36
LY5-1 3366 8 8 12 12 24 24 36 36 45 45 45 45 45 45 45 45 45 45 45 45 45 45
LY5-2 2233 6 6 12 12 24 24 36 36 45 45 45 45 45 45 45 45 45 45 45 45 45 45
Abbreviations: LY = LY3502970; V= Visit; W = w eek.
Note: Grayarea represents the dose escalation period.
CONFIDENTIAL Protocol  J2A-MC-GZGE (b)
31Maintenance Period (Visits 11-15)
During the m aintenance period, visits will occur approximately  every 3-4 weeks unt il 24 weeks 
and then 2 weeks from Weeks 24 to 26. Visit procedures should be conducted according to the 
SoA (Section 1.3).
Patient-reported outcomes quest ionnaires should be administered at Week 1 6
(Visit 12)and 
Week 24 (Visit 14), as early as possible during the visit. Preferred administration order of these 
questionnaires is
1.SF-36v2 acute form
2.DTSQs
3.DTSQc
4.Parti cipant survey  (Week 24)
Early Termination Visit
Parti cipants unable or unwilling to continue the study  for any  reason will  perform an early 
termination (ET) of treatment visit (Section 7.1). If the participant is discontinuing during an 
unscheduled visit or a scheduled visit, that visit should be performed as an ETvisit. Procedures 
shoul d be com pleted according to the SoA (Section 1.3)
.Participants who wi thdrawal  from the 
study  after si gning the inform ed consent but who have not taken a dose of study  drug pri or to 
rando mizat ion do not need to complete ETprocedures.
Patient-reported outcomes quest ionnaires should be administered at ET visit. Preferred 
administration order of these quest ionnaires is
1.SF-36v2 acute form
2.DTSQs
3.DTSQc
4.Parti cipant survey  
Safety Follow -up Period
Visit [ADDRESS_1036952] one dose of study  drug shoul dcomplete a safet y 
follow-up visit (Visit 801), according to the SoA (Section 1.3).
For p articipant swho discont inue from invest igational product (IP) early but remain in the study , 
all remaining visits should be completed per S oA (Section 1.3).
For pa rticipant s who discont inue from the study  early  (regardl ess of whether they  discontinue IP 
at the sam e time or have discont inued IP at an earlier visit), an ETvisit fo llowed by [CONTACT_49750] y 
follow-up visit (Visit 801) should be completed as per the S oA(Section 1.3).
Parti cipants are also requi red to re turn any  remaining study  diaries to the study  site at the end of 
this peri od.
4.2. Scientific Rationale for Study Design
Study  GZGE is a Phase 2 study  designed to examine the efficacy on glycemic control, 
decreasing body  weight , and safet y of QDLY3502970 compared wi th placebo and QW 
CONFIDENTIAL Protocol  J2A-MC-GZGE (b)
32dulaglut ide 1.5mg in pa rticipants with T2DMwho have inadequate glycemic control with diet 
and exercise alo ne or in combinat ion witha stable dose of met formin.
Inclusio n of an act ive comparator (dulaglut ide 1.5 mg) in Study  GZGEwill allow for a direct 
comparison of the safet y and efficacy  of QD LY350297 0 to an injectable GLP -1 RA (as well as 
to placebo) over a [ADDRESS_1036953] evaluat ionof the body  weight effects of the 2 drugs, as the putative mechanism o f action 
of LY3502970 suggests that t reatment with LY3502970 will result in cont inued weight loss over 
a 6-month peri od. The data from this trial will form the primary basis to assess dose/exposure –
response of LY3502970 efficacy  for selecti on of  doses to be included in Phase [ADDRESS_1036954] ben efit–risk characterization in 
T2DM.
The pl acebo arm  isincluded to determine whether any efficacy or safet y effects of LY3502970 
are different in magnitude from those of dulaglut ide 1.5 mg,
equivalent to or are also different 
from no treatment (i.e., place bo).
Dulaglut ide 1.5 mg was chosen to be the active comparator because it is a marketed GLP -1RA 
and has a great deal of data on its effects on HbA1c, glucose, body  weight, and AEs in the 
popul ation chosen for this study .
The current study  will enroll participants with inadequate glycemic control based on HbA1c
values ranging fro m 7.0% to 10.5%, inclusive. The study  popul ation, as defined by  [CONTACT_757411] n criteria, i s expected to include participants wit
h modestly advanced T2D Mand 
partially preserved pancreat ic cell funct ion, the key  prerequisi te for glucose -lowering efficacy 
of incret ins.
To minimize the potential confounding effect of changes inconco mitant m edicati ons, 
participants will be permitted to use conco mitant medicat ions that do n ot interfere with the 
assessment of efficacy  or saf ety characteristics of the study  treatm ents.
4.3. Justification for Dose
LY3502970 maintenance doses of 3, 12, 24, 36, and 45 mg administered orally  QD, were 
selected based on the points below.  
In the single and a 4-week mu lt iple dose study  in healthy vol unteers, GZGA, LY3502970 
doses through 24 mg were safe and well tolerated following dose escalat ion.
Although data are limited, in the 12 -week study , GZGC, in participants with T2D M, 
LY3502970 doses through 45 mg appear to be safe and tolerated fo llowing dose 
escalat ion.Furtherm ore, LY3502970 treatment through 45 mg appears to reduce glucose, 
HbA1c, and body  weight in the 12 -week study .
The select ed dose l evels and dose range will evaluate various dose escalation schemes 
and support dose exposure -response analysis o f multiple safet y and efficacy  measures to 
support select ion of dose(s) of LY3502970 with optimal benefit -risk rati o for further 
clinic al devel opment.
CONFIDENTIAL Protocol  J2A-MC-GZGE (b)
33High acute doses of GLP -[ADDRESS_1036955] scheduled procedure shown in the SoA (Secti on1.3)for the last participant in the trial 
globally .
A participant is considered to have co mpleted the study  if the part icipant has completed all 
periodsof the study  including the last vi sitor the last scheduled procedure shown in the SoA
(Secti on1.3).
CONFIDENTIAL Protocol  J2A-MC-GZGE (b)
345. Study Population
Prospective approval o f protocol  deviati ons to recrui tment and enro llment criteria, also known as 
protocol  waivers or exempt ions, is not permitted.
5.1. Inclusion Criteria
Parti cipants are eligible to be included in the study only if all o f the following criter ia apply:
Age
1.Parti cipant m ust be 18or the l egal age of  consent in the jurisdict ion in which the study is 
taking place to 75years of age inclusive, at the time of signing the inform ed consent.
Type of Participant and Disease Characteristics
2.Have been diagnosed with T2D based on the World Health Organizat ion (WHO) 
classificat ion (see Section 10.6) or other l ocally  applicable diagnostic st andards for at 
least [ADDRESS_1036956] an HbA1c value at screening o f 7.0% and 10.5% and treated with diet and 
exercise alone or with a stable dose of metformin (and not more than the l ocally approved 
dose) for at least 3 months prior to screening/Visit 1.Note : Participants from so me 
countri esmay be required to be onmetformin in order to enroll in this study.
Weight
4.Have a body  mass index (BMI) of ≥ 23 kg/m2at Visit [ADDRESS_1036957] had a stable body  weight for the 3 months prior to randomizat ion (
≤5 % body 
weight gain and/or loss )
Sexand Contraceptive/Barrier Requirements
6.Male and/or female
Contraceptive use by [CONTACT_226382] d be consistent with local regulat ions regarding the 
methods of contraception for those participat ing in clinical studies.
Women notof childbearing potential (for definit ions, see Sect ion 10.4) and men can part icipate 
in this study  consi dering the foll owing:
Male parti cipants:
oMales who agree to use highly effective/effect ive methods of contraception may  
participate in this trial.  
oPlease refer Secti on10.4 to for definit ions and addit ional guidance related to 
contraception . 
Female participants:
oWomen not of childbearing potential (WNOCBP) may participate in this trial.  
oPlease refer to Section 10.4 for definit ions and addit ional guidance related to 
contraception.
CONFIDENTIAL Protocol  J2A-MC-GZGE (b)
35Note: Hormone replacement therapy  in post -menopausal wo men is allowed but wom en m ust be 
on stabl e therapy  for 3 m onths pri or to screening/Visit 1.
Informed Consent
7.Capable of giving signed informed consent as described in Section 10.1 (Appendix 1 ),
which includes co mpliance wit h the requirements and restrictions listed in the ICF and in 
this protocol .
5.2. Exclusion Criteria
Parti cipants are excl uded from  the study  if any of the fo llowing cri teria apply:
Medical Conditions
Diabetes Related
8.Have t ype 1 diabetes mellitus (T1DM) orhistory  of ketoacidosis or hy perosm olar coma 
9.Have a history  of proliferat ive diabet ic retinopathy, diabet ic maculopathy, or severe non -
proliferat ive diabet ic retinopathy that requires immediate treatment intervent ion
10.Have had more than [ADDRESS_1036958] a history  of acute or chronic pancreat itis or elevat ion in serum 
lipase/amylase (greater than 3times the upper limit of normal [ULN]) or fast ing 
serum  triglyceride level o f >500 mg/dLat screening
Obesity Related
12. Have ob esity induced by  [CONTACT_597988] (such as Cushing’s syndrome or 
Prader -Willi syndrome)
Other Medical
13.Have a known clinically significant gastric empt ying abnorm ality (for example, severe 
diabetic gastroparesis or gastric outlet obstruction), have undergone gastric by[CONTACT_6476] 
(bariatric) surgery  or restri ctive bariatric surgery (for example, Lap -Band®), or 
chronically  take m edicat ions that di rectly affect GI mo tility
14.Have poorly  controlled hypertension ( in other words , mean seated systolic BP
160mmHg or m ean seated di astoli c BP 100mmHg)at screening , renal  artery  
stenosi s, or symptom atic postural hypotension. For parti cipants wi th uncontrolled 
hypertensio nat the screening visit, ant ihypertensive medicat ion may be started ,
and BPmust meet the protocol  criterion for hy pertensi on control  by [CONTACT_757412].
CONFIDENTIAL Protocol  J2A-MC-GZGE (b)
3615.Have a known self or family  history  (first-degree relat ive) of mult iple endocrine 
neopl asia ty pe2A or ty pe2B, thy roid C-cell hyperpl asia, or m edullary  thyroid 
carcino ma
16.Evidence of hypothy roidism or hy perthy roidism based on clinical evaluat ion 
and/or an abnormal thyro id-stimulat ing horm one that, in the opi[INVESTIGATOR_3078] n of the 
investigator, would pose a ri sk to pa rticipan t safety. Participants on a stable dose 
of thyroid replacement therapy  for at l east the pri or [ADDRESS_1036959] 6 months prior to screening:
 myocardial  infarct ion (MI), 
 unstable angina, 
 coronary  artery  by[CONTACT_9292], 
 percutaneous coronary  intervent ion (diagnostic angi ogram s are 
permitted), 
 transi ent ischemic attack (TIA), 
 cerebrovascular accident (stroke) or decompensated congestive 
heart failure , or 
 currently have [LOCATION_001] Health Associ ationClass II Ior IV heart 
failure. 
18.Have an ECG considered by [CONTACT_757413] m ay 
interfere wi th the interpretation of changes in ECG intervals at screening  
19.Medical history  ofsignificant autonomic neuropathy  as evidenced by  [CONTACT_757414],resting tachycardia, orthostati c hypotensio n, or diabet ic diarrhea
20.Have a p ersonal or fam ily history  of long QT syndrom e, family history  of sudden 
death in a first -degree relative (parents, sibling, or children) before the age of 
40years , or a personal history  of unexplained syncope within the last year. Use of 
prescri ption or over-the-counter medicat ions known to significant ly pro long the 
QT or QTc i nterval at screening.
21.Have an est imated glomerular filtration rate (eGFR) < 30mL/min/1.[ADDRESS_1036960] signs and symptoms of any other liver disease other than nonalcoho lic fatty liver 
disease (NAFLD), or any  of the f ollowing, as determined by [CONTACT_757415] 
Alanine aminotransferase (ALT )level >3.0X upper limit of normal (ULN) for 
the reference range (as determined by  [CONTACT_126158] )
alkaline phosphatase (ALP) level >1.5X ULN for the reference range, or
total bilirubin level (TBL) >1.5X ULN for the reference range (except for 
cases o f known Gilbert’s Syndrome)
CONFIDENTIAL Protocol  J2A-MC-GZGE (b)
3723.Have a serum calcitonin level (at Vi sit 1) of  
≥20 ng/L, if eGFR ≥60 mL/min/1.73 m2or 
≥35 ng/L if eGFR < 60 mL/min/1.73 m2(as determined by [CONTACT_226387] 1)
24.Have an act ive or untreated malignancy or have been in remission fro m a 
clinically significant malignancy (other than basal or squamous cell skin cancer, 
in situ carcinom as of  the cervix, or i n situ prostate cancer) for less than [ADDRESS_1036961] evidence of human immunodeficiency  virus (HIV) and/or posi tive HIV 
antibodies historically or at screening
26.Evidence of hepat itisB and/or posi tive hepat itisB surface ant igen.
27.Hepati tis C as defined by [CONTACT_226388] C virus (HCV) ribonucl eic aci d 
(RNA )or posi tive hepatit is C ant ibody  (anti-HCV). Parti cipants treated for 
hepat itis C (and diagnosed as cured) must have an RNA test at screening and also 
be RNA negat ive for at least3 years pri or to screening in order to be eligible for 
the study .
28.Have a history  of a transplanted organ (corneal transplants [keratoplast y] 
allowed).
29.Have any other condit ion (including known drug or alcoho l abuse or psy chiatric 
disorder) that, in the op inion of the invest igator, may  preclude the pa rticipant
from following and com pleting the protocol
30. H ave had a blood donation of [ADDRESS_1036962] known 
hemoglo binopathy (for example , hem olytic anemia or sickle cell anemia ), or have a 
hemoglo bin value <11 g/dL (males) or <10 g/dL (females), or any other condition known 
to interfere with HbA1c measurements
31.Have evidence of a significant, active autoimmune abnormalit
y (for example, 
lupus or rheumatoid arthrit is) that, in the opi[INVESTIGATOR_35272], is likely to 
requi re concurrent treatment with systemic glucocorticoids in the next [ADDRESS_1036963] difficult y swallowing capsules
Prior/Concomitant Therapy
34.Unless otherwise specified, all conco mitant m edicati ons shoul d be at a stabl e dose 
for at least 3 m onths pri or to randomizat ion
CONFIDENTIAL Protocol  J2A-MC-GZGE (b)
3835.Withthe exception o f stable doses of metformin, p articipant s on another OAM 
(including, but not limit ed to, sulfonylureas, DPP -4i, sodi um–glucose 
cotransport 2 inhibitors, alpha -glucosi dase inhibitors, m eglitinides) m ay be 
rando mized if the addit ional OAM treatment was discontinued at least 
3months 
prior to screening
36.Have used insulin for diabet ic control  withinthe prior year. However, short -term 
use of insulin for acute conditions is allowed ( 14days) in certain situat ions,such 
as during a hospi[INVESTIGATOR_221014] .
37.Have had any  exposure to dul agluti de, other GLP -1 analogs, or other rel ated 
compounds wi thin the pri or 3 months or any  prior history  of 
hypersensit ivity/allergies to these medicat ions. Have known or suspected 
hypersensit ivity to tri al product(s), to sel ective GLP -1 RAs or GIP/GLP -1 or 
GLP -1/GCG dual receptor agoni sts. 
Participants who previously took GLP -[ADDRESS_1036964] taken wit hin 3 months prior to screening medicat ions (prescribed or over the 
counter) or alternat ive remedies (including herbal/nutrit ional supplements) intended to 
prom ote wei ght loss
Examples include, but are not limited to:
Saxenda ®[liraglutide 3.0 mg] or other GLP- 1RA
Xenical ®[orlistat] 
Meri dia®[sibutramine] 
Acutrim ®[phenylpropano lamine] 
Sanorex ®[mazindo l] 
Adipex ®[phentermine] 
BELVIQ ®[lorcaserin] 
Qsymia ™[phentermine/topi[INVESTIGATOR_81063]] 
Contrave ®[naltrexone/bupropi[INVESTIGATOR_2394]]
WegovyTM(semaglut ide 2.4 mg), and
other similar body  weight loss medicat ion
,including over-the-counter 
(OTC )medications, for example, allī ®
39.Are receiving or have received wit hin 3 months prior to screening chronic (>2 
weeks) systemic glucocortico id therapy (excluding topi[INVESTIGATOR_2855], intraocular, intranasal, 
single intraarticular injec tion, or i nhaled preparations) or have received such 
therapy  within 4 weeks immediately prior to screening
40.Are receiving strong CYP3A inhibitors and drugs that are P-glycoprotein/breast 
cancer resistant protein ( P-gp/BCRP )substrates with narrow therapeutic index . 
Please see Sect ion 6.8concomitant medicationsfor details.
CONFIDENTIAL Protocol  J2A-MC-GZGE (b)
3941.Have a history  of use of marijuana or tetrahy drocannabino l (THC) -containing products 
within 3 m onths of enrollment or unwillingness to abstain from marijuana or THC -
containing products use during the trial
Note : If a parti cipant has used cannabidio l oil during the past 3 months but agrees to 
refrain fr om use for the durati on of  the study , the parti cipant can be enro lled.
42.Are current ly taking a central nervous system stimulant ( for example , Ritalin-
SR) with the excepti on of  caffeinated beverages at screening
43.Have an average weekly alcoho l intake that exceeds 21 units per week (males) 
and 14 units per week (females) [1 unit = 12 oz or 360 mL of beer; 5 oz or 
150mL of wine; 1.[ADDRESS_1036965] illed spi[INVESTIGATOR_17040] s].
44.Evidence of regular use of known drugs of abuse in the opi[INVESTIGATOR_3078] n of the investigator
Prior/Con current Clinical Study Experience
45.Are current ly enrolled in a clinical  study  involving an IP or any other type of medical 
research judged not to be scient ifically or medically co mpat ible with this study
46.Have part icipated, within the last [ADDRESS_1036966] ive or placebo. If the study invo lved an IP; at least [ADDRESS_1036967] ly affiliated with this study  and/or thei r immediate 
families. Immediate family  is defined as a spouse, parent, child, or sibling, whether 
biological  or legally  adopted.
51.Are empl oyees of Eli Lilly  and Com pany (Lilly ) or are em ployees o f a third-party  
organi zation involved in the study  which requi res exclusi on of their employees
52.Are, in the opi[INVESTIGATOR_3078] n of the invest igator or sponsor, unsuitable for inclusio n in the 
study
5.3. Lifestyle Considerations
Throughout the study , parti cipants may undergo medical assessment sand review of compliance 
with requirements before continuing in the study . Parti cipants will report to the clinical research 
site for safet y assessments and will remain in th e clinic unt il all procedures for that visit are 
complete and the invest igator has deemed it safe to release the participant fro m the clinic. 
CONFIDENTIAL Protocol  J2A-MC-GZGE (b)
40Per the SoA (Section 1.3), personnel will provide di abetes m anagement counseling, which will 
include instructi ons on di et and exercise and education about the signs, symptoms, and
mana gement of hyperglycemia and hypoglycemia, SMBG ,and self-inject ion .
Prescri ption or OTC medicat ions that promote weight loss are exclusio nary if used wi thin 
3months pri or to screening or between screening and rando mizat ion. These m edicat ions are al so 
not allowed at any  time during the treatment period. If started after ra ndomization, the 
medicat ions should be immediately wit hdrawn. Participant s who refuse to withdraw the weight 
loss medicati ons m ust be di scont inued fro m study  drug.  
Throughout the study , participants m ay undergo medi cal assessment sand review of complianc e 
with requirements before continuing in the study .
Meals /Diet -Parti cipants shoul d not ini tiate a structured diet and/or exercise program for weight 
reducti on during the study  other than the lifest yle and dietary measures for diabetes treatment.
For certain assessments, the participants will be required to come to the site in a fasting state, 
after an overnight fast (except for water) of at least 8 hours when clinical laboratory  assessments 
and/or weight measures are performed as specified in the S oA (Secti on1.3). 
Caffeine, Alcohol, and Tobacco- Participant s will be allowed to maintain their regular caffeine 
consumption throughout the study  period.
Alcoho l will not be permitted at least 24 hours prior to the study  site visi ts, unt il the participant 
has been discharged from the clinical research site. D aily alcohol  shoul d not exceed 3 units for 
males and 2 unit s for females .
Participants shoul dconsume no m ore than 10 cigarettes or equivalent vapi[INVESTIGATOR_757391] . 
Physical Activity -Participan ts will  be advised to maintain their regular levels of physical 
activit y/exercise during the study ; strenuous exercise within 24 hours prior to all visits shoul d be 
avoided if possible . When certain study  procedures are in progress at the site, participant s may 
be required to remain recumbent or s eated .
Blood Donation –Study  parti cipants shoul d be instructed not to donate blood or blood products 
during th e study  and f or 8 weeks fo llowing the study . 
5.4. Screen Failures
A screen failure occurs when a participant who consent sto parti cipate in the clinical study isnot 
subsequent ly rando mly assigned to study  interventio n. A minimal set of screen failure 
inform ation is required to ensure transparent reporting of screen failure participant s to m eet the 
Conso lidated Standards of Reporting Trials (CONSORT) publishing requirements and to 
respond to queries from regulatory  author ities. Minimal information includes demography , 
screen failure details, eligibilit y criteria, and any  serious adverse event (SAE) .
If, in the opi[INVESTIGATOR_3078] n of the invest igator, an ineligible lab test result is the result of an error or 
extenuat ing circumstance, then that parameter can be retested without the pa rticipant having to 
be rescreened. However, screen failures for HbA1c may  not be retested or rescreened.
CONFIDENTIAL Protocol  J2A-MC-GZGE (b)
415.5. Criteria for Temporarily Delaying 
Enrollment/Randomization/Administration of Study Intervention of 
aParticipant
Not applicable.
CONFIDENTIAL Protocol  J2A-MC-GZGE (b)
426.Study Intervention (s) and Concomitant Therapy
Study  intervent ion is defined as an y invest igational intervent ion(s), m arketed product(s), 
placebo ,or medical device (s)intended to be administered to /used by a study  parti cipant 
according to the study  protocol .
All pa rticipant s will take one capsule orally  each day  and one subcutaneous inject ion each week. 
All capsules are the same size and placebo capsules match LY3502970 capsules. Furthermore, 
the dulaglutide placebo inject ion device matches the act ive dulaglut ide inject ion device. 
Therefore, pa rticipants will not know whether they are receiving act ive LY3502970 or 
LY3502970 placebo to match , the d ose of LY3502970, or dul aglut ide 1.5 mg or dulaglut ide 
placebo to match.  
LY3502970 will be supplied in weekly  bottles wi th 10 capsules per bottle. Bottles contain 10 
capsules to account for visit windows and prevent ing pa rticipant s from missing doses eve n if it 
delays the dose escalat ion.Participants shoul d be instructed to return unused capsules.  
Disposition of Study Drug Bottles
Visit Number of Bottles of 
Capsules to be Dispensed
3 1
4 1
5-9* 2
10-13 4
14 2
*Visits [ADDRESS_1036968]. 
Dulaglut ide or matching placebo will be supplied at the monthlyvisitsas4single- dose pens .
CONFIDENTIAL Protocol  J2A-MC-GZGE (b)
436.1. Study Intervention(s) Administered
ARM Name [CONTACT_36940]350 [ADDRESS_1036969] bo
Intervention 
NameLY350 2970 LY3502970 -Placebo dulaglutide dulaglutide -
placebo
Type Drug Drug
Dose 
Formulationcapsule capsule Injectable Injectable
Unit Dose 
Strength(s)2 mg capsule LY
3 mg capsule LY
6mg capsule LY
8mg capsule LY
12mg capsule 
LY
24mg capsule 
LY
36mg capsule 
LY
45mg capsule 
LYcapsule of LY-
placebo 
to match1.5 mg/0.5 mL 
single -dose penplacebo to 
match 
dulaglutide in a 
0.5 mL single -
dose pen
Route of 
Administrationoral oral SC SC
Use experimental placebo active -comparator placebo -active -
comparator
Abbreviations: LY =LY350 2970; SC = subcutaneous .
CONFIDENTIAL Protocol  J2A-MC-GZGE (b)
446.1.1. Medical Devices
The medical devices provi ded for use in the study  are marketed prefilled single -use pens for 
dulaglut ide and prefilled single -dose pl acebo pens for dul aglut ide placebo .Any medical -device 
incidents, including those result ing from malfunct ions of the device, must be detected, 
docum ented, and reported by [CONTACT_23528] (see Sect ion 10.3.3 ).
6.2. Preparation , Handling , Storage , and Accountability
The invest igator or designee must c onfirm appropriate storage conditions have 
been maintained during transit for all study  intervent ion received and any 
discrepancies are reported and resolved before use of the study  intervent ion.
Only participants enro lled in the study  may receive study  intervent ion. Only 
authori zed study  personnel may supply , prepare, or administer study  
intervent ion. All study  interventi on must be stored in a secure, 
environmentally  controlled, and m onitored (m anual  or autom ated) area i n 
accordance with the labeled stor age condit ions wit h access limited to the 
investigator and authorized study  personnel .
The invest igator or authori zed study  personnel are responsible for study  
intervent ion accountabilit y, reconciliat ion, and record maintenance (i .e., 
recei pt, reconciliati on, and final disposit ion records).
Further gui dance and information for the final disposit ion of unused study  
intervent ions are provided in the study  training m aterials.
The study  site must store the study  drug in a l ocked and secure environment. The study  drug 
capsules may be stored at room temperature . Participant s will also be provided with single dose 
pens ( SDPs )containing dulaglutide or dulaglut ide placebo at clinic visits according to the Study  
Schedule. Dulaglut ide/matching placebo SDPs shoul d be stored refrigerated (not frozen) at 2 C 
to 8C.Dry ice should not be used for cooling. Parti cipants will also receive insulated bags with 
cooling gel packs for use in tran sporting the SDPs from the site to the hom e. Study  drug in each 
participat ing country will be labeled according to the country’s regulatory requirements.
6.3. Measures to Minimize Bias: Randomization and Blinding
All participants will be centrally assigned to r andomized study intervent ion using an interactive 
web-response system (IWRS). Before the study  is initiated, the l og in inform ation and di rections 
for the IWRS will be provided to each site.
Parti cipants will be randomly assigned to study  intervent ion in arando mizat ion rati o of 
5:5:5:5:5:3:3:3:3, including [ADDRESS_1036970] acebo injectable study  drug.
Stratificat ion will be by [CONTACT_757416]1c stratum ( ≤8.0%, >8.0% )at Visit 1.
CONFIDENTIAL Protocol  J2A-MC-GZGE (b)
45Study  intervent ion will be dispensed at the study  visits summarized in SoA (Section 1.3). 
Returned study  intervent ions should not be re -dispensed to the participants.
Blinding will be maintained throughout the conduct of the study  as described in the separate 
Blinding Plan.
Emergency  codes will be available t o the invest igator and pharmacy .A code, which reveals the 
study  interventi on (group )for a specific study  partici pant, m ay be opened during the study  only  
if the participant’s well -being requires knowledge of the participant’s treatment assignment.
If a p articipant’s study  treatment assi gnment is unblinded, the participant must be discontinued 
from the study , unless the invest igator obtains specific approval fro m a Lilly clinical research 
physician /clinical  research scient ist(CRP /CRS ) for the study  parti cipant to continue in the study . 
During the study , emergency unblinding should occur only by  [CONTACT_226390]’s 
emergency code.
In case of an emergency , the invest igator has the sole responsibilit y of determining if unblinding 
of a parti cipan t’s treatm ent assi gnment i s warranted for m edical  management of the event. The 
participant’s safet y must always be the first consideration in making such a determinat ion. 
Where feasible and when timing of the emergent situation permits, the invest igator sh ould 
attem pt to contact [CONTACT_226391] a participant’s treatment 
assignment. If the invest igator decides that unblinding is warranted, it is the responsibilit y of the 
investigator to promptly document the decisio n and rationale and notify  Lilly  as soon as possible.
6.4. Study Intervention Compliance
Parti cipant com pliance wi th study  drug will be assessed at each visit. Compliance will be 
assessed by  [CONTACT_757417] (capsules /single dose pens ). 
Study drug compliance will be determined by  [CONTACT_82374]: 
Study  drug administration data will be recorded by [CONTACT_465201].
The parti cipant s will be instructed to return any unused study drug and/or empt y 
vials at the next visit to the study  site for the purpose of performing drug 
accountabilit y.
In addit ion to the assessment of a participant’s compliance wit h the study  drug administration, 
other aspects of compliance with the study  treatm ents will  beassessed at each visit based on the 
participant’s adherence to the visit schedule, complet ion of study ,study  drug administrati on logs, 
and any  other parameters the invest igator considers necessary .
Parti cipants consi dered to be poorly compliant with thei r medicat ion, and/or the study  
procedures will receive addit ional training and instruction, as required, and will be reminded of 
the importance of complying with the protocol. Additional unscheduled visits may  be scheduled 
if study  site personnel determine that a parti cipant requi res addi tional training for the study  drug 
preparati on and inject ion techniques. 
CONFIDENTIAL Protocol  J2A-MC-GZGE (b)
466.5. Dose Modification
Participants who do not tolerate the first capsule dose escalat ion, in other words from 2 mg or 3 
mg to 6mg (or placebo equivalent), will need to discontinue from study  treatm ent. If  a 
participan t does not tol erate a dose l evel higher than 6mg for 1week (for example ,moderate -to-
severe nausea, vo miting, or diarrhea) and the investigator does not believe that the pa rticipan t 
will tol erate the dose with further exposure, then the invest igator may reduce the dose to the next 
lower target dose (for example , 3 m g, 12 m g, 24 mg, or 36 m g). If  this dose i s tolerated after 2
weeks, the dose should be increased per ori ginal protocol  dose escalation until the target dose is 
achieved. If this dose escalat ion is not tolerated, the dose should be reduced to the next lower 
target dose that was tolerated ( for example , 
3mg, 12 m g,24 m g, or 36 mg). The pa rticipant will 
remain at that dose level for the duration of the study . Maintenance doses of [ADDRESS_1036971] 
moderate to severe nausea and/or vomit ing following [ADDRESS_1036972] ions (2 weeks of treatment) and the 
investigato r believes the participant will not tolerate the injectable treatment with further dosing 
will need to discont inue the injectable study treatment. The participant should continue taking 
the capsule study  treatm ent.
In order to m aintain blinding to study  drug, the site shoul dwork through the IWRS web site 
portal  for dose m odificati ons.
6.6. Continued Access to Study Intervention after the End of the Study
LY3502970 will not be made available to participants after conclusion o f the study .
6.7. Treatment of Overdose
Capsule Study Drug
For thi s study , any total dose estimated from where the pa rticipant is in the dose -escalation 
regimen or treatment -maintenance regimen within a 48-hour time period that is greater than [ADDRESS_1036973] ion 
10.3.1 . For example, if a part icipant takes 3 45 -mg capsules within 48 hours or all o f the capsules 
in a bottl e at one time for dose escalat ions beginning with the 12 mg dose, those would be 
considered overdoses. The investigator should assume that all participants are assigned to LY 4-1 
treatm ent group if the event occurs during Week 2 through We
ek 11, and to the LY 5 treatm ent 
group after Week 11 considering where the participant would be in the dose escalat ion and how 
many capsules were taken for calculat ion of the potential overdose.
Injectable Study Drug
For thi s study , taking m ore than 1 inje ction within a 72 -hour period is considered an overdose.
Overdose Treatment
In the event of an overdose for either the capsule or the injectable study  treatm ent, the 
investigator should
CONFIDENTIAL Protocol  J2A-MC-GZGE (b)
47Contact [CONTACT_10990] .
Evaluate the participant to determine, in consultat ion with the medical mo nitor, whether 
study  interventi on shoul d be interrupted or whether the dose should be reduced.
Closely  monitor the parti cipant for any  AE/SAE and laboratory  abnorm alities for at least 
1 week. Based on the known AE profile o f LY3502970 , the fo llowing are the possible 
AEs related to an overdose:
oSevere GI events that lead to dehy dration and require m edical  intervent ion 
oCV abnorm alities such as increase in heart rate, decrease in BP, 
supraventricular arrhy thmias/cardiac conduct ion disorders
oHypoglycemia
Implement m edical intervention/mo nitoring according to the clinical presentation.
Obtain a plasma sample for PK analysis as soon as possible from the date of the last dose of 
study  interventi on if requested by  [CONTACT_426886] (determined on a case -by-case basis).
Docum ent the quanti ty of the excess dose as well as the duration of the overdose in the case 
report form ( CRF ).
6.8. Concomitant Ther apy
Allowed con comitant m edicati ons shoul d be taken according to label instructi ons. Any 
medicat ion or vaccine (including OTC or prescri ption medicines, vitamins, and/or herbal 
supplements) or other specific categories of interest) that the participant is receiving at the time 
of enro llment or receives during the study  must be recorded along wit h
reason for use
dates of administration including start and end dates
dosage information including dose and frequency for concomitant therapy  
of special interest
The medical monitor should be contact[CONTACT_757418] .  
Drugs that maybe affected by [CONTACT_226395] d be separated from study drug 
administration by [CONTACT_2669] 2 to 4 hours .
Parti cipants can not be taking strong CYP3A inducers or inhibitors and drugs that are sensit iveP-
glycoprotein /breast cancer resistan tprotein ( P-gp/BCRP )substrates with a narrow therapeutic 
index. In order to be eligible for screening into this study , those drugs need to be washed out for 
at least [ADDRESS_1036974] of strong CYP3A4 inhibitors, which are listed below:
boceprevir
cobicistat
danoprevir and ritonavir
elvitegravir and ritonavir 
CONFIDENTIAL Protocol  J2A-MC-GZGE (b)
48grapefruit juice
indinavi r and ri tonavir 
itraconazo le 
ketoconazo le 
lopi[INVESTIGATOR_5326] r and ri tonavir 
paritaprevi r and ri tonavir  
ombitasvir and/or dasabuvir
posaconazo le 
ritonavi r 
saquinavir and ritonavir 
telaprevir
tipranavir and ritonavir 
telithromycin
troleando mycin 
voriconazo le 
clarithromycin
nefazodon, 
nelfinavir
In order to be eligible for screening into this study , parti cipants taking the following ant i-fungal 
agents 
ketoconazo le 
itraconazo le 
voriconazo le, or 
posaconazole
shoul d discont inue taking these medicat ions for at least 2 weeks prior to screening. However, i f
the participant is unable to wash out these drugs, then,if appropriate ,the participant could swi tch 
to 
miconazo le
clotrimazol e,or 
fluconazo le. 
For parti cipants prescribed clarithro mycin or telithromycin , azithromycin may be considered as 
an alternative option . Participants who chronically use these drugs should be excluded.
Examples of sensit ive P-gp substrates are : 
digoxin 
fexofenadine 
loperamide 
quinidine 
talino lo
l,and
vinblast ine
Participants taking these drugs are excluded from being screened for this study .
CONFIDENTIAL Protocol  J2A-MC-GZGE (b)
49Examples of sensit ive BCRP substrates are :
coumestrol , 
daidzein, 
genistein, 
prazosin, and 
sulphasalazine
.
Participants taking these drugs are excluded from being screened for this study .
Initial doses of LY3502970 may delay  gastri c emptying and have the potential to transient ly 
impact the rate of absorption of conco mitantly admi nistered oral  medicinal products. Ifan orally  
administered drug has a narrow therapeutic index and its oral absorption is sensit ive to gastric 
emptying time, then LY3502970 and that drug should not be administered simultaneously 
because exposure to the non-study drug may be affected . It is recommended that the drugs are 
administered at least [ADDRESS_1036975] increased exposure due to 
delayed gastri c empt ying and are commo nly used in participants with T2DM :
levothy roxine
sulfo nylureas
warfarin/coumarins
ethinyl estradiol
oxycodone
6.8.1. Management of Participants with Gastrointestinal Symptoms
In the Phase 1program , the m ost comm only reported treatment -emergent adverse events 
(TEAEs) for participants receiving LY3502970 were nausea , vomiting, and diarrhea. To mit igate 
GI symptoms and manage part icipants wi th intolerable GI AEs, the invest igator should:  
Advise participan ts to eat smaller meals, for example, splitt ing 3 daily meals into 4 ,or 
moresmaller m eals, and to stop eating when they  feel full.Also, pa rticipant s may be 
inform ed that l
ower -fat m eals coul d be better tol erated.
Prescribe symptomat ic med ication (f or example, ant i-emetic or antidiarrheal medicat ion)
per local country  availabilit y and individual pa rticipant needs. Use of symptomat ic
medicat ion shoul d be captured as concomitant medicat ion in the eCRF.
Temporarily  interrupt study drug (omit 1 to 3 doses). The data related to temporary  
interrupti on of  study  treatm ent shoul d be documented i n source documents and entered 
on the eCRF.
After the interruption, restart at the same dose with the pa rticipant taking medicat ion to
alleviate their GI sympt oms.
If intolerable GI symptoms or events persist despi[INVESTIGATOR_10902], see Section 6.5.  
CONFIDENTIAL Protocol  J2A-MC-GZGE (b)
506.8.2. Hyperglycemia Rescue Medicine
Invest igators will be trained on how to apply decisio n criteria for the timing and method of 
intervent ion in pa rticipant s who do not reach glycemic targets dur ing the 26-week treatment 
period. An addi tional therapeut ic intervent ion should be considered in pa rticipant s who meet the 
following criteria :
The pa rticipant s are fully  com pliant wi th assigned therapeutic regimen .
AND
In the absence of any  acute condi tion that rai ses BGeither of the fo llowing occurs :
o During the first [ADDRESS_1036976] -randomization: An average fast ing glucose 
level above 270 mg/dL (15.0 mmo l/L) occurs over at least a 2
-week period 
(at least 4 values/week mu st be available) ; 
Or
o Average FBG >240 mg/dL (>13.3 mmo l/L) over any  2-week peri od or 
longer from Week 6 to Week 12 postrandomization;
Or
o Average FBG >200 mg/dL (>11.1 mmo l/L) over any  2-week peri od or 
longer after Week 12.
If these condit ions are met ,then participant s may begin treatment with another 
antihyperglycemic agent as determined by  [CONTACT_9682]. If treatm ent wi th another 
antihyperglycemic agent is inst ituted, then study  drug (both oral and injectable) shoul d be 
perm anent ly discont inued. Participant smay remain in the study  for safety  follow-up, but the date 
at whi ch they  begin rescue therapy  will be the last date for collect ion of efficacy measures.
CONFIDENTIAL Protocol  J2A-MC-GZGE (b)
517. Discontinuation of Study Intervention and Participant 
Discontinuation/Withdrawal
Discontinuati onof specific sites or of the study  as a who le are handled as part of Appendix 1
(Secti on 10.1).
7.1. Discontinuation of Study Intervention
In rare instances, it may be necessary  for a parti cipant to perm anent ly discont inue study  
intervent ion. If study  intervent ion is perm anent ly discontinue d, the parti cipant willremain in the 
study  to be evaluated for all planned efficacy and safet y measures . See the SoA (Secti on 1.3) for 
data to be collected at the time of discont inuat ion of study  intervent ion and fo llow-up and for any  
further evaluat ions that need to be completed.
Possible reasons leading to permanent discontinuatio n of IP:
Parti cipant Decisio n
The participant or the participant’s designee (for example, parents or legal guardian) 
requests to discont inue IP.
Invest igator Decisio n
othe invest igator decides that the pa rticipant shoul d be discont inued fro m the 
study  medicat ion
Any medicat ion for wei ght loss is given for more than 1 week
Parti cipants will be discont inued fro m the IPin the fo llowing ci rcumstances :
oDiagnosis of cirrhosis after randomizat ion (refer to Secti on [IP_ADDRESS] for details )
oPancreat itis or pancreatic cancer (refer to Secti on8.3.3.2 for details) 
oDiagnosis of medullary thyro id carcino ma (MTC) after randomizat ion
oDiagnosis of an active or untreated malignancy  (other than basal  or squam ous 
cell skin cancer, in situ carcino mas of the cervix, or in situ prostate cancer) after 
rando mizat ion  
oAny TEAE, SAE, or clinically significant laboratory  value for which the 
investigator believes that permanent study  drug di scontinuat ion is the appropriate 
measure to be taken
oA female par ticipant beco mes pregnant
oDiagnosis of T1DM or latent autoimmune diabetes in adults
If the participan t devel ops any exclusi on criteria during the course of the study , the 
investigator should call the sponsor to determine whether discont inuat ion of study  drug is 
necessary
Significant non -compliance with the protocol
Study  drug shoul d be tem porarily discont inued in any individual suspected of having a severe or 
serious allergic reaction to study  drug or other serious safet y concerns. Study  drug m ay be 
resta rted when/if it is safe to do so, in the opi[INVESTIGATOR_3078] n of the invest igator.
CONFIDENTIAL Protocol  J2A-MC-GZGE (b)
52If study  drug i s permanently discont inued, the pa rticipant shoul d rem ain in the study . The 
participant shoul dcontinue participation in the study , attend all  visits, and undergo m ost pro tocol  
procedures.  
Parti cipants discont inuing from the IPprematurely for any reason should co mplete AE and other 
follow-up procedures per Section 1.3(SoA), Section 8.3(Adverse Events and Serious Adverse 
Events), and Section 8.2(Safet y Assessments) of the protocol.  
7.1.1. Liver Chemistry Stoppi[INVESTIGATOR_226352] d be interrupted or discont inued if one or more of these condit ions occur:
Elevation Exception
ALT or AST >8x ULN
ALT or AST >5x ULN for more than [ADDRESS_1036977] >3x ULN and either TBL >2x ULN or INR >1.5 In participants with Gilbert’s syndrome, 
doubling of direct bilirubin should be used 
for drug interruption/ discontinuation 
decisions rather than TBL>2x ULN.
ALT or AST >3x ULN with the appearance of fatigue, nausea, 
vomiting, right upper quadrant pain or tenderness, fever, rash, 
and/o r eosinophilia (>5%)
ALP >3x ULN, when the source of increased ALP is the liver
ALP >2.5x ULN and TBL > 2x ULN In participants with Gilbert’s syndrome, 
doubling of direct bilirubin should be used 
for drug interruption/ discontinuation 
decisions rather than TBL>2x ULN.
ALP >2.5x ULN with the appearance of fatigue, nausea, 
vomiting, right upper quadrant pain or tenderness, fever, rash, 
and/o r eosinophilia (>5%)
Source: FDA Guidance for Industry: Drug-Induced Liver Injury: Premarketing Clinical Evaluation, July [ADDRESS_1036978] results return to baseline and if a self -limit ed non -drug 
etiology is identified.
7.1.2. QTc Stoppi[INVESTIGATOR_347082] a clinically significant finding is ident ified (including, but not limited to changes fro m baseline 
in QT interval corrected using Fridericia’s formula [ QTcF ])after enrollment, the invest igator or 
qualified designee will determine if the participant can cont inue in the study andif any change in 
participant management is needed .This review of the ECG printed at the time of collect ionmust 
be docum ented .Any new clinically relevant finding should be reported as an AE.
7.1.3. Temporary Discontinuation
After rando mizat ion, the invest igator may interrupt study  drug, for exam ple, due to an AE ( for 
example , nausea of moderate severi tyorvomit ing), or a clinically  significant l aboratory  value. If 
CONFIDENTIAL Protocol  J2A-MC-GZGE (b)
53study  drug interrupti on is due to an AE, the event is to be follow ed and docum ented. Every  effort 
shoul d be made by [CONTACT_757419], as soon as it is safe to do so (See Section 7.1.4 for restarting 
study  drug). The dates of study  drug interrupti on and restart must be documented. The data 
related to interruption of study  treatm ent will be docum ented in source documents and entered on 
the eCRF .
7.1.4. Restarting Study Drug after Interruption
Capsule Study Drug
If the number of consecut ive missed capsule doses is ≤7, the treatm ent can be restarted at the 
same dose .
Parti cipants who have missed >7 days of capsule study  drug will need to restart the study  drug at 
the 8 m g dose (LY3502970 treatment groups 2, 3, 4 -1, 4-
2, 5-1, and 5 -2) and dose escalate 
according to the protocol. LY3502970 treatment group 1 (2/3 mg group) will restart study  drug 
at [ADDRESS_1036979] igator will use the IWRS web site portal to receive the appropriate study  drug 
dispensing information to preserve blinding of the study  drug .
7.2. Participant Discontinuation/ Withdrawal from the Study
A participant may withdraw from  the study :
●at any time at his/her own request 
●at the request of his/her designee (for example, parents or legal guardian)
●at the discretion of the invest igator for safet y, behavi oral, com pliance, or 
administrative reasons
●if enro llment in any other clinical study involving an invest igational product or 
enrollment in any other type o f medical research judged not to be scient ifically or 
medically co mpat ible with this study
●if the participant , for any  reason, requi res treatm ent wi th another therapeuti c agent 
that ha s been demo nstrated to be effect ive for treatment of the study  indicat ion, 
discontinuat ion from the study  drug occurs pri or to introduction of the new agent .
Discontinuati on is expected to be uncommo n.
CONFIDENTIAL Protocol  J2A-MC-GZGE (b)
54At the time of discont inuing from the study , if possible, an early discont inuat ion visit should be 
conducted, as shown in the SoA. See the SoA (Section 1.3) for data to be collected at the time o f 
study  discont inuat ion and fo llow-up and for any  further eval uations that need to be completed.
The parti cipant will be permanently discont inued from both the study  interventi on and the study  
at that time.
If the participant withdraws consent for disclos ure of  future inform ation, the s ponsor m ay retain 
and cont inue to use any data collected before such a withdrawal o f consent .If a participant
withdraws fro m the study , he/she may  request destructi on of  any s amples taken and not tested ,
and the invest igator must document this in the site study records .
7.2.1. Discontinuation of Inadvertently Enrolled Participants
If the sponsor or invest igator ident ifies a participant who did not meet enrollment criteria and 
was inad vertently  enrolled, then the participant shoul d be di scontinued from study  treatm ent 
unless there are extenuat ing circumstances that make it medically advisable for the participant to 
continue on study  treatm ent. If the investigator and the Lilly CRP /CRS agree i t is medically 
appropriate to continue, the invest igator must obtain documented approval fro m the Lilly
CRP /CRS to allow the inadvertent ly enro lled participant to continue in the study with or without 
treatm ent wi th IP. Safet y follow-up shoul d be p erform ed as outlined in Sect ion1.3(SoA), 
Secti on8.2(Safet y Assessments) , and Section 8.3(Adverse Events , Seri ous Adverse Events, and 
Product Complaint s) of the protocol.
7.3. Lost to Follow -up
A participant will be considered lost to follow -up if he or she repeatedly fails to return for 
scheduled visits and is unable to be contact[CONTACT_17066]. Si te personnel or desi gnee are 
expected to m ake diligent attempts to contact [CONTACT_10971] a scheduled visit 
or were otherwise unable to be fo llowed up by [CONTACT_779] .
CONFIDENTIAL Protocol  J2A-MC-GZGE (b)
558. Study Assessments and Procedures
Study  procedures and their timing are summarized in the SoA (Secti on 1.3).
Immediate safet y concerns shoul d be discussed wit h the s ponsor immediately  
upon occurrence or awareness to determine if the participant should continue or 
discontinue study  interventi on.
Adherence to the study  design requi rements, including those specified in the SoA
(Secti on 1.3), is essent ial and required for study  conduct.
All screening evaluat ions must be com pleted and reviewed to confirm that
potenti al participant s meet all eligibilit y criteria. The invest igator will maint ain a 
screening log to record details o f all participant s screened and to confirm 
eligibilit y or record reasons for sc reening failure, as applicable.
8.1. Efficacy Assessments
Primary:
The primary  efficacy  measure is change fro m baseline in HbA1c , as determined by  [CONTACT_443204] .
Secondary:
The fo llowing secondary  efficacy measures will be collected at the times shown in the SoA
(Secti on 1.3).
HbA 1c as determined by [CONTACT_2237]
Fasting blood glucose ( FBG )as determined by  [CONTACT_19690]
Body weight (see Section 10.8 for measurement procedure) 
Exploratory:
BMI (see Section 10.8 for measurement procedure)
Waist circumference (see Section 10.8 for measurement proc edure)
Seven -point SMBG (see Section 10.8 for measurement procedure)
Mechanist ic biomarkers: to explore potential mechanisms o f action related to changes in 
glucose, li pid, and/or nutri ent metabolism, markers will be assessed .
Patient-reported outcomes (see Sect ion 10.9 for details )
oShort Form -36 versi on 2 Heal th Survey  acute f orm, 1 -week recall versio n
oDiabetes Treatm ent Satisfaction Questionnaire -Status Versi on 
oDiabetes Treatm ent Satisfaction Questionnaire -Change Versio n 
oParti cipant Survey
8.2. Safety Assessments
Planned time po ints for all safet y assessments are provided in the SoA (Section 1.3).
CONFIDENTIAL Protocol  J2A-MC-GZGE (b)
568.2.1. Physical Examinations
A co mplete physical examinat ion will include, at a minimum, assessments of the CV, 
respi [INVESTIGATOR_696] , GI,and neuro logicalsystems. Hei ght and weight will also be measured and recorded
as per the SoA Section 1.3. Refer to Sect ion 10.8 for further details on weight measurements.
A brief physical examinat ion will include, at a minimum, assessments of the skin, lungs, CV
system , and abdom en (liver and spleen).
Invest igators sh ould pay  special attenti on to clinical signs related to previous serious illnesses .
8.2.2. Vital Signs
For each participant , vital signs m easurements shoul d be conducted according to the 
Schedule of Act ivities (Section 1.3) and fo llowing the study -specific recommendations 
included in Section 10.8).
Any clinically  significant findings from vital signs measurement that result in a diagnosis and
that occur after the participant receives the first dose of study  intervent ion shoul d be reported to
Lilly or its desi gnee as an AE via eCRF.
8.2.3. Electrocardiograms
For each p articipant , 12-lead ECGs should be co llected according to Section 1.3.
All digital ECGs will be obtained using centrally provided ECG machines and will be 
electroni cally transmitted to a designated central ECG laboratory .
12-lead ECGs should be obtained afte r the subject has rested in a supi[INVESTIGATOR_226354] [ADDRESS_1036980] ion of blood samples for laboratory  
testing, including PK trough l evel samples.
Screening and early terminat ionECGs may be co llected as single ECGs .  All  other ECGs are to 
be recorded in triplicate ;
consecut ive replicate ECGs will be obtained at approximately [ADDRESS_1036981] ion of more ECGs than expected at a particular time point is allowed when needed to 
ensure high -qualit y records.
Electrocardiograms will init ially be interpreted by  a qualified physician (the investigator or 
qualified designee) at the site as soon after the ti me of  ECG collection as possible, and ideally  
while the pa rticipant is still present, to determine whether the participant meets entry  criteria and 
for immediate participant management, should any clinically relevant findings be identified. Any 
clinically significant findings fro m ECGs that result in a diagnosis and that occur after the 
participant receives the first dose of the invest igational treatment should be reported to Lilly or 
its designee as an AE. The invest igator (or qualified designee) is responsible for determining if 
any change in pa rticipant management is needed, and must document his/her review o f the ECG 
printed at the time of evaluat ion.
After enro llment, if a clinically significant increase in the QT/QTc interval fro m baseline or 
other clinically significant quantitative or qualitat ive change fro m baseline is identified, the 
CONFIDENTIAL Protocol  J2A-MC-GZGE (b)
57participant will be assessed by [CONTACT_324010] ( for example , palpi[INVESTIGATOR_814], near 
syncope, and syncope) and to determine whether the pa rticipant can continue in the study . The 
investigator or qualified designee is responsible for determining if any change in pa rticipant.
management is needed and must document his/her review of the ECG printed at the time of 
evaluat ion from at least 1 of the replicate ECGs from each time point.
All digital ECGs will be obtained using centrally provided ECG machines and will be 
electroni cally transmitted to a designated central ECG laboratory . The central  ECG laboratory  
will perform a basic qualit y control  check ( for example , dem ographics and study  details) and 
then store the ECGs in a database. At a future time, the stored ECG data may  be over -read by  a 
cardi ologist at the central  ECG l aboratory  for further evaluat ion of machine -read measurements 
or to m eet regul atory  requi rements.
The m achine -read ECG intervals and HRmay be used for data analysis and report -writing 
purposes, unless a cardio logist over -reading of the ECGs is conducted prior to co mpletion of the 
final study  report (in which case, the over -read data would be used).
Any treatment -emergent clinically significant ECG finding result ing in a diagnosis shoul d be 
reported as an AE in the eCRF.
8.2.4. Clinical Safety Laboratory Tests
●See Secti on10.2 (Appendix 2 )for the list of clinical laboratory tests to be 
perform ed and the So A (Section 1.3) for the timing and frequency.
●The invest igator must review the laboratory resul ts, docum ent this review, and 
report any clinically relevant changes occurring during the study as an AE . The
laboratory  resul ts must be retained wit h source documents unless a Source 
Docum ent Agreement or com parable document cites an electronic location that 
accommodates the expected retention duration. Clinically significant abnormal 
laboratory  findings are tho se which are not associated with the underlying disease, 
unless judged by [CONTACT_41411]'s condit ion.
●All laboratory  tests wi th values considered clinically  significantly abnorm al 
during participat ionin the study or within [ADDRESS_1036982] dose of study  
intervent ion shoul d be repeated until the values return to normal or baseline or are 
no longer consi dered clinically  significant by  [CONTACT_17068] m edical mo nitor.
○If such values do not re turn to normal/baseline wit hin a peri od of  time judged 
reasonable by [CONTACT_3170], the etio logy shoul d be ident ified and the 
sponsor notified.
○All protocol -requi red laboratory  assessments, as defined in Appendix 2
(Secti on 10.2), must be conducted in accordance wit h the SoA (Section 1.3), 
standard collect ion requirements.
CONFIDENTIAL Protocol  J2A-MC-GZGE (b)
58●If laboratory  values fro m non-protocol  specified l aboratory  assessments 
perform ed at an invest igator -designated local laboratory requi re a change in 
participant management or are considered clinically significant by  [CONTACT_17062] 
(for example , SAE or AE or dose modificat ion), then report the informat ion as an 
AE.
8.2.5. Pregnancy Testing 
Female participants will undergo a serum pregnancy test at screening .
8.2.6. Safety Monitoring
Lilly will periodically  review evolving aggregate safet y data wi thin the study  by [CONTACT_82393]. The study  team  will review safet y reports in a blinded fashio n(for applicable blinded 
study  period)according to the schedule provided in the Trial -Level  Safety  Review plan. Lilly  
will also review SAEs within t ime frames mandated by  [CONTACT_221056]. The Lilly 
CRP /CRS will, as appropriate, consult with the functionally independent Global Pat ient Safet y 
(GPS) therapeutic area physician or clinical scient ist. Safet y monitoring will include review of 
hepat ic, pancreat ic, CV, thyroid c-cell funct ion, and renal safet y data. The hepatic safety  
monitoring plan is provided below; for additional informat ion, please see also Section 10.5.
[IP_ADDRESS]. Hepatic Safety Monitoring
Close hepatic monitoring
Laboratory  tests ( Secti on 10.2), including AL T, AST, ALP , TBL, D. Bil, GGT , and CK, should be 
repeated within 48 to 72 hours to confirm the abnormalit y and to determine if it is increasing or 
decreasing, if one or m ore of these condit ions occur:
If a participant with baseline results 
of ... develops the following elevations:
ALT or AST <1.[ADDRESS_1036983] ≥3XULN
ALP <1.5X ULN ALP ≥2XULN
TBL <1.5X ULNTBL ≥2XULN (except for pa rticipant s with Gilbert’s 
syndrome)
ALT or AST ≥1.5XULN ALT or AST ≥2Xbaseline
ALP ≥1.5XULN ALP ≥2Xbaseline
TBL ≥1.5XULNTBL ≥1.5Xbaseline (except for pa rticipant s with 
Gilbert’s syndrome)
If the abnormalit y persists or worsens, clinical and laboratory  monitoring, and evaluat ion for 
possible causes of abnormal liver tests should be init iated by  [CONTACT_17070] -designated m edical mo nitor. At a minimum, this eva luation shoul d include physical 
examinat ion and a thorough medical history , including symptoms, recent illnesses (for example, 
heart failure, systemic infect ion, hypotension, or seizures), recent travel, history  of concomi tant 
medicat ions (including OTC ), herbal and dietary  suppl ements, history  of alcohol  drinking and 
other substance abuse. 
CONFIDENTIAL Protocol  J2A-MC-GZGE (b)
59Initially, monitoring of symptom s and hepat ic biochemical tests should be done at a frequency o f 
1 to 3 times weekly , based on the participant ’s clinical condit ion and hepat ic biochemical tests. 
Subsequently , the frequency  of monitoring may  be lowered to once every  1 to 2 weeks, if the 
participant ’s clinical condit ion and l ab resul ts stabilize. Moni toring of AL T, AST , ALP, and TBL  
shoul d cont inue unt il levels normalize o r return to approximate baseline levels.
Compr ehensive hepatic evaluation  
A comprehensive evaluat ion shoul d be perform ed to search for possible causes of liver injury  if 
one or m ore of these condit ions occur:
If a participant with baseline 
results of... develops the following elevations:
ALT or AST <1.[ADDRESS_1036984] ≥3XULN with hepatic signs/symptoms*, or
ALT or AST ≥5XULN
ALP <1.5X ULN ALP ≥3XULN
TBL <1.5X ULN TBL ≥2XULN (except for pa rticipant s with Gilbert’s syndrome)
ALT or AST ≥1.5XULN ALT or AST ≥2Xbaseline with hepatic signs/symptoms*, or
ALT or AST ≥3Xbaseline
ALP ≥1.5XULN ALP ≥2Xbaseline
TBL ≥1.5XULN TBL ≥2Xbaseline (except for p articipan ts with Gilbert’s syndrome) 
* Hepatic signs/symptoms are severe fatigue, nausea, vomiting, right upper quadrant abdominal pain, fever, rash, 
and/o r eosinophilia >5% .
At a minimum, this evaluat ion should include physical examinat ion and a thorough medical 
history , as outlined above, as well as tests for PT -INR; tests for viral hepat itis A, B, C, or E; tests 
for autoimmune hepatit is; and an abdominal imaging study  (for exam ple, ul trasound or 
computeri zed tomography [ CT]scan). 
Based on the pa rticipan t’s history  and ini tial resul ts, further testing should be considered in 
consultation wit h the Lilly -designated m edical m onitor, including tests for hepatit is D virus 
(HDV), cy tomegalovirus (CMV), Epstein -Barr vi rus (EBV), acetaminophen levels, 
acetaminophen protein adducts, urine toxico logy screen, W ilson’s disease, blood alcoho l levels, 
urinary  ethyl  glucuronide, and blood phosphat idylethano l. Based on the circumstances and the 
investigator ’s assessment of the participant ’s clinical condit ion, the investigator should consider 
referring th e parti cipant for a hepatologist or gastroenterologist consultation, magnet ic resonance 
cholangiopancreatography  (MRCP), endoscopi c retrograde cholangiopancreatography  (ERCP), 
cardi ac echocardi ogram , or a liver biopsy .  
Additional hepatic data collection (hepatic safety CRF) in study participants who have 
abnormal liver  tests during the study 
Addit ional hepatic safet y data collect ion in hepat ic safet y CRF sshoul d be performed in study  
participants who meet 1 or more of the fo llowing 5 condi tions:
1.Elevat ion of serum AL T to ≥5XULN on 2 or more consecutive blood tests (if baseline 
ALT <1.[ADDRESS_1036985])
CONFIDENTIAL Protocol  J2A-MC-GZGE (b)
60In parti cipants wi th baseline ALT ≥1.5X ULN, the thresho ld is ALT ≥3Xbaseline 
on 2 or more consecutive tests
2.Elevated TBL  to ≥ 2XULN (if baseline TBL  <1.[ADDRESS_1036986]) (except for cases of known 
Gilbert ’s syndrom e)
In parti cipants wi th baseline TBL  ≥1.5X ULN, the thresho ld should be TBL  ≥2X
baseline
3.Elevat ion of serum ALP to ≥2XULN on 2 or more consecutive blood tests (if baseline 
ALP <1.[ADDRESS_1036987])
In parti cipants wi th baseline ALP ≥1.5X ULN, the thresho ld is ALP ≥2Xbaseline 
on 2 or more consecutive blood tests
4.Hepati c event consi dered to be a SAE
5.Discontinuati on of  study  drug due to a hepati c event 
Note: the interval between the two consecut ive blood tests should b e at l east [ADDRESS_1036988] Complaints
The definit ions of the fo llowing events can be found in Appendix 3 (Secti on 10.3):
AEs
SAEs
Product complaints (PCs)
These events will be reported by  [CONTACT_17071] (or, when appropriate, by  a caregiver, surrogate, 
or the participant's legally authorized representative).
The invest igator and any qualified designees are responsible for detecting, documenting, and 
recording events that meet these definit ions and remain responsible for fo llowing up events that 
are seri ous, considered related to the study  intervent ion or stud y procedures, or that caused the 
participant to di scont inue the study  drug. (see Sectio n7).
Care will  be taken not to introduce bias when detecting events. Open -ended and non -leading 
verbal quest ioning of the participant is the preferred method to inquire about event occurrences.
For some studies, participants are not always able to provide valid verbal responses to 
open -ended quest ions. In these circumstances, another method of detecting events must be 
specified.
After the init ial report, the invest
igator is required to proactively follow each participant at 
subsequent visits/contacts. All SAEs and AEs o f speci al interest (as defined in Sect ion 8.3.3 ) will 
be followed unt il resolution, stabilization, the event is otherwise explained, or the participant is 
lost to foll ow-up (as defined in Section 7.3). For PCs, the invest igator is responsible for ensuring 
that follow-up includes any supplemental invest igations as indicated to elucidate the nature 
and/or causalit y. Further informat ion on f ollow-up procedures i s provi ded in Appendix 3
(Secti on 10.3).
8.3.1. Timing and Mechanism for Collecting Events
Thistable describes the timing, deadline s,and m echanism for collect ing events.
CONFIDENTIAL Protocol  J2A-MC-GZGE (b)
61Event Collection 
StartCollection 
StopTiming for Reporting to 
Sponsor or DesigneeMechanism for 
ReportingBack -up 
Method 
of 
Reporting
Adverse Event
AE start of 
study drugparticipation 
in study has 
endedShould be recorded in the 
eCRF as soon as possible.  
The sponsor will 
periodically evaluate 
safety data in the eCRF.AE eCRF N/A
Serious Adverse Event
SAE and 
SAE updates 
–prior to 
start of study 
interventio n 
anddeemed 
reasonably 
possibly 
related with 
study 
proceduressigning of 
the informed 
consent 
form (ICF ) start of 
interventio nWithin 24 hours of 
awarenessSAE eCRF SAE 
paper 
form
SAE and 
SAE updates
–after start 
of study 
interventio nstart of 
interventio nparticipation 
in study has 
endedWithin 24 hours of 
awarenessSAE eCRF SAE 
paper 
form
SAE *–after 
participant’s 
study 
participation 
has ended 
andthe 
investigator 
becomes 
awareAfter 
participant’s 
study 
participation 
has endedN/A Promptly SAE paper form N/A
CONFIDENTIAL Protocol  J2A-MC-GZGE (b)
62Event Collection 
StartCollection 
StopTiming for Reporting to 
Sponsor or DesigneeMechanism for 
ReportingBack -up 
Method 
of 
Reporting
Pregnancy
Pregnancy 
in female 
participants 
and female 
partners of 
male 
participantsAfter the 
start of 
study 
interventio n90 days or [ADDRESS_1036989] 
participant 
visitWithin 24 hours (see 
Section 8.3.2)Pregnancy paper 
formSAE 
paper 
form
Product Complaints
PC
associated 
with an SAE
or might 
have led to 
an SAEStart of 
study 
interventio nEnd of study 
interventio nWithin [ADDRESS_1036990] Complaint 
formN/A
PC not 
associated 
with an SAEStart of 
study 
interventio nEnd of study 
interventio nWithin [ADDRESS_1036991] Complaint 
formN/A
Updated PC 
information— — As soon as possible upon 
site awarenessOriginally completed 
Product Complaint 
form with all changes 
signed and dated by 
[CONTACT_134108]/A
PC (if 
investigator 
becomes 
aware)Participation 
in study has 
endedN/A Promptly Product Complaint 
form
*Serious adverse events should not be reported unless the investigator deems them to be possibly related to study 
treatment or study participation.
8.3.2. Pregnancy
Collection of pregnancy information
Male participants w ith partners who become pregnant
CONFIDENTIAL Protocol  J2A-MC-GZGE (b)
63●The invest igator will attempt to collect pregnancy info rmation on any male 
participant’s female partner who beco mes pregnant while the male participant is 
in this study . This applies only  to m ale parti cipants who receive study  drug.
●After obtaining the necessary  signed informed consent from the pregnant female 
partner direct ly, the invest igator will record pregnancy informat ion on the 
appropriate form and submit it to the sponsor within 24 hours of learning of the 
partner’s pregnancy. The female partner will also be fo llowed to determine the 
outcom e of the pregnancy . Informati on on the status of the mother and child will 
be forwarded to the sponsor. Generally, the fo llow-up will be no longer than [ADDRESS_1036992] imated de livery date. Any terminat ion of the pregnancy 
will be reported regardless of gestational age, fetal status (presence or absence of 
anomalies) or indicat ion for the procedure. 
Female participants who become pregnant
●The invest igator will co llect pregnanc y information on any female participant 
who beco mes pregnant while part icipating in this study . The init ial inform ation 
will be recorded on the appropriate form and submitted to the sponsor within 24 
hours of learning of a parti cipant's pregnancy . 
●The p articipant will be fo llowed to determine the outcome of the pregnancy . The 
investigator will co llect fo llow-up inform ation on the participant and the neonate 
and the information will be forwarded to the sponsor. Generally, fo llow-up will 
not be required fo r longer than 6 to 8 weeks bey ond the estimated delivery  date. 
Any terminat ion of pregnancy  will be reported, regardl ess of gestati onal age, fetal 
status (presence or absence of anomalies) or indication for the procedure.
●While pregnancy  itself is not co nsidered to be an AE or SAE, any  pregnancy  
complicat ion or el ective terminat ion of a pregnancy  for m edical  reasons will be 
reported as an AE or SAE. 
●A spontaneous abortion (occurring at <20 weeks gestational age) or still birth 
(occurring at ≥20 weeks gestational age) is always considered to be an SAE and 
will be reported as such. 
●Any post -study pregnancy related SAE considered reasonably related to the study 
intervent ion by [CONTACT_170272] 8.3.[ADDRESS_1036993] igator is not obligated to actively seek this 
inform ation in former study  parti cipants, he or she may learn o f an SAE thr ough 
spontaneous reporting.
●Any female part icipant who becomes pregnant while participat ing in the study  
will discont inue study  intervent ion.If the participant is discont inued from the 
study , follow the standard di scont inuat ion process and cont inue direct ly to the 
follow-up phase. The fo llow-up on the pregnancy  outcome shoul d continue 
independent of intervent ion or study  discontinuat ion. 
8.3.3. Adverse Events of Special Interest 
The fo llowing are AEs that will be adjudicated by  [CONTACT_757420]  J2A-MC-GZGE (b)
64 pancreat itis (see Sect ion [IP_ADDRESS] )
 major adverse CVevents (see Section [IP_ADDRESS] ), 
 supraventricular a rrhythmias and cardiac conduction disorders (Section [IP_ADDRESS] )
 drug-induced liver injury ,and
 deaths.
The fo llowing are addi tional adverse events of speci al interest (AESI)
 hypoglycemia (Level 2 and 3)
 severe persistent hy perglycemia
 thyroid malignancies and C -cell hyperpl asia
 hepatobiliary  disorders
 severe GI AEs , and
 acute renal events.
Sites shoul d collect addi tional details and data regarding these AEs, as instruc ted on the 
applicable eCRFs, and detailed below.
[IP_ADDRESS]. Hypoglycemia 
Upon ICF signing, all participants will be educated about signs and symptoms of hypoglycemia,
how to treat hy poglycemia, and how to collect appropriate informat ion for each epi[INVESTIGATOR_757392].
Parti cipants who devel op persi stent or recurrent unexplained hypoglycemia during the treatment 
period will be asked to reduce the dose or discont inue any conco mitant gl ucose -lowering agents 
other than study  drug. Study  drug discont inuat ion for recurre nt hypoglycemia shoul d be 
considered only if these events continue despi[INVESTIGATOR_757393].
All hypoglycemic epi[INVESTIGATOR_134055] a specific eCRF and shoul d not be recorded as 
AEs unless the event meets serious criteria. If a hypoglycemic event meets severe criteria (see 
definit ion below), i t shoul d be recorded as serious on the AE and SAE eCRFs, and reported to 
Lilly as an SAE.
Invest igators should use the fo llowing definit ions and criteria when diagnosing and c ategori zing 
an epi[INVESTIGATOR_105397] (the BG values in this sect ion refer to values 
determined by a laboratory  or Internati onal Federati on of  Clinical  Chemistry  and Laboratory  
Medicine blood -equival ent gl ucose m eters and strips) in accordance with the 2020 American 
Diabetes Association posit ion statem ent on glycemic targets (ADA 2020) as below. Level [ADDRESS_1036994] :
Level 1 hypoglycemia: 
Glucose <70 mg/dL (3.9 mmol/L) and ≥ 54 mg/dL (3.0 mmol/L): Level [ADDRESS_1036995] -acting carbohydrates. Providers 
should continue to counsel partic ipants to treat hypoglycemia at this glucose alert value.
CONFIDENTIAL Protocol  J2A-MC-GZGE (b)
65Level 2 hypoglycemia: 
Glucose <54 mg/dL (3.0 mmol/L): This isalso referred to as documented or BGconfirmed 
hypoglycemia with glucose <54 mg/dL (3.0 mmo l/L). This glucose threshold is clinically 
relevant regardless of the presence of absence of symptoms of hypoglycemia. 
Level 3 hypoglycemia: 
Severe hypoglycemia (in adults): A severe event characterized by [CONTACT_226405]/or 
physical status requiring assistance for treatment of hypoglycemia. For example, p articipants
hadaltered mentalstatus, and cou ld not assist in their own care, or were semiconscious or 
unconscious, or experienced comawithorwithout seizures, andthe assistance of another 
person was needed to actively  administer carbohydrate, glucagon, or other resuscitative
actions. Glucose measurements may not be available during such an event, but neurological 
recovery attributable to the restoration of glucose concentration tonormal isconsidered
sufficient evidence that the event was induced by [CONTACT_226406].
The determinat ion of a hypoglycemic event as an epi[INVESTIGATOR_144033], as defined above, is made by  [CONTACT_317782] a participant simply  having rece ived assistance.
If a hypoglycemic event meets the criteria of severe hypoglycemia, the 
investigator must record the event as serious on the AE CRF and report it to 
Lilly as an SAE.
Nocturnal hypoglycemia :
Nocturnal hypoglycemia is a hypoglycemia event (including severe hypoglycemia) that 
occurs at night and presumably during sleep.
[IP_ADDRESS]. Pancreatitis 
Diagnosis of acute pancreatitis
Acute pancreat itis is an AE of interest in all studies with LY3502970, including this study. The 
diagnosis of acute pancreat itis requi res 2 of the following 3 features ( Banks and Freeman 2006
): 
abdo minal pain, characterist ic of acute pancreat itis (that i s, epi [CONTACT_24365] c pain 
radiating to the back, often associated with nausea and vo miting)
serum  amylase (total, pancreat ic, or both) an d/or lipase ≥3X ULN
characterist ic findings of acute pancreat itis on CT scan or magnet ic resonance 
imaging (MRI)
If acute pancreat itis is suspected, the invest igator should
obtain appropriate laboratory  tests, including pancreatic amylase and lipase
perfor m imaging studies, such as abdo minal CT scan wit h or without contrast, 
or abdominal MRI, and
CONFIDENTIAL Protocol  J2A-MC-GZGE (b)
66evaluate for possible causes of acute pancreatit is, including alcoho l use, 
gallstone or gall bladder disease, hypertriglyceridemia, and conco mitant 
medicat ions.
Discontinuation for acute pancreatitis
If acute pancreat itis is suspected by [CONTACT_3170] , the participant must temporarily discont inue 
use of the IP. In this case, the participant needs to receive an appropri ate alternat ive glucose 
lowering regimen . Afterwards, if pancreat itisis confirmed by  [CONTACT_757421], the IP 
must be permanent ly discont inued ,and the participant needs to be followed throughout the 
durati on of  the study . If the case i s not confirmed, then the participant can restart the IP if the 
investigator deems as clinically appropriate as described in Section 6.5(Dose Modificat ion).
Case adjudication and data entry
An independent clinical endpo int committee (CEC) will adjudicate all suspected cases of acute 
pancreat itis. Relevant data fro m participants wi th acute pancreatit is will be entered into a 
specifically designed eCRF page. The adjudicat ion committee represent ative will enter the 
resul ts of adjudicat ion in acorresponding eCRF page.
Asymptomatic elevation of pancreatic amylase and/or lipase
Serial measures of pancreat ic enzymes have limit ed clinical value for predicting epi[INVESTIGATOR_757394] s (Nauck et al . 201 7; Steinberg et al. 2017a, 
2017b). Therefore, further diagnostic fo llow
-up of  cases o f asymptom atic el evati on of  pancreat ic 
enzymes (lipase and/or pancreat ic amylase ≥3X ULN) i s not m andated but m ay be performed 
based on the invest igator’s clinical judgment and assessment of the participant’s overall clinical 
condi tion.
[IP_ADDRESS]. Thyroid Malignancies and C -Cell Hyperplasia 
Individuals with personal or family history  of MTC and/or MEN2 will be excluded fro m the 
study . Parti cipants who are diagnosed with MTC and/or MEN2 during the study  will have study  
drug stopped and should cont inue follow-up wi th an endocrino logist. Addit ionally, parti cipants 
who have a serum calcitonin level o f ≥20 ng/L, if eGFR ≥ 60 mL/min/1.73 m2or ≥35 ng/L i f 
eGFR < 60 mL/min/1.[ADDRESS_1036996] asms (including MTC ,papi[INVESTIGATOR_757395], and others ) and measurements of calcitonin. 
These data will be captured in specific eCRFs. The purpose of calcitonin measurements is to 
assess the potential of LY3502970 to affect thy roid C-cell funct ion, which may indicate 
development of C -cell hyperpl asia and neop lasms.
If an increased calcitonin value (see definit ions below) is observed in a participan t who has been 
administered a medicat ion that is known to increase serum calcitonin , then this medicat ion 
shoul d be stopped ,and calcitonin levels should be measured after an appropriate washout period.
For participan tswho require addit ional endocrine assessment because of increased calcitonin 
concentration as defined in this sect ion, data from the fo llow-up assessment will be co llected in 
the specific sect ion of the eCRF.
CONFIDENTIAL Protocol  J2A-MC-GZGE (b)
67Calcitonin Measurements in Participants with eGFR ≥60 mL/min /1.73 m2
A significant increase in calcitonin for participants with eGFR ≥60 mL/min/1.73 m2is defined 
below. If a participant ’s laboratory  resul tsmeet th esecriteria, these clinically  significant 
laboratory  resul tsshoul d be recorded as an AE. 
Serum calcitonin value ≥20 ng/L and <35 ng/L AND ≥50% increase from the screening 
value. These participants will be requested to repeat the measurement within 1 month. If 
this repeat value is increas ing (≥10% increase), the study  drug shoul d be discontinued, 
and the participant shoul dundergo addi tional endocrine assessment and longer -term 
follow
-up by  [CONTACT_757422].
Serum calcitonin value ≥35 ng/L AND ≥50% over the screening value . In these 
participants , study  drug shoul d be discont inued, and the participant shoul d be 
recommended to immediately undergo addit ional endocr ine assessments and longer -term 
follow
-up by  [CONTACT_1629] e ndocrino logist.
Calcitonin Measurement in Participants with eGFR <60 mL/min /1.73 m2
A significant increase in calcitonin for participants with eGFR <60 mL/min /1.73 m2is defined as 
a serum calcitonin value ≥35 ng/L AND ≥50% over the screening value. If a participant ’s labs 
meet th esecriteria, these clinically  significant l abs shoul d be recorded as an AE. 
In these participants, if the increased concentration of calcitonin is confirmed, the parti cipant 
must be recommended to immediately undergo addit ional endocr ine assessments and longer -
term follow
-up by  [CONTACT_757423] .
[IP_ADDRESS]. Major Adverse Cardiovascular Events 
Nonfatal CVAEs will be adjudicated by  a commi ttee of  physicians external to Lilly  with 
cardi ology expertise. This committee will be blinded to treatment assignment. The nonfatal CV
AEs to be adjudicated include
myocardial  infarct ion 
hospi [INVESTIGATOR_34069]
hospi [INVESTIGATOR_226360]
coronary  intervent ions (such as coronary  artery by[CONTACT_261780]), and 
cerebrovascular events, including cerebrovascular accident (stroke) and transient 
ischemic attack.
[IP_ADDRESS]. Supraventricular A rrhythmias and Cardiac Conduction Disorders
Treatment -emergent cardiac conduc tion disorders will be further evaluated. Participants who 
develop any event from these groups of disorders should undergo an ECG, which should be 
submitted to the central reading center. Additional diagnostic tests to determine exact diagnosis 
shoul d be p erformed, as needed. The specific diagnosis will be recorded as an AE. Events that 
meet criteria for serious conditions as described in Section 10.3.2 mustbe reported as SAEs. 
CONFIDENTIAL Protocol  J2A-MC-GZGE (b)
[IP_ADDRESS]. Deaths
All deaths will be adjudicated by  a commi ttee of  physicians external to Lilly . This commi ttee 
will be blinded to treatment assignment.
[IP_ADDRESS]. Hepatobiliary Disorder s
All events of TE biliary  colic, chol ecyst itis,cholelithi asisor other suspected events related to 
acute gallbladder disease should be evaluated and addit ional diagnost ic tests performed, as 
needed. In cases of elevated liver markers, hepat ic monitoring shoul d be ini tiated as outlined in 
Secti on [IP_ADDRESS] .
[IP_ADDRESS]. Severe Gastrointestinal Adverse Events 
LY3502970 and dulaglut ide may cause severe GI AEs, such as nausea, vo miting, and diarrhea. 
Inform ation about severe GI AEs as well as ant iemetic or anti diarrheal  use will  be collected in 
the AE and c onco mitant medicat ions eCRF s, respectively. For detailed informat ion concerning 
the management of GI AEs, please refer to Secti on6.8.1.
[IP_ADDRESS]. Acute Renal Events
Renal safety  will be assessed based on repeated renal funct ional assessment as well as 
assessment of AEs s uggest ive o f acute renal failure or worsening of preexist ing chroni c renal  
failure . 
Gastrointestinal AEs have been reported wit h LY3502970 including nausea, diarrhea, 
and vo miting.This is consistent with other GLP-1R agoni sts (Aroda and Ratner 2011). The 
events may lead to dehy dration, which could cause a deterioration in renal function, including 
acute renal failure. Participants shoul d be advised to notify  invest igators in case of severe nausea, 
frequent vomit ing, or symptoms of dehydrat ion.
8.4. Pharmacokinetics
Bloodsamples will be collected from all rando mized participants in ac cordance wi thschedule 
provi ded in Sect ion 1.3and at ET for measurement of plasma concentrati ons of LY3502970. 
Participants may  need to return to the clinical site for PK -specific visits to provide post -dose PK 
samples dependent on the t ime window of PK sampling . Only  samples from  parti cipants 
assigned to treatment with LY3502970 will be analyzed for drug concentration. 
Date and time o f each sample and the most recent LY3502970 dose pri or to PK blood draw must 
be recorded. Drug concentra tion informati on that woul d unblind the study  will not be reported to 
study  sites or blinded personnel while the study  is blinded. 
Samples will  be analyzed at a l aboratory  approved by  [CONTACT_17077] a facilit y 
designated by  [CONTACT_456]. Concentrations of LY3502970 will be assayed using a validated 
liquid chro matography  mass spectrom etry method. Analyses of samples collected from 
participants who received placebo or dulaglut ide are not planned. Bioanalyt ical samples 
collected to measure IP concentrations will be retained for a maximum o f [ADDRESS_1036997] ion and handling of blood sam ples will  be provi ded by [CONTACT_456].
CONFIDENTIAL Protocol  J2A-MC-GZGE (b)
698.5. Pharmacodynamics
Efficacy measures will be used as indicators of pharmacodynamic response.
8.6. Genetics
Not applicable .
8.7. Biomarkers
In addit ion to the planned bio marker research as indicated in the SoA ( Section 1.3), bio marker 
research on stored nonpharmacogenetic samples may beperformed to address questions of 
relevance to drug disposit ion, target engage ment, PD, mechanism  of acti
on, vari ability of 
participant response (including safet y), and clinical outcome. Sample co llection is incorporated 
into clinical  studi es to enable examinat ion of these questions through measurement of 
biomolecules including prot eins, lipi[INVESTIGATOR_805], and other cellular elements .
Serum  and plasma samples for nonpharmacogenetic bio marker research will be co llected at the 
times specified in the SoA (Secti on1.3)where local regulat ions allow.
Samples may beused for research on the drug target, disease process, variable response to 
LY3502970, pathway s associ ated wi th diabetes mellitus and related clinical traits or 
complicat ions, including nonalcoho lic steatohepatitis or obesit y, mechanism  of action of 
LY3502970, and/or research method, or for validating diagnost ic tools or assay(s) related to 
diabetes m ellitus, related clinical traits, or complications .
All samples will be coded w ith the p
articipant number. These samples and any data generated 
can be linked back to the participant only by [CONTACT_757424]. 
Samples will  be retained at a facilit y selected by  [CONTACT_82395] a m aximum  [ADDRESS_1036998] igation of variable response that may not be observed unt il later 
in the development of LY3502970 or after LY3502970 becomes co mmercially available.
8.8. Immunogenicity Assessments
Not applicable .
8.9. Health Economic s
Not applicable .
CONFIDENTIAL Protocol  J2A-MC-GZGE (b)
709. Statistical Considerations
9.1. Statistical Hypotheses
The study  hypothes is for the primary object ive is that at least one dose l evel of QD oral doses of 
LY3502970 is superior in change fro m baseline for HbA1c relat ive to placebo at Week 26, in 
participants wi th T2DM inadequately controlled wit h diet and exercise alo ne or treate d with a 
stable dose of met formin.
9.1.1. Multiplicity Adjustment
Treatment comparisons will be performed for the primary  object ive at the full significance level 
of 0.05. No m ultiplicity adjustm ents will be m ade for the analysis of secondary  and expl oratory  
objectives.
9.2. Analyses Sets
For the purposes of analysis, the fo llowing analysis popul ation and data sets are defined:
Participant Analysis 
Population /DatasetsDescription
Entered Participants All p articipants who sign informed consent .
Randomized All participants who are randomly assigned a study drug. 
Efficacy Analysis Set (EAS) Data obtained during the treatment period from a ll random ized participants 
who are exposed to at least 1 dose of study drug . Excludes data after 
permanent discontinuation of study drug or initiation of rescue medication . 
Participants will be included in the treatment group to which they were 
randomly  assigned.  
Full Analysis Set(FAS) Data obtained during the treatment period from a ll random ized participan ts 
who are exposed to at least 1 dose of study drug , regardless of adherence to 
study drug or initiation of rescue medication . Participants will be included in 
the treatment group to which they were randomly  assigned.  
Safety Analysis Set(SS) Data obtained during the treatment period plus safety follow -up from all 
random ized participants who are exposed to at least 1 dose of study drug , 
regardless of adherence to study drug or initiation of rescue medication . 
Participants will be included in the treatment group to which they were
randomly  assigned.  
CONFIDENTIAL Protocol  J2A-MC-GZGE (b)
719.3. Statistical Analyses
9.3.1. General Considerations
Statistical analysis o f this study  will be the responsibilit y of Lilly or i ts desi gnee. Any  change to 
the data analysis methods described in the protocol will require an amendment ONLY if it 
changes a principal feature of the protocol. Any other change to the data analysis methods 
described in the protocol, and the just ificat ion for making the change, will be described in the 
statist ical analysis plan (SAP) or the clinical study  report (CSR). Additional exploratory  analyses 
of data will be conducted, as deemed appropriate.
Unless otherwise noted, all tests of treatment effects will be conducted at a 2 -sided alpha level o f 
0.05, and confidence intervals ( CIs )will be calculated at 95%, [ADDRESS_1036999] non -missing measurement at or before randomization visit (prior to 
first dosing of study  drug) unless otherwise specified. 
The primary  estimand (a precise definit ion of the treatment effect to be estimated) of interest in 
comparing efficacy of LY3502970 doses with placebo is the “efficacy est imand ”(Sect ion 2.3.1 ).
The primary  efficacy  assessment gui ded by [CONTACT_941] “efficacy est imand” will be conducted using the 
EAS (Secti on9.2).To estimate the “efficacy  estimand”, w hen change from baseline is included 
as a response variable of analysis models, the participants will be included in the analysis only if 
a baseline and at least [ADDRESS_1037000] m odel repeated m easures (MMRM) analysis will be used to 
analyze continuous longitudinal variables . All the longitudinal observations at each scheduled 
postbaseline visit will be included in the analysis. The model for the analysis of the primary 
efficacy  endpoint of change from baseline in HbA1c will include the fixed class effects of 
treatm ent(placebo, dulaglut ide, LY1, LY2, LY3, LY4 -1, LY 4-2, LY 5-1, LY5 -2), strata
(country , HbA1c stratum [≤8%, >8% ]), visit, and treatment -by-visit interact ion, as well as the 
continuous, fixed covariate of basel ine value. An unstructured covariance structure will be used 
to model the wi thin-participant errors. Significance tests will be based on least squares (LS) 
means and Ty pe III tests. If thi s analysis fails to converge, the following covariance structures 
will be tested in order:
Toeplitz with heterogeneit y
Autoregressive with heterogeneit y 
Com pound symmetry  with heterogeneous variances 
Toeplitz 
Autoregressive
Com pound symmetry  without heterogeneous variances 
The first covariance structure that converges will be used. The Kenward- Roger approximat ion 
will be used to estimate deno minator degrees of freedom.
Addit ional supplemental  estimands may be explored for the primary and secondary efficacy 
endpo ints.
CONFIDENTIAL Protocol  J2A-MC-GZGE (b)
72Unless specified otherwise, safet y assessments will be guided by  [CONTACT_226415]3502970 doses wi th placebo and dulaglut ideirrespect ive of adherence to study  drug. Thus, 
safet y analyses will be conducted using the SS.
For continuous measures, summary statist ics will include sample size, m ean, SD, m edian, 
minimum, and maximum for both the actual and the change fro m baseline measurements. LS 
means and standard errors derived from the analysis models will also be displayed for the change 
from baseline measurements. Treatment comparisons will be displayed showing the treatment 
difference LS means and the 95% CIs for the treatment differences, alo ng with the p- values for 
the treatment comparisons. 
For categorical measures, summary  stati stics will include sample size, frequency, and 
percentages. A logistic regressio n model with treatment and strata as fixed effects and the 
continuous baseline value as a covariate will be used to examine the treatment difference in 
binary  efficacy outcom es.Fisher’s exact test or Pearson’s chi -square test will be used for 
treatm ent com parisons in other categorical outcomes .
Other stati stical methods may be used, as appropriate, and details will be described in the SAP.
9.3.2. Primary Endpoint (s)/Estimand(s) Analysis
The primary  efficacy  assessment, gui ded by [CONTACT_941] “efficacy  estimand” , will be conducted using the 
EAS for the primary endpo int (change from baseline in HbA1c at Week 26). 
For the “efficacy  estimand ”, the hy potheti cal strategy  is used to handle the intercurrent events 
(permanent discontinuation of study  drug orinitiationof rescue medicat ion), so only data 
collected before the occurrence of any intercurrent events will be used in the MMRM analysis
(Secti on9.3.1 ) through which the potential efficacy  measures (after the intercurrent events) had 
participant s had not intercurrent events will be implicit lyimputed. 
The primary  efficacy  com parison will  be based on the contrast between each treatm ent group of 
LY3502970 and placebo at Week 26 (Visit 1 5) from the MMRM analysis of change from 
baseline in HbA1c using the EAS ( Secti on9.2). The analysis model and select ion of covariance 
structure is described in Sect ion 9.3.[ADDRESS_1037001] ical power, the evaluat ion of the primary  endpoint for LY 4(36 mg) and LY5 (45 m g)will 
be made by [CONTACT_757425] s, 
i.e.,combine LY4-[ADDRESS_1037002] ive at the full significance level 
of 0.05.
9.3.3. Secondary Analyses
The following secondary  study  objectives will be analyz ed on the EAS: 
Difference between LY3502970 and dulaglut ide in change fro m baseline in HbA1c at 
Week 26 
Percentage of participants with HbA1c ≤6.5% and of <7.0% at Week 26
Change from baseline in fast ing BGat 26 weeks
Change from baseline in body  weightat Week 26
Percent change in body  weight f rom baseline at Week 26
CONFIDENTIAL Protocol  J2A-MC-GZGE (b)
73Percentage of participants with ≥5%, ≥10% body  weight loss from baseline at Week 26
Actual  and change from  baseline in HbA1c, FBG, and body  weight, and percent change in body  
weight will be analyzed by  [CONTACT_757426] m odel for the “efficacy  estimand ” as described in 
Secti on 9.3.1 .
Treatment comparisons for the percentage of participants with HbA1c <7.0% and ≤6.5% and 
percentage of participants with ≥5%, ≥10% body  weight loss will  be analyzed using a logistic 
regression wit h treatm ent and strata as fixed effects and the continuous baseline value as a 
covari ate.  
9.3.4. Tertiary/ Exploratory Analysis
ABayesian approach will be used as the dose –response model for change in HbA1c and body  
weight from baseline to the [ADDRESS_1037003] ionary for Regul atory  
Activities (MedDRA) and reported with preferred terms and s ystem  organ cl ass. Sel ected notabl e 
AEs of interest may be reported using high -level term s or Standardized MedDRA Queries. 
Summary  statistics will be provided for incidence of TEAEs, SAEs, study  discontinuati on due to 
AEs, study  drug di scontinuati on due to AEs, deaths, and other CV endpoints. Counts and 
proporti ons of  parti cipants experiencing AEs will be reported for each treatment group, and 
Fisher’s exact test will be used to compare the treatment groups.
[IP_ADDRESS]. Adverse Event of Special Interest
Summaries and a nalyses for incidence of AESIs will be provided by [CONTACT_3148]. The details of 
analysis of AESI (as defined in Sect ion 8.3)will be provided in the SAP.
[IP_ADDRESS]. Other Adverse Event Assessments 
[IP_ADDRESS].1. Gastrointestinal Events
Summaries and analyses for incidence and severit y of nausea, vo miting, and diarrhea will be 
provi ded by [CONTACT_91014].
[IP_ADDRESS].2. Hypoglycemia Events 
Hypoglycemic events will be analyzed. Inci dence and rate of hypoglycemia will be reported. 
Some analyses m ay be conducted excluding data after introducing another antihyperglycemic 
therapy .
CONFIDENTIAL Protocol  J2A-MC-GZGE (b)
[IP_ADDRESS]. Central Laboratory Measures, Vital Signs, and Electrocardiograms 
Actual and change fro m basel ine to postbaseline values of central laboratory measures, vital 
signs, and selected ECG parameters will be summarized at each scheduled visit. Continuous 
variables, as well as the change fro m baseline for these vari ables, will be analyzed by [CONTACT_757427] 9.3.1 .The percentages of participants with treatment -emergent 
(TE) abnorm al, high, or l ow m easures (including laboratory , vital, and ECG parameters) will be 
summarized and co mpared between treatment groups using Fisher’s exact test.
9.3.6. Pharmacokinetic/Pharmacodyna mic Analyses
LY3502970 concentration data will be summarized and analyzed using a populat ion PK 
approach via nonlinear mixed -effects m odeling. The relationships between LY3502970 dose 
and/or concentration and selected efficacy, tolerabilit y, and safet y endpoints m ay be 
characterized. Addit ionally, the impact of intrinsic and extrinsic factors, such as age, weight, 
gender, and renal funct ion on PK and/or PD parameters, may be examined as needed. Addit ional 
analyses may be conducted if they are deemed appropr iate. 
9.3.7. Subgroup Analyses 
Subgroup analyses of the primary  endpoint will be made to assess consistency  of the intervention 
effect across the fo llowing subgroups using the “efficacy estimand ”:
Age group: < 65 vs ≥ 65 years
Sex: female vs male
HbA1c stratum (≤8.0%, >8.0%)
BMI ( ≤30 kg/m2, >30 kg/m2)
Race
Ethnicit y
Country /Regi on
If the number of participants is too small (less than [10%]) within a subgroup, then the subgroup 
categori es may be redefined prior to unblinding the study . Further details on the statistical 
analysis will be provided in the SAP.
Analyses for HbA1c and change from baseline in HbA1c will be performed using an MMRM 
model that includes the sam e fixed effects given for the primary  analysis model plus factors of 
subgroup, [ADDRESS_1037004] ion of treatment, visit and subgroup. The interaction of subgroup and 
treatm ent at the primary  endpoint (Week 26) will be evaluated to assess the treatment by  
[CONTACT_757428]. Addi tional subgroup analyses may also be performed.
9.4. Interim Analys is 
An interim efficacy and safet y assessment after all participants complete Visit 12 (Week 16) of 
the treatment period maybe conducted to provide inform ationfor dose escalation scheme sand 
clinical trial material  packaging for future studi es. If conducted, a n internal Assessment 
CONFIDENTIAL Protocol  J2A-MC-GZGE (b)
75Committee ( AC)will be formed to review the interim analyses for the safet y and efficacy  reports 
in an unblinded manner. Addit ional interim analyses may be conducted. Details on the timing of 
the interim analyses, operational support, and unblinding will be specified in the AC charter and 
in the study  unblinding plan. Informat ion that m ay unblind the study  during the analyses will not 
be reported to study  sites or blinded study  team  members before the study  has been unblinded for 
the final data base lock. Study  sites wil l receive information about interim results only if deemed 
necessary  for the safet y of the participants. The trial will not be stopped based on the superiorit y 
of LY3502970 versus placebo ordulaglutide 1.[ADDRESS_1037005] igators will remain blinded until the complet ion 
of the study . 
The cancellat ion or addit ion of an interim analysis can be determined at any  time during the 
study  and will not requi re a protocol  amendment.
Unblinding details are specified in the unblinding plan section of the SAP or in a separate 
unblinding plan document .The SAP will describe the planned int erim analyses in greater detail .
9.5. Sample Size Determination
Approximately 370 parti cipants will be rando mly assigned to study  drug in a rando mizat ion rati o 
of5:5:5:5:5:3:3:3:3, including 50 participants per treatm ent group to placebo, dul aglut ide, LY1, 
LY2 and LY3 treatm ent groups , and 30 participants per treatm ent group to LY4- 1, LY4- 2, LY5 -
1 and LY5 -2 treatm ent groups .
The sample size calculat ion is based on the primary  efficacy estimand and its endpoint (change 
from baseline to Week 26 in HbA1c ).Assuming a SD of 1.1%, a 2 -sided al pha level  of 0.05, 40
completers for oneLY3502970 treatm ent group and 40 completers for the placebo group can 
provi de >90% power to detect a treatm ent difference of 
-0.9% between the LY3502970
treatm ent group andplacebo (
LY3502970 –Placebo) in change fro m baseline HbA1c at Week 
26.  T aking into consi derati on a potenti allyhigher dropout rate due to gastrointestinal events in 
the higher dose sof LY, 50participant s for placebo arm and 60 pa rticipant s per treatm ent group
(or 30 p articipants per dose escalation regimen )for LY4 and LY5 shoul d be rando mized . 
Assuming a same 20% dropout rate for dulaglut ide, LY1, LY2 ,and LY3, 50 parti cipants per 
treatm ent group shoul d be rando mized . 
CONFIDENTIAL Protocol  J2A-MC-GZGE (b)
7610. Supporting Documentation and Operational Considerations
10.1. Appendix 1: Regulatory, Ethical, and Study Oversight 
Considerations
10.1.1. Regulatory and Ethical Considerations
●This study  will be conducted i n accordance wit h the protocol and with the 
following:
○Consensus ethical principles derived from international guidelines including 
the Decl aration of Helsinki and Council for International Organizations of 
Medical Sciences (CIOMS) International Ethical Guidelines
○Applicable ICH Good Clinical Practice (GCP) Guidelines
○Applicable laws and regulations
● The protocol, protocol amendments, ICF, IB, and other relevant documents ( for 
example , advertisements) must be submitted to an Institutional Review 
Board/ Independent Ethics Committee ( IRB/IEC )by [CONTACT_97277]/IEC before the study  is initiated.
●Any amendments to the protocol will require IRB/IEC approval before 
implementation of changes made to the study  desig n, except for changes 
necessary  to eliminate an immediate hazard to study  parti cipants.
●Protocol s and any substantial amendments to the protocol will require healt h 
authori ty approval  prior to ini tiation except for changes necessary  to eliminate an 
immed iate hazard to study  parti cipants .
●The invest igator will be responsible for the fo llowing:
○Provi ding wri tten summaries of the status of the study  to the IRB/IEC 
annually or more frequently in accordance with the requirements, policies, and 
procedures e stablished by [CONTACT_1201]/IEC
○Notifying the IRB/IEC of SAEs or other si gnificant safet y findings as required 
by [CONTACT_1744]/IEC procedures
○Provi ding oversight of study  conduct for parti cipants under thei r responsibilit y 
and adherence to requirements of 21 C ode of Federal  Regulat ions (C FR), ICH 
guidelines, the IRB/IEC, European regulat ion 536/2014 for clinical studies (if 
applicable), and all other applicable local regulat ions
●Invest igator sites are compensated for participat ion in the study as detailed in the 
clinical trialagreement .
10.1.2. Informed Consent Process
●The invest igator or his/her representative will explain the nature of the study , 
including the risks and benefit s,to the participant or his/her l egally  authori zed 
representative and answer all questi ons regarding the study .
CONFIDENTIAL Protocol  J2A-MC-GZGE (b)
77●Parti cipants m ust be inform ed that thei r parti cipat ion is vo luntary. Partici pants or 
their legally authori zed representative swill be required to sign a statement of 
inform ed consent that meets the requirements of 21 CFR 5 0, local regulat ions, 
ICH guidelines, privacy  and data protecti on requi rements, where applicable, and 
the IRB/IEC or study center.
●The m edical  record m ust include a statem ent that wri tten inform ed consent was 
obtained before the participant was enter ed in the study  and the date the written 
consent was obtained. The authorized person obtaining the informed consent must 
also sign the ICF.
●Parti cipants m ust be reconsented to the most current version of the ICF(s) during 
their parti cipat ion in the study .
●A copy  of the ICF(s) m ust be provi ded to the participant or the participant’s 
legally authorized representati veand is kept on file.
10.1.3. Data Protection
●Parti cipants will be assigned a unique ident ifier by [CONTACT_456]. Any part icipant 
records ,datasets or tissue samples that are transferred to the sponsor will contain 
the identifier only; participant names or any  informat ion which would make the 
participant i dentifiable will not be transferred.
●The parti cipant must be inform ed that hi s/her personal  study -related data will be 
used by [CONTACT_17079] h local data protecti on law. The level o f 
disclosure m ust al so be explained to the participant who will be required to give 
consent for his/her data to be used as described in the informed consent .
●The parti cipant must be inform ed that hi s/her m edical  records m ay be examined 
by [CONTACT_17080] y Assurance auditors or other authorized personnel appo inted by  
[CONTACT_456], by  [CONTACT_17081]/IEC m embers, and by  [CONTACT_17082].
● T he sponsor has processes in place to ensure data protection, informat ion securit y 
and data integrit y. These processes include appropriate contingency plan(s) for 
appropriate and timely  response in the event of a data securit y breach.
10.1.4. Dissemination of Clini cal Study Data
Report Preparation
An invest igator will sign the final CSR for this study, indicat ing agreement that, to the best of his 
or her knowledge, the report accurately  describes the conduct and results of the study .
Public Access to Reports and Data
Reports
The sponsor will disclose a summary o f study  information, including tabular study results, on 
publically  available websites where required by  [CONTACT_17087].
Data
CONFIDENTIAL Protocol  J2A-MC-GZGE (b)
78The sponsor provides access to all individual participant data collected during the trial, after 
anonymizat ion, wi th the excepti on of  PK data. Data are available to request 6 months after the 
indicat ion studi ed has been approved in the US and European Unio n (EU) and after primary 
publicat ion acceptance, whichever is later. No expi[INVESTIGATOR_757396] m ade available. Access is provided after a proposal has been approved by  [CONTACT_757429] a signed data 
sharing agreement. Data and documents, including the study  protocol , SAP, CSR, bl ank or 
annotated CRFs , will  be provi ded in a secure data sharing environment for up to [ADDRESS_1037006].com .
Publications/Publication Policy
The publicat ion policy is described in the letters of agreement between the sponsor and the 
investigators and inst itutions.  
10.1.5. Data Quality Assurance
●All participant data relat ing to the study  will be recorded on printed or electronic 
CRF sunless transmitted to the sponsor or designee electronically  (for example , 
laboratory  data). The investigator is responsible for verifying that data entries are 
accurate and correct by  [CONTACT_134123].
●The invest igator must maintain accurate documentation (source data) that 
supports the informat ion entered in the CRF.
●The invest igator must permit study -related m onitoring, audi ts, IRB/IEC review, 
and regulatory  agency inspect ions and provide direct a ccess to source data 
docum ents.
●Moni toring details describing strategy  (for example , risk-based i nitiatives in 
operati ons and qualit y such as risk management and mit igation strategi es and 
analyt ical risk- based mo nitoring), methods, responsibilit ies and requirements, 
including handling of nonco mpliance issues and monitoring techniques are 
provi ded in t he Monitoring Plan.
●The sponsor or designee is responsible for the data management of this study  
includin g qualit y checking of the data.
●The sponsor assumes accountabilit y for acti ons delegated to other individuals 
(e.g., contract research organizat ions).
●Study  monitors will perform  ongoing source data verification to confirm that data 
entered into the CRF by [CONTACT_1191], complete, and 
verifiable fro m source docum ents; that the safet y and ri ghts of  parti cipants are 
being pro
tected; and that the study  is being conducted in accordance with the 
currently approved protocol and any other study  agreem ents, ICH GCP, and all 
applicable regu latory  requi rements.
CONFIDENTIAL Protocol  J2A-MC-GZGE (b)
79● Records and documents, including signed ICFs, pertaining to the conduct of this 
study  must be retained by  [CONTACT_757430] (CTA) unless local regulations or inst itutional policies 
requi re a l onger retenti on peri od. No records m ay be destroy ed during the 
retenti on per iod without the wri tten approval  of the sponsor. No records may  be 
transferred to another location or party  without written notificat ion to the sponsor .
●In addit ion, sponsor or its representatives will periodically check a sample of the 
participant data recorded against source documents at the study site. The study 
may be audited by s ponsor or its representati ves, and/or regulatory  agencies at 
any time. Invest igators will be given notice before an audit occurs.
Data Capture System
The invest igator is responsible for ensuring the accuracy , com pleteness, l egibili ty, and timeliness 
of the data reported to the sponsor.
Data collected via the sponsor- provided data capture system will be stored at a third par ty. The 
investigator will have cont inuous access t o the data during the study  and unt il deco mmissio ning 
of the data capture sy stem (s).Prior to decommissioning, the invest igator will receive an archival 
copy  of pertinent data for retention.
Data m anaged by  a central  vendor, such as laboratory  test data, w ill be stored electronically in 
the central  vendor’s database system and electronic transfers will be provi ded to the invest igator 
for review and retent ion. Data will subsequent ly be transferred fro m the central  vendor to the 
Sponsor data warehouse.
Data f rom com plaint forms submitted to sponsor will be encoded and stored in the global 
product complaint management sy stem .
10.1.6. Source Documents
●Source documents provide evidence for the existence of the participant and 
substant iate the integrity  of the data coll ected. Source documents are filed at the 
investigator’s site.
●Data reported on the CRF or entered in the eCRF that are transcribed fro m source 
docum ents m ust be consistent with the source documents or the discrepancies 
must be explained. The invest igator may need to request previous medical records 
or transfer records, depending on the study . Also, current medical records must be 
available.
●Definit ion of what constitutes source data can be found in Section10.1.[ADDRESS_1037007] participant to enter screening andwill be the study  start 
date.
CONFIDENTIAL Protocol  J2A-MC-GZGE (b)
80Study or Site Termination
The sponsor designee reserves the right to close the study  site or terminate the study  at any  time 
for any  reason at the sol e discret ion of the sponsor. Study  sites will  be cl osed upon study  
completion. A study  site is considered cl osed when all required documents and study  supplies 
have been co llected and a study -site closure visi t has been perform ed.
The invest igator may init iate study -site closure at any  time, provi ded there i s reasonable cause 
and sufficient notice is given in advance of the intended terminat ion.
Reasons for the early closure of a study  site by [CONTACT_17095]:
For study  terminat ion:
●Discontinuati on of  further study  intervent ion developm ent
For si te terminati on:
●Failure of the invest igator to comply wit h the protocol, the requirements of the 
IRB/IEC or local healt h authorit ies, the sponsor's procedures, or GCP guidelines
●Inadequate recrui tment (evaluated after a reasonable amount of time) of 
participants by  [CONTACT_3170]
●Total  number of participants included earlier than expected .
If the study  is prem aturely  terminated or suspended, the sponsor shall prompt ly inform  the 
investi gators, the IECs/IRBs, the regulatory  authorit ies, and any contract research organizat ion(s) 
used in the study  of the reason for terminat ion or suspensio n, as specified by [CONTACT_17096]. The investigator shall prompt ly inform  the participant and shoul d assure 
appropriate participant therapy  and/or foll ow-
up.
Discontinuation of the Study
The study  will be di scontinued if Lilly or its designee judges it necessary  for m edical, safet y, 
regul atory , or other reasons consistent with applicable laws, regulat ions, and GCP.
A safet y invest igation will be triggered to determine if the study  shoul d be terminated early  
based on the fo llowing cri teria:
Three study  participants develop the same TEAE or SAE considered possibly  or probably 
related to study  drug that is severe or medically  significant, but not immediately life 
threatening; or where hospi[INVESTIGATOR_757397]; or is 
disabling; or limit
s self -care act ivities of daily living 
OR
Two study  participants develop any  TEAE or SAE regardl ess of attribut ion to study  drug 
that has life -threatening consequences or requires urgent intervent ion
OR
Death of any study  parti cipant at any  time rel ated to AE that is consi dered possibly  or 
probably  related to study drug study  drug .
CONFIDENTIAL Protocol  J2A-MC-GZGE (b)
8110.1.8. Publication Policy
In accordance with the sponsor’s publication po licy,the resul ts of this study  will be submitted 
for publicat ion by a peer -reviewed journal.
10.1.9. Investigator Information
Researchers withappropri ateeducation, training ,andexperience, asdetermined by[CONTACT_177262],
willparticipate asinvest igators inthisclinical trial.
CONFIDENTIAL Protocol  J2A-MC-GZGE (b)
8210.2. Appendix 2: Clinical Laboratory Tests
●The tests detailed in the table below will be performed by [CONTACT_2237] .
●Local  laboratory  resul
ts are only  required in the event that the central laboratory  
resul ts are not available in t ime for either study  intervent ion administration and/or 
response evaluat ion. If a local sample is required, it is important that the sample 
for central  analysi s is obtained at the same time. Addi tionally , if the l ocal 
laboratory  resul ts are used to m ake ei ther a study  intervent ion decisio n or 
response evaluat ion, the results must be recorded .
●In circumstances where the sponsor approves local laboratory  testin g in lieu of 
central  laboratory  testing (in the table below), the local laboratory  must be 
qualified in accordance wit h applicable local regulations.
●Protocol -specific requirements for inclusio n or exclusio n of participants are 
detailed in Sect ion 5of the protocol.
●Addit ional tests may be performed at any  time during the study  as determined 
necessary  by [CONTACT_17097] l regul ations.
●    Invest igators must document their review o f the laboratory  safet y resul ts.
Laboratory /analy te resul ts that coul d unblind the study  will not be reported to invest igative sites 
or other blinded personnel until the study  has been unblinde d.
Clinical Laboratory Tests Comments 
Hematology Assay ed by [CONTACT_11007] -designated laboratory
Hemoglobin
Hematocrit
Erythrocy te count (RBCs - red blood cells)
Mean cell volume 
Mean cell hemoglobin
Mean cell hemoglobin concentration 
Leukocytes (WBCs - white blood cells) 
Differential
   Neutrophils, segmented
   Lymphocy tes
   Monocytes
   Eosinophils
   Basophils
Platelets
Cell morphology (RBCs and WBCs)
CONFIDENTIAL Protocol  J2A-MC-GZGE (b)
83Clinical Chemistry Assay ed by [CONTACT_11007] -designated laboratory
Sodium
Potassium
Chloride
Bicarbonate
Total bilirubin
Direct bilirubin
Alkaline phosphatase (ALP)
Alanine aminotransferase (ALT)
Aspartate aminotransferase (AST)
Gamma -glutamyl transferase (GGT)
Blood urea nitrogen (BUN)
Creatinine 
Creatine kinase (CK)
Uric acid
Total protein
Albumin
Calcium
Phospho rus
Glucose
Lipid Panel Assay ed by [CONTACT_11007] -designated laboratory
High -density lipoprotein cholesterol (HDL -C)
Low-density  lipoprotein cholesterol (LDL -C)
Very  low-density  lipoprotein cholesterol 
(VLDL -C)
Total cholesterol 
Triglycerides
Urinalysis Assay ed by [CONTACT_11007] -designated laboratory
Specific gravity
pH
Protein
Glucose
Ketones
Bilirubin
Urobilinogen
Blood
Nitrite
Urine leukocyte esterase
Microscopic examination of sediment (as 
indicated)
CONFIDENTIAL Protocol  J2A-MC-GZGE (b)
84Hormones (female) Assay ed by [CONTACT_11007] -designated laboratory
Serum pregnancy  
Follicle stimulating hormone (FSH)
Estradiol
Urine Chemistry Assay ed by [CONTACT_11007] -designated laboratory
Albumin
Creatinine
Calculations Generated by [CONTACT_11007] -designated 
laborato ry
eGFR (CKD -EPI) 
Urinary  albumin/creatinine ratio (UACR)
Pharmacokinetic Samples –LY3502970
concentrationAssay ed by [CONTACT_11007] -designated laboratory. 
Results will not be provided to the
investigative sites.
Exploratory samples Assay ed by [CONTACT_11007] -designated laboratory. 
Results will not be provided to the 
investigative sites.
Explo ratory  storage samples: 
Serum
Plasma (EDTA)
   Plasma (P800)
Whole blood (EDTA) 
LY3502970 concentrations (PK) Assay ed by [CONTACT_11007] -designated laboratory. 
Results will not be provided to the 
investigative sites.
Hypersensitivity Tests Laborato ry assessments should be 
performed if the participant 
experiences generalized urticaria or if 
anaphy laxis is suspected.
Collect sample after the participant 
has been stabilized, and within 1 to 2 
hours of the event; however, 
samples may be obtained as late as 
[ADDRESS_1037008] the time at 
which the sample was collected.
Obtain a follow -up sample at 
the next regularly scheduled 
visit or after 4 weeks, 
whichever is later .
CONFIDENTIAL Protocol  J2A-MC-GZGE (b)
85Tryptase Assay ed by [CONTACT_11007] -designated 
laborato ry. Results will not be 
provided to the investigative sites.
Note :If a tryptase sample is obtained 
more than 2 hours after the event (that 
is, within 2 to 12 hours), or is not 
obtained because more than [ADDRESS_1037009] void urine 
following the event. Obtain a follow -up 
urine for N -methy lhistamine testing at 
the ne xt regularly scheduled visit or 
after 4 weeks, whichever is later.
Drug -specific IgE Will be performed if a validated assay 
is available.
Assay ed by [CONTACT_11007] -designated laboratory. 
Results will not be provided to the 
investigative sites .
Basophil activation test Will be performed if a validated assay 
is available.
Assay ed by [CONTACT_11007] -designated 
laborato ry. Results will not be 
provided to the investigative sites.
Note: The basophil activation test is an 
in vitro cell -based assay that only 
requires a serum sample. It is a surrogate 
assay  for drug -specific IgE, but is not 
specific for IgE.
Complement (C3, C3a, and C5a) Assay ed by [CONTACT_11007] -designated laboratory. 
Results will not be provided to the 
investigative sites .
Cytokine panel (IL‐6, IL‐1 β, and 
IL‐10)Assay ed by [CONTACT_11007] -designated laboratory. 
Results will not be provided to the 
investigative sites.
CONFIDENTIAL Protocol  J2A-MC-GZGE (b)
8610.3. Appendix 3: Adverse Events and Serious Adverse Events : Definitions
and Procedures for Recording, Evaluating, Follow- up, and 
Reporting
The definit ions and procedures detailed in this appendix are in accordance wit h 
International Organizat ion for Standardizat ion (ISO) [ZIP_CODE].
Both the invest igator and the sponsor will comply with all local medical device 
reporting requirements.
The detecti on and docum entati on procedures described in this protocol apply to all 
sponsor m edical devices provided for use in the study . See Secti on6.1.[ADDRESS_1037010] of 
sponsor medical devices).
10.3.1. Definition of AE
AE Definition
a.An AE is any  untoward m edical occurrence in a participant administered a pharmaceutical 
product and which does not necessarily have a causal relat ionship wi th the study  
intervent ion. An AE can therefore be any unfavorable and unintended sign (including an 
abnorm al laboratory  finding), symptom, or disease (new or exacerbated) temporally 
associ ated wi th the use of a medicinal (investigational) product, whether or not related to 
the medicinal (invest igational) product .
b.An AE is any  untoward m edical occurrence, unintended disease or injury , or untoward 
clinical signs (including abnormal laboratory  finding) i n study  parti cipants, users, or other 
persons, whether or not related to the invest igational medical device. This definit ion 
includes events related to the invest igational medical device or comparator and events 
related to the procedures invo lved except fo r events in users or other persons, which only 
include events related to invest igational devices.
Events Meeting the AE Definition
Any abnormal laboratory  test resul ts (hematol ogy, clinical chemistry , or uri nalysis) or 
other safet y assessments ( for example , ECG, radi ological scans, vi tal signs 
measurements), including those that worsen from baseline, considered clinically 
significant in the medical and scientific judgment of the invest igator ( that is, not rel ated 
to progression of underlying disease).
Exacerbat ion of a chronic or intermittent pre -exist ing condit ion including either an 
increase in frequency and/or intensit y of the condi tion.
New condit ion detected or diagnosed after study  intervent ion administration even 
though it may have been present b efore the start of the study .
Signs, symptoms, or the clinical sequelae of a suspected drug -drug interaction.
Signs, symptoms, or the clinical sequelae of a suspected overdose of either study  
intervent ion or a concomitant medicat ion. Overdose per se will n ot be reported as an 
AE/SAE unless it is an intentional overdose taken with possible suicidal/self -harming 
intent. Such overdose sshoul d be reported regardless of sequelae.
CONFIDENTIAL Protocol  J2A-MC-GZGE (b)
87Lack of efficacy or failure of expected pharmaco logical act ion per se will not be 
reported as an AE or SAE. Such instances will be captured in the efficacy assessments. 
However, the signs, symptoms, and/or clinical sequelae result ing fro m lack of efficacy 
will be reported as AE or SAE if they fulfill the definit ion of an AE or SAE.
Events NOT Meeting the AE Definition
Any clinically  significant abnormal laboratory  findings or other abnormal safet y 
assessments that are associated with the underlying disease, unless judged by [CONTACT_11009]’s condit ion.
The disease/disorder being studied or expected progressio n, signs, or symptom s of the 
disease/disorder being studied, unless more severe than expected for the participant’s 
condi tion.
Medical or surgical procedure ( for example , end oscopy , appendectomy ): the condi tion 
that leads to the procedure is the AE.
Situations in which an untoward medical occurrence did not occur (social and/or 
convenience admissio n to a hospi[INVESTIGATOR_307]).
Anticipated day -to-day fluctuations of pre -exist ing disease(s) or condit ion(s) present or 
detected at the start of the study  that do not worsen.
10.3.2. Definition of SAE
An SAE is defined as any untoward medical occurrence that, at any dose , meets one or 
more of the criteria listed :
a.Results in death
b.Is life -threatening
The term  life-threatening in the definit ion of serious refers to an event in which the participant 
was at risk of death at the time of the event. It does not refer to an event, which hypothetically 
might have caused death, if it were more severe.
c.Requires inpatient hospi[INVESTIGATOR_1081]
 In general, hospi[INVESTIGATOR_757398] (usually invo lving at least an overnight stay ) for 
observat ion and/or treatm ent that woul d not have been appropriate in the 
physician’s office or outpatient setting. Complicat ions that occur during 
hospi [INVESTIGATOR_99453]. If a com plicat ion prol ongs hospi [INVESTIGATOR_757399], the event is serious. When in doubt as to whether 
hospi [INVESTIGATOR_757400] , the AE shoul d be considered serious.
CONFIDENTIAL Protocol  J2A-MC-GZGE (b)
88 Hospi[INVESTIGATOR_17048] a pre -existing condit ion that di d not 
worsen from baseline is not considered an AE.
d.Results in persiste nt disability/incapacity
The term disabili ty means a substant ial disrupt ion of a person’s abilit y to conduct 
norm al life f unctions.
This definit ion is not intended to include experiences of relat ively minor medical 
significance such as unco mplicated headac he, nausea, vomit ing, di arrhea, influenza, 
and accidental trauma ( for example , sprained ankle) which may  interfere wi th or 
prevent every day life f unctions but do not constitute a substant ial disruption.
e.Is a congenital anomaly/birth defect
Abnorm al pregna ncy outcom es (e.g., spontaneous abortion, fetal death, stillbirth, 
congenital ano malies, ectopi c pregnancy) are considered SAEs.
f.Other situations:
Medical or scient ific judgment should be exercised by [CONTACT_757431]- threatening or resul t in death or hospi[INVESTIGATOR_226364] m ay jeopardi ze the parti cipant or m ay require medical or surgical intervent ion to 
prevent one of the oth er outcomes listed in the above definit ion. These events should 
usually be considered serious.
Examples of such events include invasive or malignant cancers, intensive treatment in 
an emergency room or at home for allergic bronchospasm, blood dyscrasias or
convulsio ns that do not result in hospi[INVESTIGATOR_3094], or development of drug dependency or 
drug abuse.
g.Resulted in medical or surgical intervent ion to prevent life -threatening illness or injury or 
perm anent impairment to a b ody structure or a body  function.
10.3.3. Definition of Product Complaints
Product Complaint
a.A product complaint is any written, electronic, or oral communicat ion that alleges 
deficiencies related to the identit y, qualit y, durability , reliabilit y, safet y, effect iveness or 
perform ance of a study  interventi on. When the abilit y to use the study  intervent ion safely  
is impacted, the fo llowing are also product complaints:
b.Deficiencies in labeling informat ion, and
c.Use errors for device or drug-device combination products due to ergonomic design 
elements of the product.
CONFIDENTIAL Protocol  J2A-MC-GZGE (b)
89d.Product complaints related to study  interventions used in clinical trials are collected in 
order to ensure the safet y of parti cipants, m onitor quali ty, and to facili tate process and 
product improvements.
e.Invest igators will instruct p articipants to contact [CONTACT_11010] a product complaint or problem wit h the study  intervention so that the situation can be 
assessed.
f.An event may meet the definit ion of both a product complaint and an AE/SAE. In such 
cases , it shoul d be reported as both a product complaint and as an AE/SAE.
10.3.4. Recording and Follow -Up of AE and/or SAE and Product Complaints
AE,SAE ,and Product Complaint Recording
When an AE/SAE /product com plaint occurs, i t is the responsibilit y of the investi gator 
to revi ew all  documentati on (for example , hospi [INVESTIGATOR_1088], laboratory  reports, 
and diagnostics reports) related to the event.
The invest igator will then record all relevant AE/SAE /product complaint informat ion 
in the part icipant’s medical records, in accordance with the invest igator’s normal 
clinical practice. AE/SAE information is reported on the appropriate (e)CRF page and 
product complaint informat ion is reported on the Product Complaint Form .
Note: An event may meet the definit ion of both a product complaint and an AE/SAE. 
In such cases, it should be reported as both a product complaint and as an AE/SAE.
It is notacceptable for the invest igator to send photocopi[INVESTIGATOR_10914]’s medical 
records to Sponsor or designee in lieu of co mpletion of the (e)CRF page for AE/SAE 
and the Product Complaint Form for product complaints .
There m ay be instances when copi[INVESTIGATOR_014] o f medical records for certain cases are requested 
by [CONTACT_757432] . In thi s case, all part icipant identifiers, with the exception o f 
the participant number, will be redacted on the copi[INVESTIGATOR_17051] n to Sponsor or designe e.
The invest igator will attempt to establish a diagnosis of the event based on signs, 
symptoms, and/or other clinical informat ion. Whenever possible, the diagnosis (not the 
individual signs/symptoms) will be documented as the AE/SAE.
Assessment of Inten sity
The invest igator will make an assessment of intensit y for each AE and SAE reported during 
the study  and assign it to one of the fo llowing categori es:
Mild: A type of adverse event that is usually  transient and m ay requi re only  minimal  
treatm ent or therapeutic intervent ion. The event does not generally interfere wit h usual 
activit ies o f daily living.
Moderate: A type of adverse event that is usually alleviate d with addi tional specific 
therapeuti c intervent ion. The event interferes with usual act ivities o f daily living, 
CONFIDENTIAL Protocol  J2A-MC-GZGE (b)
90causing disco mfort but poses no significant or permanent risk of harm to the research 
participant.
Severe: A type of adverse event that interru pts usual act ivities of daily living, or 
significant ly affects clinical status, or may  require intensive therapeut ic intervent ion. 
An AE that is assessed as severe should not be confused wit h a SAE. Severe is a 
category  utilized for rati ng the intensit y ofan event; and both AEs and SAEs can be 
assessed as severe.
An event is defined as “serious”when i t meets at least one of the predefined outcomes 
as described in the definit ion of an SAE, NOT when it is rated as severe.
Assessment of Causality
The invest igator is obligated to assess the relationship between study intervent ion and 
each occurrence of each AE/SAE. The investigator will use clinical judgment to 
determine the relat ionship/
A “reasonable possibilit y”of a rel ationship conveys that there a re facts, evidence, 
and/or arguments to suggest a causal relat ionship, rather than a relat ionship cannot be 
ruled out.
Alternat ive causes, such as underlying disease(s), concomitant therapy, and other risk 
factors, as well as the temporal relationship of t he event to study intervent ion 
administration will be considered and invest igated.
The invest igator will also consult the Invest igator’s Brochure (IB) in his/her 
assessment.
For each AE/SAE, the invest igator must document in the medical notes that he/she h as 
reviewed the AE/SAE and has provided an assessment of causalit y.
There m ay be si tuations in which an SAE has occurred and the invest igator has 
minimal informat ion to include in the init ial report to Sponsor or designee . However, i t 
is very important tha t the investigator always make an assessment of causalit y for 
every event before the init ial transmissio n of the SAE data to Sponsor or designee .
The invest igator may change his/her opi[INVESTIGATOR_3078] n of causalit y in light of fo llow-up 
inform ation and send a SAE foll ow-up report wi th the updated causalit y assessment.
The causalit y assessment is one of the cri teria used when determining regulatory  
reporting requirements.
Follow -up of AEs and SAEs
The invest igator is obligated to perform or arrange for the conduct of supplemental 
measurements and/or evaluat ions as medically indicated or as requested by [CONTACT_226428]/or causalit y of the AE or SAE as fully as possible . 
CONFIDENTIAL Protocol  J2A-MC-GZGE (b)
91This m ay include addit ional laboratory  tests or investigations, histopathological 
examinat ions, or consultation with other health care professio nals.
If a participant dies during participation in the study or during a recognized fo llow-up 
period,the inv estigator will provide Sponsor or designee with a copy  of any 
post-mortem findi ngs including histopathology . 
10.3.5. Reporting of SAEs
SAE Reporting via an Electronic Data Collection Tool
The primary  mechanism  for reporting an SAE will be the electronic data collection 
tool.
If the electronic system is unavailable, then the site will use the SAE paper form  
(see next section) in order to report the event within 24 hours.
The site will enter the SAE data into the electronic sy stem  as soon as i t becom es 
available.
After the study  is com pleted at a given site, the electronic data collect ion tool  will 
be taken off -line to prevent the entry  of new data or changes to existing data.
If a site receives a report of a new SAE fro m a study  parti cipant or receives updated 
data on a previously reported SAE after the electronic data collection tool has been 
taken off -line, then the site can report this informatio n on a SAE paper form (see 
next section) or to the medical monitorby [CONTACT_756].
Contacts for SAE reporting can be found in study  start up m aterials and from  the 
study  CRA .
SAE Reporting via Paper Form
Facsimile transmissio n of the SAE paper form is the preferred method to transmit this 
inform ation to the medical mo nitor or Lilly Glo bal Patient Safet y.
Initial notificati on via telephone does not replace the need for the invest igator to 
complete and sign the SAE CRF pages within the designated reporting time frames.
Contacts for SAE reporting can be found in study  start up m aterials.
10.3.6. Regulatory Reportin g Requirements
SAE Regulatory Reporting
Prom pt notificat ion by [CONTACT_32847] a SAE is essent ial so 
that legal obligat ions and ethical responsibilit ies towards the safet y of 
participants and the safet y of a study  intervent ion under clinical invest igation 
are met.
CONFIDENTIAL Protocol  J2A-MC-GZGE (b)
92●The sponsor has a legal responsibilit y to notify both the l ocal regulatory  
authori ty and other regul atory  agencies about the safet y of a study  intervent ion 
under clinical invest igation. The sponsor will co mply wit h country -specific 
regul atory  requi rements rel ating to safet y reporting to the regulatory  authori ty, 
Institutional Review Boards (IRB)/Independent Ethics Committees (IEC) , and 
investigators.
●An invest igator who receives an invest igator safety report describing a SAE or 
other specific safet y informat ion (for example , summary  or list ing of SAEs) 
from the sponsor will review and then file it along with the Invest igator’s 
Brochure and will notify the IRB/IEC, if appropriate according to local 
requi rements.
CONFIDENTIAL Protocol  J2A-MC-GZGE (b)
9310.4. Appendix 4: Contraceptive and Barrier Guidance
10.4.1. Definitions
Word/Phrase Definition
Women of child 
bearing potentialFema les are considered a woman of childbearing potential if
they have had at least one cycle of menses, or
they have Tanner [ADDRESS_1037011] develo pment.
Any amount of spotting should be considered menarche.  If Tanner Staging of 
breasts is performed as part of study procedures, please refer to the Reproductive, 
Pregnancy and Pediatrics Safety Committee Safety Guidance for Children in 
Clinical Trial regarding Tanner staging.
Women not of 
childbearing 
potentialFema les are considered women not of childbearing potential if
they have a congenital anomaly such as Mullerian agenesis, 
they are infertile due to surgical sterilization, or 
they are post-menopausal.
Examples of surgical sterilization include 
hysterectomy, 
bilateral oophorectomy, and 
tubal ligation.
Postmenopausal 
stateThe postmenopausal state should be defined as:
1.A woman at any age at least [ADDRESS_1037012] -surgical bilateral oophorectomy 
with or without hysterectomy, confirmed by [CONTACT_31083]; or 
2.A woman at least [ADDRESS_1037013] 
uterus, not on hormone therapy*, who has had cessation of menses for at 
least 12 consecutive months without an alternative medical cause, AND 
With a follicle -stimulating hormone >40 mI U/mL; or 
3.A woman [ADDRESS_1037014] 55 years of age with a diagnosis of menopause prior to 
starting hormone replacement therapy
* Women should not be taking me dications during amenorrhea such as oral 
contraceptives, hormones, gonadotropin -releasing hormone, anti -estrogens, 
selective estrogen receptor modulators (SERMs), or chemotherapy that could 
induce transient amenorrhea.
Reproductive 
Toxicology 
StudiesEmbryo-fetal studies are toxicity studies in pregnant animals designed to identify 
abnor malities in the development of fetuses, which could indicate potential for 
teratogenicity in humans.  The relevant dosing period is during organogenesis.
10.4.2. Contraception Guidance
Women of childbearing potential are excluded from participation in this study .
The table below describes contraception guidance for men.
CONFIDENTIAL Protocol  J2A-MC-GZGE (b)
94Topic Guidance
For all men should refrain from sperm donation for the 
duration of the study and for [ADDRESS_1037015] participant visit
Contraception for men with partners of 
childbearing potential  either remain abstinent (if this is their 
preferred and usual lifestyle), or
 must use condoms during intercourse 
for the duration of the study, and 
 for [ADDRESS_1037016] 
participant visit
Contraception for men in exclusively same sex 
relationships, as their preferred and usual lifestyleAre not required to use contra ception
Examples of highly effective, effective and unacceptable methods of contraception can be found below.
Methods Examples
Highly effective contraception combination oral contraceptive pi[INVESTIGATOR_31076]-pi[INVESTIGATOR_4382]
implanted contraceptives
injectable contraceptives
contraceptive patch (only women <198 
pounds or 90 kg)
total abstinence
vasectomy (if only sexual partner)
fallopi[INVESTIGATOR_31077] (if confirmed by 
[CONTACT_31084][INVESTIGATOR_8913])
combined contraceptive vaginal ring, or 
intrauterine devices
Effective contraception male or female condoms with spermicide 
diaphragms with spermicide or cervical 
sponges
barrier method with use of a spermicide
ocondom with spermicide
o diaphragm with spermicide, or
ofemale condom with spermicide
Note:  The barrier method must include use of a 
spermicide ( in other words , condom with 
spermicide, diaphragm with spermicide, female 
condom with spermicide) to be considered 
effective.
CONFIDENTIAL Protocol  J2A-MC-GZGE (b)
95Methods Examples
Ineffective forms of contraceptionspermicide alone 
immunocontraceptives
periodic abstinence
fertility awareness (calendar method, 
temperature method, combination of 
above 2, cervical mucus, symptothermal)
withdrawal,
post coital douche
lactational amenorrhea
CONFIDENTIAL Protocol  J2A-MC-GZGE (b)
9610.5. Appendix 5: Liver Safety: Suggested Actions and Follow -up 
Assessments 
See protocol S ection [IP_ADDRESS] for guidance on appropri ate test sel ection.
The Lilly -designated central laboratory  must com plete the analysis of all selected testing except 
for microbi ology testing.
Local  testing m ay be per formed in addit ion to central testing ,when necessary ,for immediate 
participant m anagement.
Results will be reported if a validated test or calculation is available.
Hematology Clinical Chemistry
Hemoglobin Total bilirubin
Hematocrit Direct bilirubin
Erythrocy tes (RBCs -red blood cells) Alkaline phosphatase (ALP)
Leukocytes (WBCs -white blood cells) Alanine aminotransferase (ALT)
Differential: Aspartate aminotransferase (AST)
    Neutrophils, segmented Gamma -glutamyl transferase (GGT)
    Lymphocytes Creatine kinase (CK)
    MonocytesOther Chemistry
    Basophils Acetaminophen
    Eosinophils Acetaminophen protein adducts
Platelets Alkaline phosphatase isoenzymes
Cell morphology (RBC and WBC) Ceruloplasmin
CoagulationCopper
Ethyl alcohol (EtOH)
Prothrombin time, INR (PT -INR) Haptoglobin
SerologyImmunoglobulin IgA (quantitative)
Hepatitis A virus (HAV) testing: Immunoglobulin IgG (quantitative)
    HAV total antibody Immunoglobulin IgM (quantitative)
    HAV IgM antibody Phosphatidylethanol (PEth)
Hepatis B virus (HBV) testing:Urine Chemistry
    Hepatitis B surface antigen (HBsAg) Drug screen
    Hepatitis B surface antibody (anti -HBs) Ethyl glucuronide (EtG)
    Hepatitis B core total antibody (anti -HBc)Other Serology
    Hepatitis B core IgM antibody Anti- nuclear antibody (ANA)
    Hepatitis B core IgG antibody Anti-smooth muscle antibody (ASMA) a
CONFIDENTIAL Protocol  J2A-MC-GZGE (b)
97Hematology Clinical Chemistry
    HBV DNA d Anti- actin antibody b
Hepatis C virus (HCV) testing: Epstein -Barr virus (EBV) testing:
    HCV antibody     EBV antibody
    HCV RNA d     EBV DNA d
Hepatitis D virus (HDV) testing: Cytomegalovirus (CMV) testing:
    HDV antibody     CMV antibody
Hepatitis E virus (HEV) testing:     CMV DNA d
    HEV IgG antibody Herpes simplex virus (HSV) testing:
    HEV IgM antibody     HSV (Type 1 and 2) antibody 
    HEV RNA d     HSV (Type 1 and 2) DNA d
Microbiology c Liver kidney microsomal type 1 (LKM -1) antibody
Culture:
    Blood
    Urine
Abbreviations: Ig = immunoglobulin; INR = international normalized ratio .
aNot required if anti -actin antibody is tested.
bNot required if anti -smooth muscle antibody (ASMA) is tested.
cAssay ed ONLY by [CONTACT_1697] -designated local laboratory; no cent ral testing available.
dReflex/confirmation dependent on regulatory requirements, testing availability, or both .
CONFIDENTIAL Protocol  J2A-MC-GZGE (b)
9810.6. Appendix 6: World Health Organization Classification of Diabetes 
and Diagnostic Criteria
Type 1 Diabetes: Type 1 diabetes i s judged to be present when the classical symptoms of 
diabetes (thi rst, polyuri a, wast ing and stupor, or coma) are associated with readily detectable 
concentrations of glucose and ketone bodies in the blood and urine. Insulin treatment is 
necessary  not only to control hyperglycemia but also to prevent spontaneous ketosis and death.
Type 2 Diabetes: Type 2 diabetes, although often asymptomat ic, may also present with classical 
hyperglycemic symptoms (thirst, polyuria, weight loss), but despi[INVESTIGATOR_81093], ketone 
bodies are present in only  low concentrati ons in the blood and urine. Coma is rare in t ype2 
diabetes, but m ay resul t from extrem e hyperglycemia and hyperosmo larity; lactic acidosis or 
ketoacidosis can also occur in fulminat ing illness (for example, severe infect ion or m esenteri c 
artery  throm bosis) due to an acute increase in insulin require ments, but spontaneous ketosis does 
not occur. Some pat ients with type 2 di abetes later progress to a state of absolute insulin 
deficiency (Albert i and Zimmet 1998). 
CONFIDENTIAL Protocol  J2A-MC-GZGE (b)
9910.7. Appendix 7: [LOCATION_001] Heart Association Functional Classification 
of Heart Failure
Class Symptomatology 
I No limitation of physical ac tivity. Ordinary physical activity does not cause undue fatigue, 
palpi[INVESTIGATOR_226367] n, dy spnea.
II Slight limitation of physical activity. Comfortable at rest. Ordinary physical activity results in 
fatigue, palpi[INVESTIGATOR_332], dyspnea.
III Marked limitation of physical activity. Comfortable at rest. Less than ordinary activity causes 
fatigue, palpi[INVESTIGATOR_332], or dys pnea.
IV Unable to carry on any physical activity without discomfort.  Symptoms of heart failure at rest. 
If any physical activity  is undertaken , discomfort increases.
CONFIDENTIAL Protocol  J2A-MC-GZGE (b)
[ZIP_CODE].8. Appendix 8: Protocol GZGE Standardized Protocols for the
Measurement of Height, Weight, Waist Circumference, Vital Signs 
and 7-Point Self -Monitoring Blood Glucose (SMBG)
The fo llowing inform ation has been adapted fro m standardized physical measurement protocols 
for the WHO’s STEPwise approach to Surveillance (STEPS) (WHO 2017). 
Measuring Height
Step 1. Ask the participant to remove their footwear and any headgear (light headgear worn for 
religious reasons can remain, but this should be worn by [CONTACT_757433] m easured).
Step 2. Ask the participant to sta nd on the calibrated height measuring board (stadio meter) or 
against a wall wit h their feet together and their knees straight with their heels against the 
backboard, the stadio meter, or the wall.
Step 3. Ask the participant to look straight ahead without t ilting their head up.
Step 4. Ask the participant to breathe in and stand tall. Measure and record the participant’s 
height in cent imeters to [ADDRESS_1037017]. 
Measuring Weight
Body  weight m easurements shoul d be done in a consistent manner using a calibrat ed 
electroni c scale capable of measuring weight in kilograms to [ADDRESS_1037018].
All weights for a given participant should be measured using the same scale, whenever 
possible, at approximately the same time in the mo
rning after evacuat ion of bladder 
conte nts.  
Body  weight shoul dbe measured in fasting state. If the participant is not fast ing, the 
participant shoul d be called in for a new visit within the visit window to have the fast ing 
body  weight m easured.
Step 1 . Ask the participant to empt y their pock ets, remove their footwear, outerwear (coat, 
jacket, etc.), and any  headgear (li ght headgear worn for religious reasons can remain, but this 
shoul d be worn by  [CONTACT_226430] t when weight i s measured).
Step 2 . Make sure the scale is placed on a firm, flat, even surface (not on carpet, on a slopi[INVESTIGATOR_126154], or a rough, uneven surface).
Step [ADDRESS_1037019] Circumference
Waist circumference should be measured in the horizontal plane and at the midpoint 
between the lower margin o f the last pal pable rib and the top of the ili ac crest .
CONFIDENTIAL Protocol  J2A-MC-GZGE (b)
101Measurements should be taken at the end of a normal expi[INVESTIGATOR_134067] a nonstretchable 
measuring tape. The tape should lie flat against the skin without compressing the soft 
tissue.
The waist circumference should be measured twice, rounded to the nearest 0.5 cm. The 
measuring tape should be removed between the 2 measurements. Both measurements 
will be recorded in the eCRF. If the difference between the 2 measurements exceeds 
1cm, this set of measurements should be discarded and the 2 measurements repeated.
Step 1 : Ask the participant to wear litt le clothing (if available, garments could also be used).
Step 2 : Ask the participant to stand with their feet close together, arms at their side, body weight 
evenly distributed.
Step 3 : Ask the participant to relax and measure the participant’s waist circumference.
Vital Sign Measurements
Vital sign m easurements (bl ood pressure and heart rate, measured by [CONTACT_117682]) should be 
taken before obtaining an ECG tracing and before collect ion of blood samples for 
labora tory testing.
The parti cipant shoul d sit quietly for 5 minutes before vital signs measurements are 
taken.
For each parameter, 2 measurements will be taken using the same arm, preferably the 
nondo minant arm.
The recordings should be taken at least 1 minute apart. Each measurement of sitting 
pulse and BP needs to be recorded in the eCRF.
BP m ust be taken with an automated blood pressure instrument.
If blood pressure and pulse measurements are taken separately, pulse shoul d be taken 
prior to bl ood pressure .
Note: In the event pulse measurement cannot be taken via an automated blood pressure 
instrum ent, the preferred location for measurement of pulse is the radial artery . 
7-Point Self -Monitoring Blood Glucose
Seven-point SMBG profiles consist of m easurements obtained before each meal, approximately  
2hours after each meal, and at bedtime on a day  during the week before the scheduled clinic 
visit. Parti cipants will record their SMBG levels in their diaries, accordi ng to instructions. The 
complete [ADDRESS_1037020] be collected on a subsequent day .
CONFIDENTIAL Protocol  J2A-MC-GZGE (b)
[ZIP_CODE].9. Appendix 9: Patient -Reported Outcomes
Short Form -36 version 2 Health Survey acute form, 1 week recall version
TheShort Form -36 versi on 2 Heal th Survey acute form  (SF-36v2 acute ), 1-week recall version is 
a 36-item generic, participant -compl
etedmeasure designed to assess the following 8 domains
• Physical Funct ioning 
• Rol e Physical
• Bodily Pain
• General Healt h
• Vitality
• Soci al Functioning 
• Rol e Em otional, and
• Mental  Heal th. 
The Physical Funct ioning domain assesses limitations due to health “now” while the remaining 
domains assess fun ctioning “in the past week.” Each do main is scored individually  and 
inform ation from these 8 dom ains are further aggregated into 2 health component summary 
scores: Physical Component Summary  and Mental Com ponent Summary . Items are answered on 
Likert scales of varying lengths (3- point, 5 -point, or 6- point scales). Scoring of each domain and 
both summary  scores are norm  based and presented in the form of T -scores, with a mean of [ADDRESS_1037021] deviat ion of 10; higher scores indicate better levels o f functionand/or better health 
(Marui sh 2011).
Diabetes Treatment Satisfaction Questionnaire- Status Version 
The Diabetes Treatm ent Satisfact ion Quest ionnaire -Status Version (DTSQs) (Bradley and Lewis 
1990; Bradley  1994) is a diabetes -specific pat ient-reported out come instrument that assesses the 
overall treatm ent sati sfact ionand perceived frequency of hyperglycemia and hypoglycemia . It is 
appropriate for use in both ty pe [ADDRESS_1037022] few weeks, prior to the visit. Each i tem is rated 
on a 7 -point Likert scale. I tems 1, 4, 5 -7, and 8 are rated from 0 (very dissat isfied) to 6 (very  
satisfied) and can be su mmed up to produce a treatment satisfact ion score. Item s 2 and 3 evaluate 
the perceived frequency of hyper glycemia and hypoglycemia andare rated fro m 0 (none of the 
time) to 6 (most of the time).
Diabetes Treatment Satisfaction Questionnaire- Change Versi on
The Diabetes Treatm ent Satisfact ion Quest ionnaire -Change Version ( DTSQ c)(Bradley 1999) 
was designed to overcome potential ceiling effects in the status version.  The DTSQc has the 
same [ADDRESS_1037023] ion rather than abso lute treatm ent satisfacti on.
Each i tem is scored on a scale of -3 to +3.  For all items except items 2 (perceived frequency o f 
hyperglycemia) and item 3 (perceived frequency  of hypoglycemia): 
CONFIDENTIAL Protocol  J2A-MC-GZGE (b)
103the higher the score, the greater the improvement in treatment satisfaction
the lower the score, the greater the deterioration in treatment satisfact ion, and
a score of 0 represents no change. 
For i tems 2 and 3: the l ower the score, the better the perception.
Participant Survey
The Parti cipant Survey  is a parti cipant -completed form , which includes quest ions to understand 
participant experience withand preference for study treatm ents (injectable vs. oral) , and the 
factors i nfluencing their preferences. 
CONFIDENTIAL Protocol  J2A-MC-GZGE (b)
[ZIP_CODE].10. Appen dix 10: Provisions for Changes in Study Conduct During 
Exceptional Circumstances
Implementation of this appendix
The changes to procedures described in this appendix are temporary measures intended to be 
used only during specific time periods as directed by  [CONTACT_31085] h the 
investigator.
Exceptional circumstances
Except ionalcircumstances are rare events that may cause di srupt ions to the conduct of the study .
Examples include pandemics or natural disasters . These disrupt ionsmay limit the abilit y of the 
investigators, participants, or both to attend on -site visi ts or to conduct pl anned study  procedures.
Implementing changes under exceptional circumstances
In an except ional circumstance, after receiving the sponsor’s written a pproval, sites may 
implement changes if permitted by [CONTACT_24550]. 
After approval by [CONTACT_31086], regulatory  bodi es and any  other relevant l ocal 
authori ties, implementation of these except ional circum stance changes will not ty pi[INVESTIGATOR_31078], unless they  have specific requirements in which 
notification is required (for example, upon implementation and suspensio n of changes). All 
approval s and notificat ions must be retained in the study  records.
If the sponsor grants written approval  for changes in study  conduct, the sponsor will also provide 
additional written guidance ,if needed.
Considerations for making a change
The prevailing considerat ionfor making a change is e nsuring the safet y of study  participants.
Addit ional important considerat ions for making a change are compliance with GCP , enabling 
participants to continue safely in the study and m aintaining the integrit y of the study . 
Informed consent
Addit ional consent fro m the parti cipant will  be obtained
, if required, for:
participat ion in remote visits, as defined in Section “Remote Visits,”
dispensat ion of addit ional study  interventi onduring an extended treatment period, 
alternate delivery  of study  interventi on and ancillary  supplies, and
provi sion of their personal  or medical  information requi red pri or to implementation of 
these activit ies. 
Changes in study conduct during e xceptional circumstances
Changes in study  conduct not described in this appendix, or not consistent with applicable local 
regul ations, are not allowed .
The fo llowing changes in study  conduct will not be considered protocol deviat ions.
Remote visits
Types of remote visits
CONFIDENTIAL Protocol  J2A-MC-GZGE (b)
105Telemedicine: Telephone or techno logy-assisted virtual  visit s, or both, are acceptable to 
complete appropri ate assessments . Assessments to be co mpleted in this manner include, but are 
not limited to, adverse events , SMBG values andconcomi tant m edicat ions 
Mobile healthcare:
Healthcare visi ts may be perform ed by  a mobile hea lthcare provider at locations other than the 
study  site when parti cipants cannot travel to the site due to an except ional circumstance if wri tten 
approval  is provi ded by [CONTACT_456] .Procedures performed at such visit s include, but are not 
limited to, concomitant medicat ions,SMBG values, vital signs ( BPand PR), body  weight, 
collect ion of blood samples, physical assessments, administration of PROs if validated for these 
types of  visit s, administrati on of  study  intervent ion, and collect ion of healt h informa tion. 
Other alternative locations:   
During exceptional circumstances, laboratory  sampl es may be drawn locally , if needed outsi de of 
mobile healthcare visit s.
Data capture
In source document sand the CRF , the study site should capture the visit method ,with a specific 
explanat ion for any  data missing because of missed in -person site visits.
Safety reporting
Regardless of the ty pe of  remote visi ts implemented, the protocol r equirements regarding the 
reporting of AEs, SAEs, and PCsremain unchanged. 
Return to on -site visits
Every effort shoul d be made to enable participant sto return to on -site visi ts as soon as 
reasonably  possible, while ensuring the safet y of both the parti cipant sand the sitestaff.
Local laboratory testing option
Local  laboratory  testing m ay be conducted in lieu of central laboratory  testing. However, central 
laboratory  testing must be retained for: Visits 3, 10, and [ADDRESS_1037024] be 
qualified in accordance wit happlicable local regulati ons
.
Study interv ention and ancillary supplies (including participant diaries)
When a participant is unable to goto thesite to receive study supplies during normal on -site 
visits, the si te shoul d work wi th the sponsor to determine appropriate actions . These act ions may
include: 
asking the participant to go to the site and receive study supplies from site staff 
without com pletion of a full study  visit, 
asking theparticipant ’s designee to go to the site and receive study supplies on a 
participant’s behalf, and
arranging delivery  of study  supplies .
These requi rements m ust be m etbefore action is taken :
CONFIDENTIAL Protocol  J2A-MC-GZGE (b)
106Alternate delivery  of study  interventi on shoul d be perform ed in a manner that does 
not com promise treatm ent blinding and ensures product integrit y. The exist ing 
protocol  requi rements for product accountabilit y remain unchanged, including 
verification o f participant’s receipt of study  supplies.
When delivering supplies to a locat ion other than the study  site (for exam ple, 
participant’s ho me), the invest igator , spon sor, or both shoul d ensure oversight of the 
shippi[INVESTIGATOR_226369] y and product qualit y (that is, storage 
condi tions maintained and intact packaging upon receipt) .
Instructi ons may be provided to the participant or designee on the final disposit ion of 
any unused or com pleted study  supplies .
Screening period guidance
To ensure safet y of study  participants, l aboratory values and other eligibilit y assessments taken 
at screening visit are valid for a maximum o f 30days. The following rul es will be applied for 
active, nonrando mized participants who se participation in the study  must be paused due to 
exceptional circumstances :
If screening is p aused for l ess than 30days fro m screening visits to randomizat ion 
visit: the parti cipant will proceed to the next study  visit per the usual SoA, 
provi ded that randomization visit must be conducted within 30days fro m first 
screening/lead -in visit.
oThe site should conduct the next visit if the parti cipant’s eligibilit y criteria 
are confirmed ,and the site shoul d docum ent the reason for delay.
oDue to the pause in screening, sites should also reconfirm the impacted
participant’s consent and document this confirmat ionin the source 
docum entati on.
If screening is paused for m ore th an 30days from screening visit s to 
rando mizat ion visit , theparticipant m ust be discontinued because of screening 
interrupti on due to an except ional circumstance. This is documented as a screen 
failure in the CRF. The participant can reconsent and be resc reened as a new 
participant. The screening procedures per the usual SoA shoul d be f ollowed, 
starting at screening visit to ensure parti cipant eligibilit y by [CONTACT_261786].
Adjustments to v isit windows 
Whenever possible and safe to do so, as determined by [CONTACT_3170]’s discretion , participants 
shoul d complete the usual SoA. To maximize the possibilit y that these visits can be conducted as 
on-site visi ts, the windows for visits may be adjusted, upon further guidance from  thesponsor . 
This minimizes missing data and preserv es the intended conduct of the stud y.
This table describes the allowed adjust ments to visit windows .
CONFIDENTIAL Protocol  J2A-MC-GZGE (b)
107Visit Number Tolerance
Visit [ADDRESS_1037025] w ill be documented
Sites will ident ify and document the details o f how participants, visit ty pes, and conducted 
activit ies were affected by [CONTACT_31087]. Di spensing/shipment records of study  
intervent ion and relevant communicat ions, including delegat ion, should be filed with site study  
records.
Source documents at alternate locations
Source documents generated at a location other than the study site should be part of the 
investigator’s source documentation and should be transferred to the site in a secure and timely 
manner. 
CONFIDENTIAL Protocol  J2A-MC-GZGE (b)
[ZIP_CODE].11. Appendix 11: Abbreviations and Definitions
Term Definition
AC Assessment Committee
ADA American Diabetes Association
AE adverse event
AESI adverse event of special interest
ALP alkaline phosphatase
ALT alanine aminotransferase
ANA antinuclear antibody
ASM A anti-smooth muscle antibody
AST aspartate aminotransferase
AUC area under the curve
BG blood glucose
blinding/masking A double -blind study is one in which neither the participant nor any of the investigator 
or sponsor staff who are involved in the treatment or clinical evaluation of the subjects 
are aware of the treatment received.
BMI body mass index
BP Blood pressure
CEC Clinical endpoint committee
CFR Code of Federal Regulations
CI Confidence interval
CIOMS Council forInternational Organizations ofMedical Sciences
CK creatine kinase
CKD- EPI [INVESTIGATOR_757401]  J2A-MC-GZGE (b)
109complaint A complaint is any written, electronic, or oral communication that alleges deficiencies 
related to the identity, quality, purity, durability, reliability, safety or effectiveness, or 
performance of a drug or drug delivery system.
compliance Adherence to all study -related, good clinical practice (GCP), and applicable regulatory 
requirements.
CONSORT Consolidated Standards of Reporting Trials
CRF Case report form
CRP clinical research physician: Individual responsible for the m edical conduct of the study.  
Responsibilities of the CRP may be performed by a physician, clinical research 
scientist, global safety physician or other medical officer.
CRS clinical research scientist
CSR Clinical study report
CV cardiovascular
D. bil. Direct bilirubin
DTSQc Diabetes Treatment Satisfaction Questionnaire -Change Version
DTSQs Diabetes Treatment Satisfaction Questionnaire -Status Version
EAS Efficacy analysis set
EBV Epstein -Barr virus
ECG Electrocardiogram
eCRF Electronic case report form
eGFR estimated glomerular filtration rate
enroll The act of assigning a participant to a treatment. Participants who are enrolled in the 
study are those who have been assigned to a treatment.
enter Participants entered into a study are those who sign the informed consent form directly 
or through their legally acceptable representatives.
ERCP endoscopic retrograde cholangiopancreatography
ET Early  termination
FAS Full analysis set
FBG fasting blood glucose
FSH follicle stimulating hormone
GI gastrointestinal
CONFIDENTIAL Protocol  J2A-MC-GZGE (b)
110GCP good clinical practice
GGT gamma - glutamyl transferase
GLP-[ADDRESS_1037026]
GPS Global Patient Safety
HbA1c hemoglobin A1c
HAV, HBV, HCV, HDV,
HEVhepatitis A virus, hepatitis B virus , hepatitis C virus, hepatitis D virus, hepatitis E virus
HIV human immunodeficiency virus
HR heart rate
HSV herpes simplex virus
IB Investigator’s Brochure
ICF informed consent form
ICH International Council for Harmoni zation
IEC Independent Ethics Committee
Ig immunoglobulin
informed consent A process by [CONTACT_9444] a participant voluntarily confirms his or her willingness to 
participate in a particular study, after having been informed of all aspects of the study 
that are relevant to the participant’s decision to participate. Informed consent is 
documented by [CONTACT_3553] a written, signed and dated informed consent form .
interim analysis An interim analysis is an analysis of clinical study data, separated into treatment groups, 
that is conducted before the final reporting database is created/locked.
IP Investigational produc t is apharmaceutical form of an active ingredient or placebo 
being tested or used as a reference in a clinical trial, including products already on the 
market when used or assembled (formulated or packaged) in a way different from the 
autho rized form, or markete d products used for an unauthorized indication, or marketed 
products used to gain further information about the authorized form.
IRB Institutio nal Review Board
IWRS interactive web -response sy stem
LH luteinizing hormone
LS least squares
LY LY3502970
CONFIDENTIAL Protocol  J2A-MC-GZGE (b)
111MAD multiple -ascending dose
MEN2 multiple endocrine neoplasia type [ADDRESS_1037027] model repeated measures
MRCP magnetic resonance cholangiopancreatograph y
MTC medullary carcinoma of the thyroid
OTC over-the-counter
participant Equivalent to CDISC term “subject”: an individual who participates in a clinical trial, 
either as recipi[INVESTIGATOR_10930] a control
PC product complaint
PK/PD pharmacokinetics/pharmacodynamics
PR pulse rate
Pro-C3 biomarker for liver fibrosis
PRO/ePRO patient -reported outcomes/electronic patient -reported outcomes
PT-INR Prothrombin time
QD once-daily
QTc corrected QT interval
QW once-weekly
OTC over the counter
SAD Single -ascending dose
SAE serious adverse event
SAP statistical analysis plan
SS Safety analysis set
screen The act of determining if an individual meets minimum requirements to become part of 
a pool of potential candidates for participation in a clinical study. 
SF-36 v2 acute form Short Form -36 version 2 health survey acute form
SDPs single dose pens
SMBG self-monitoring of blood glucose
SoA schedule of activities
CONFIDENTIAL Protocol  J2A-MC-GZGE (b)
112T1DM Type 1 diabetes mellitus
T2DM Type 2 diabetes mellitus
TBL total bilirubin
TEAE Treatment -emergent adverse event:  An untoward medical occurrence that emerges 
during a defined treatment period, having been absent pretreatment, or worsens relative 
to the pretreatment state, and does not necessarily have to have a causal relationship 
with this treatment.
THC tetrahy drocannabinol
TXP treatment
UACR Urinary  albumin creatinine ratio
ULN Upper limit of normal
WHO World Health Organization
Wks weeks
WNOCBP women not of childbearing potential
CONFIDENTIAL Protocol  J2A-MC-GZGE (b)
[ZIP_CODE].12. Appendix 12: Protocol Amendment History
The Protocol Amendment Summary of Changes Table for the current amendment is located 
directly before the Table of Contents (TOC).
Amendment a: 30 June 2021
This amendment is considered to be nonsubstant ialbased on the criteria set forth in Art icle 10(a) 
of Directive 2001/20/EC of the European Parliament and the Council o f the European Unio n 
because it neit her significant ly impacts the safet y or physical/mental integrit y of parti cipants nor 
the scientific v alue of  the study .
Overall Rationale for the Amendment
There was a ty pographical error in the Secti on 2.3 Benefit/Risk assessment . The section referred 
to ambulatory  blood pressure m onitoring (ABPM). ABPM is not being conducted in this study; 
however, it i s being co llected in a Phase 2 obesit y study  (J2A -MC-GZGI) that will be conducted 
at the sam e time as this study .
Section # and 
NameDescription of Change Brief Rationale
2.3.1. Risk 
AssessmentDeleted reference to ABPM, as it 
will not be conducted in this 
study .ABPM is not being conducted in this 
study  but is being conducted in a Phase 
2 study  evaluat ing the effects of 
LY3502970 in participants with obesit y 
or overweight with comorbidit ies. 
Throughout the 
protocolMinor edi torial changes m ade 
throughout the protocol.Correcti on
CONFIDENTIAL Protocol  J2A-MC-GZGE (b)
[ZIP_CODE]. References
[ADA] American Diabetes Associat ion. 6. Glycemic targets: standards of medical care in 
diabetes -2020. Diabetes Care. 2020;43(suppl 1):S66 -S76. https://doi.org/10.2337/dc20 -S006
Albert i KG, Zimmet PZ. Definit ion, diagnosis and cl assificat ion of diabetes mellitus and its 
complicat ions. Part 1: diagnosis and classificat ion of diabetes mellitus provisio nal report of a 
WHO consultation. Diabet Med. 1998;15(7):539 -553. https://doi.org/10.1002/(SICI)1096-
9136(199807) 15:7<539:AID -DIA668>3.0.CO;2 -S
Aroda VR, Ratner R. The safet y and tol erabilit y of GLP -1 receptor agonists in the treatment of 
type 2 di abetes: a review. Diabetes Metab Res Rev . 2011;27(6):528 -542. 
https://doi .org/10.1002/dmrr.1202
Baggi oLL, Drucker DJ. Bi ology of incretins: GLP -1 and GIP. Gastroenterology . 
2007;132(6):2131 –2157. https://doi.org/ 10.1053/j.gastro.2007.03.054
Banks PA, Freeman ML; Practice Parameters Committee of the American Co llege of 
Gastroenterology . Practi ce gui delines in acute pancreatit is. Am J Gastroenterol . 
2006;101(10):2379 -2400. https://doi.org/10.1111/j.1572 -0241.2006.[ZIP_CODE].x
Baylis s WM, Starling EH .The m echanism  of pancreati c secret ion.J Physiol. 1902; 28:325 –353.
https://d oi.org/ 10.1113/jphysio l.1902.sp000920
Bradl ey C. (Ed). Handbook of psy chology and diabetes: a gui de to psy chological measurement 
in diabetes research and practice; Harwood Academ ic Publishers, 1994. 
Bradl ey C. Di abetes Treatm ent Satisfaction Questionnaire: Change versio n for use alongside 
status versio n provi des appropri ate sol ution where ceiling effects occur. Diabetes Care . 
1999 :22(3):530 -532. https://doi.org/10.2337/diacare.22.3.[ADDRESS_1037028] ion 
developed fro m the responses of people wit h tablet -treated diabetes. Diabet Med. 
1990;7(5):445 -451. https://doi.org/10.1111/j.[ADDRESS_1037029] T, et al.Once weekly dulaglutide versus once -daily liraglut ide 
in metformin-treated pati ents wi th type2 diabetes (AWARD -6): a randomised, open -label, 
phase 3, non -inferiorit y trial. Lancet . 2014; 384(9951):1349–1357.
https://doi .org/10.1016/S0140 -6736(14)[ZIP_CODE]-4
Giorgino F, Benroubi  M, Sun JH, et al. Efficacy  and safet y of once weekly  dulaglut ide versus 
insulin glargine in pat ients with type2 diabetes on met formin and glimepi[INVESTIGATOR_14956] (AWARD -2). 
Diabet es Care . 2015;38(12):2241–2249. https://doi.org/10.2337/dc14 -1625
Jendle J, Grunberger G, Blevins T, et al. Efficacy and safet y of dulagl utide in the treatment of 
type2 diabetes: a com prehensive review of the dulaglut ide clinical data focusing on the 
AWAR D phase 3 clinical trial program. Diabetes Metab Res Rev . 2016;32(8):776 –790.
https://doi .org/10.1002/dmrr.2810
Lau J, Bl och P, Schäffer L, et al. Discovery  of the once -weekly glucagon -like peptide -1 (GLP -1) 
analogue semaglutide. J Med Chem. 2015; 58:7370 –80.   
https://doi .org/10.1021/acs.jmedchem.5b00726
CONFIDENTIAL Protocol  J2A-MC-GZGE (b)
115Maruish ME, ed. User’s Manual for the SF -36v2 Heal th Survey . 3rd ed. Lincoln, RI: Qualit y 
Metri c Incorporated; 2011.
Nauck MA, Ni edereichho lz U, Ettler R, et al. Glucagon -like peptide 1 inhibit ion of gastri c 
emptying outweighs its insulinotropic effects in healthy humans .Am J Physiol . 1997;273( 5 Pt 
1):E981 –8. https://doi.org/ 10.1152/ajpendo
Nauck M, Frid A, Hermansen K, et al. for the and for the LEAD -2 Study  Group. Efficacy  and 
safet y compar ison of liraglut ide, glimepi[INVESTIGATOR_14956], and placebo, all in co mbinat ion with metformin, 
in type2 diabetes: the LEAD (liraglut ide effect and action in diabetes) -2 study . 
Diabetes Care . 
2009;32(1):84 –90.https://doi.org/10.2337/dc08 -1355
Nauck M. Incretin therapi[INVESTIGATOR_014]: h ighlight ing commo n features and differences in the modes of 
action of  glucagon -like peptide -1 receptor agoni sts and di peptidyl peptidase -4 inhibitors. 
Diabetes Obes Metab . 2016;18(3):203 -216.  https://doi.org/ 10.1111/dom.[ZIP_CODE]
Nauck MA, Meier JJ, Schmidt W E. Incretin -based glucose -lowering medicat ions and the risk o f 
acute pancreatit is and/or pancreatic cancer: reassuring data from cardio -vascular outcome 
trials. Diabetes Obes Metab . 2017;19(9):1327- 1328. https://doi.org/10.1111/dom.[ZIP_CODE]
Pratl eyRE,Aroda VR, Lingvay I,et al. SUSTAIN 7 investigators . Semaglut ide versus 
dulaglut ide once weekly in patients with type 2 diabetes (SUSTAIN 7): a randomised, open -
label, phas e 3b trial . Lancet Diabetes Endocrinol. 2018;6(4):275 -286.   
https://doi .org/ 0.1016/S2213-8587(18)[ZIP_CODE]-X
Scheen AJ. Dulaglut ide for the treatm ent of  type 2 di abetes. Expert Opin Biol 
Ther. 2017;17(4):485 -496. https://doi.org/ 10.1080/14712598.2017.1296131
Steinberg WM, Buse JB, Ghorbani MLM, et al.; LEADER Steering Committee; LEADER Trial 
Invest igators. Amylase, lipase, and acute pancreatitis in people wit h type 2 di abetes treated 
with liraglut ide: results from the LEADER rando mized trial. Diabetes Care . 
2017a;40(7):966 -972. https://doi.org/10.2337/dc16 -[ADDRESS_1037030] of liraglut ide on amylase, lipase, and 
acute pancreatit is in part icipants wi th overwei ght/obesi ty and norm oglycemia, predi abetes, or 
type 2 di abetes: secondary  analyses of pooled data fro m the SCALE clinical development 
program. Diabet es Care . 2017b;40(7):839 -848. https://doi.org/10.2337/dc16 - 2684
Trulicit y [summary of product characterist ics].Indianapo lis, IN: Eli Lilly  and Com pany ; 2020 .
Trulicit y [package insert] .Indianapo lis, IN: Eli Lilly and Company ; [ADDRESS_1037031] for the treatment of ty pe 2 di abetes. Regul Pept. 2010; 164:58 –64.
https//doi.org/10.1016/j.regpep.2010.05.008
[WHO] World Healt h Organizat ion. WHO STEPS surveillance manual: the WHO STEPwise 
approach to noncommunicable disease risk factor surveillance. Updated January  26, 2017. 
Accessed May  04, 2020. https://www.who.int/ncds/surveillance/steps/STEPS_Manual.pdf
Leo Document ID = 3a662cc0-d0a4-4912-b29e-a3a0309049de
Approver: 
Approval Date & Time: 27-Oct-2021 00:43:02 GMT
Signature [CONTACT_32869]: Approved
Approver: 
Approval Date & Time: 27-Oct-2021 00:51:01 GMT
Signature [CONTACT_32869]: Approved
[COMPANY_003]
[COMPANY_003]